Document:

Collaboration and license agreement between the Registrant and Sanofi

 Exhibit 10.28 
 CONFIDENTIAL 
 COLLABORATION AND LICENSE AGREEMENT 

by and between 

Rib-X Pharmaceuticals, Inc. 
 and 
 Sanofi 

Effective as of June 28, 2011 
 Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting
confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Table of Contents 

 

							
	 	  	 	  	Page	 
		
	 ARTICLE I - DEFINITIONS
	  	 	1	  
		
	 ARTICLE II - RESEARCH PROGRAM
	  	 	14	  
			
	 2.1
	  	 Overview
	  	 	14	  
	 2.2
	  	 Conduct of Research Program
	  	 	14	  
	 2.3
	  	 Research Plans
	  	 	14	  
	 2.4
	  	 Costs
	  	 	14	  
	 2.5
	  	 Know-how Exchange
	  	 	14	  
	 2.6
	  	 Record-keeping
	  	 	15	  
	 2.7
	  	 Nomination of Candidate Compound
	  	 	15	  
	 2.8
	  	 Development and Commercialization Option
	  	 	15	  
	 2.9
	  	 Limitation on Activities During Option Period
	  	 	16	  
	 2.10
	  	 Effectiveness of License
	  	 	16	  
	 2.11
	  	 Returned Compounds
	  	 	16	  
	 2.12
	  	 Use of Third Parties
	  	 	16	  
		
	 ARTICLE III - GOVERNANCE; DECISION-MAKING
	  	 	16	  
			
	 3.1
	  	 Formation and Membership
	  	 	16	  
	 3.2
	  	 Responsibilities
	  	 	17	  
	 3.3
	  	 Administrative Matters
	  	 	17	  
	 3.4
	  	 Meetings
	  	 	18	  
	 3.5
	  	 Decision Making
	  	 	18	  
	 3.6
	  	 Status Reports
	  	 	18	  
	 3.7
	  	 Alliance Managers
	  	 	19	  
		
	 ARTICLE IV - LICENSES AND ASSIGNMENTS
	  	 	19	  
			
	 4.1
	  	 Research Licenses
	  	 	19	  
	 4.2
	  	 Development and Commercialization Licenses
	  	 	20	  
	 4.3
	  	 Sublicensing Rights
	  	 	20	  
	 4.4
	  	 Rights Retained by the Parties
	  	 	21	  
	 4.5
	  	 Diligence
	  	 	21	  
	 4.6
	  	 Exclusivity
	  	 	21	  
	 4.7
	  	 Right of First Negotiation
	  	 	22	  
	 4.8
	  	 Section 365(n) of the Bankruptcy Code
	  	 	22	  
		
	 ARTICLE V - PROFIT-SHARE OPTION
	  	 	23	  
			
	 5.1
	  	 US Profit Share Option
	  	 	23	  
	 5.2
	  	 Data Package and Option Period
	  	 	23	  
	 5.3
	  	 Development of US Profit Share Product
	  	 	24	  
	 5.4
	  	 Shared Development Costs
	  	 	25	  
	 5.5
	  	 Record-Keeping
	  	 	25	  
	 5.6
	  	 Commercialization of US Profit Share Product
	  	 	25	  
	 5.7
	  	 Sales and Distribution
	  	 	26	  
	 5.8
	  	 Promotional Materials
	  	 	26	  

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 i 

 Table of Contents 

 

							
	 	  	 	  	Page	 
		
	 ARTICLE VI - FINANCIAL PROVISIONS
	  	 	27	  
			
	 6.1
	  	 Initial License Payment
	  	 	27	  
	 6.2
	  	 Research Milestone
	  	 	27	  
	 6.3
	  	 Option Exercise Fee
	  	 	27	  
	 6.4
	  	 Milestone Payments
	  	 	28	  
	 6.5
	  	 Sales Milestones Payments
	  	 	28	  
	 6.6
	  	 Notification of Achievement
	  	 	29	  
	 6.7
	  	 Licensed Product Royalties
	  	 	29	  
	 6.8
	  	 Net Profit/Loss
	  	 	30	  
	 6.9
	  	 Royalty Payment by Rib-X
	  	 	31	  
	 6.10
	  	 Accounting
	  	 	31	  
	 6.11
	  	 Taxes
	  	 	32	  
	 6.12
	  	 Records and Inspection
	  	 	33	  
		
	 ARTICLE VII - INTELLECTUAL PROPERTY MATTERS
	  	 	34	  
			
	 7.1
	  	 Ownership
	  	 	34	  
	 7.2
	  	 Prosecution and Maintenance of Patent Rights
	  	 	34	  
	 7.3
	  	 Third Party Infringement
	  	 	36	  
	 7.4
	  	 Patent Invalidity Claim
	  	 	38	  
	 7.5
	  	 Patent Marking
	  	 	38	  
	 7.6
	  	 Paragraph IV Certification
	  	 	38	  
	 7.7
	  	 Settlement
	  	 	38	  
	 7.8
	  	 Yale Agreement
	  	 	38	  
		
	 ARTICLE VIII - CONFIDENTIAL INFORMATION
	  	 	39	  
			
	 8.1
	  	 Treatment of Confidential Information
	  	 	39	  
	 8.2
	  	 Permitted Uses
	  	 	39	  
	 8.3
	  	 Exceptions
	  	 	40	  
	 8.4
	  	 Additional Limits on Disclosure by Rib-X
	  	 	40	  
	 8.5
	  	 Publication Rights
	  	 	41	  
	 8.6
	  	 Return of Confidential Information
	  	 	41	  
	 8.7
	  	 Press Releases and Other Disclosures
	  	 	41	  
		
	 ARTICLE IX - REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	42	  
			
	 9.1
	  	 Mutual Representations
	  	 	42	  
	 9.2
	  	 Rib-X’s Representations and Warranties
	  	 	43	  
	 9.3
	  	 Sanofi’s Representations
	  	 	44	  
	 9.4
	  	 Covenants of the Parties
	  	 	44	  
	 9.5
	  	 No Warranty
	  	 	45	  
		
	 ARTICLE X - INDEMNIFICATION
	  	 	45	  
			
	 10.1
	  	 Indemnification by Sanofi
	  	 	45	  
	 10.2
	  	 Indemnification by Rib-X
	  	 	46	  
	 10.3
	  	 Procedure
	  	 	46	  
	 10.4
	  	 Insurance
	  	 	47	  
	 10.5
	  	 No Consequential Damages
	  	 	47	  

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 ii 

 Table of Contents 

 

							
	 	  	 	  	Page	 
		
	 ARTICLE XI - TERM AND TERMINATION
	  	 	47	  
			
	 11.1
	  	 Term
	  	 	47	  
	 11.2
	  	 Termination
	  	 	47	  
	 11.3
	  	 Effects of Termination
	  	 	49	  
		
	 ARTICLE XII - DISPUTE RESOLUTION
	  	 	53	  
			
	 12.1
	  	 Referral of Unresolved Matters to Executives
	  	 	53	  
	 12.2
	  	 Final Decision-Making
	  	 	53	  
	 12.3
	  	 Arbitration
	  	 	54	  
	 12.4
	  	 Equitable Relief
	  	 	55	  
	 12.5
	  	 No Arbitration of Patent Matters
	  	 	55	  
		
	 ARTICLE XIII - MISCELLANEOUS
	  	 	55	  
			
	 13.1
	  	 No Use of Name
	  	 	55	  
	 13.2
	  	 Governing Law
	  	 	56	  
	 13.3
	  	 Waiver
	  	 	56	  
	 13.4
	  	 Notices
	  	 	56	  
	 13.5
	  	 Entire Agreement; Amendment
	  	 	57	  
	 13.6
	  	 Headings
	  	 	57	  
	 13.7
	  	 Severability
	  	 	57	  
	 13.8
	  	 Assignment
	  	 	57	  
	 13.9
	  	 Counterparts
	  	 	58	  
	 13.10
	  	 Force Majeure
	  	 	58	  
	 13.11
	  	 Non-solicitation
	  	 	58	  
	 13.12
	  	 Third Party Beneficiaries
	  	 	58	  
	 13.13
	  	 Relationship of the Parties
	  	 	59	  
	 13.14
	  	 Performance by Affiliates
	  	 	59	  
	 13.15
	  	 Construction
	  	 	59	  

  

			
	 Exhibit A
	  	 Research Plan

	 Exhibit B
	  	 Rib-X Internal Compound Modeling Criteria and List of Rib-X Existing Compounds

	 Exhibit C
	  	 Description of [***]

	 Exhibit D
	  	 Target Profiles

	 Exhibit E
	  	 Rib-X Know-how to be Provided to Sanofi for Conduct of Research Program

	 Exhibit F
	  	 Example of Calculation of Net Profit/Loss

	 Exhibit G
	  	 Key Countries for Patent Filings

	 Exhibit H-1
	  	 Form of Rib-X Press Release

	 Exhibit H-2
	  	 Form of Sanofi Press Release

	 Exhibit I
	  	 Rib-X Patent Rights

	 Exhibit J
	  	 Third Party Agreements

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 iii 

 CONFIDENTIAL 
 COLLABORATION AND LICENSE AGREEMENT 
 This Collaboration and License
Agreement (“Agreement”), dated as of the 28th day of June, 2011 (the “Effective Date”), is entered into by and between Rib-X Pharmaceuticals, Inc., a Delaware corporation, having a principal office at 300 George
Street, Suite 301, New Haven, CT 06511-6663 (“Rib-X”), and Sanofi, a société anonyme organized under the laws of France, having a principal office located at 174 avenue de France, 75013, Paris, France
(“Sanofi”). 
 INTRODUCTION 
 WHEREAS, Rib-X is a biopharmaceutical company focused on discovering and developing broad spectrum antibiotics; 
 WHEREAS, Sanofi is a global pharmaceutical company with expertise and capability in the research, development, manufacture and commercialization of pharmaceutical products; 

WHEREAS, Rib-X has a drug discovery program focused on developing novel small molecule antibiotics based on Rib-X’s existing [***]
of compounds that bind to [***] of the 50S subunit of the ribosome; 
 WHEREAS, Sanofi desires to collaborate with Rib-X on the
identification and development of novel antibiotics based on RX04 Compounds (as defined herein), and to acquire an option to further develop and commercialize certain compounds of interest resulting from such collaboration, in each case, on the
terms and conditions set forth in this Agreement; and 
 WHEREAS, Rib-X desires to collaborate with Sanofi on the identification
and development of such antibiotics, and to grant Sanofi certain rights, in each case, on the terms and conditions set forth in this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Rib-X and
Sanofi agree as follows: 
 ARTICLE I - DEFINITIONS 

When used in this Agreement, each of the following terms, whether used in the singular or plural, will have the meaning set forth in this
Article I: 
 1.1 “Affiliate” as to any entity means any other entity that, directly or indirectly, controls,
is controlled by or is under common control with such entity. For the purposes of this definition, “control” refers to any of the following: (i) direct or indirect ownership of fifty percent (50%) or more of the voting securities
entitled to vote for the election of directors in the case of a corporation, or of fifty percent (50%) or more of the equity interest with the power to direct management in the case of any other type of legal entity; (ii) status as a
general partner in any partnership; or (iii) any other arrangement where an entity possesses, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, by contract or
otherwise. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 1 

 1.2 “Alliance Manager” has the meaning set forth in Section 3.7.

 1.3 “Applicable Law” means all applicable laws, statutes, rules, and regulations as may be in effect from
time to time, including applicable regulations, guidelines and other requirements of relevant Regulatory Authorities. 
 1.4
“Back-up Compound” with respect to any Target Compound, means another RX04 Compound that has all of the following properties when compared to such Target Compound: 

 

	 	(i)	is built on the same [***] as such Target Compound; 

  

	 	(ii)	occupies the same additional [***] as such Target Compound; 

  

	 	(iii)	has the same Target Profile as such Target Compound; 

  

	 	(iv)	has the same [***] activity as such Target Compound; and 

  

	 	(v)	has at least [***] with such Target Compound, as defined by a [***] computed by [***] on molecular properties built by [***], based on the key properties and weights
specified in the table below: 

  

							
	 [***]
 Descriptor
	  	 Explanation
	  	Weight	 
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  
	 [***]
	  	[***]	  	 	[***]	  

 For purposes of determining the [***] under clause (v), the mere presence of [***] will not be treated as [***].

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 2 

 1.5 “Business Day” means a day that is not a Saturday, a Sunday, nor a day
on which banking institutions in New York, New York or Paris, France are authorized by law to remain closed. 
 1.6
“Calendar Quarter” means each of the three (3) month periods ending on March 31, June 30, September 30, and December 31 of any year. 

1.7 “Calendar Year” means each successive period of twelve (12) months commencing on January 1, ending on
December 31. 
 1.8 “Candidate Compound” means any Target Compound that is nominated as a Candidate
Compound under Section 2.7. 
 1.9 “Clinical Trial” means a Phase 1 Clinical Trial, a Phase 2 Clinical
Trial, a Phase 3 Clinical Trial or a Phase 4 Clinical Trial. 
 1.10 “COGS” or Cost of Goods Sold”
means the aggregate of internal and external costs of Sanofi and its Affiliates to Manufacture the quantities of US Profit Share Product used in Development of the US Profit Share Product in the United States or sold by Sanofi or any of its
Affiliates or Sublicensees in the United States, which shall include the following to the extent reasonably allocable to the Manufacture of such US Proft Share Product, all [***], provided, that any such amounts that are included in COGS will not be
included in the calculation of Third Party and other Permitted Sales and Marketing Expenses so as not to double count such amounts. 
 1.11 “Collaboration Compound” means any RX04 Compound that is identified or reduced to practice (or can be reasonably expected to be reduced to practice) by or on behalf of either Party
or any of its Affiliates during the Research Term, in each case excluding Rib-X Existing Compounds. 
 1.12
“Commercialization” and “Commercialize” means all pre-launch and post-launch activities undertaken by the Parties or any of their Affiliates relating to the marketing, promotion, offering for sale, distribution and
sale of a US Profit Share Product in the United States, including conducting post-approval clinical trials; advertising; promotion; strategic marketing; market research; sales meetings; detailing; sample drops; activities related to national
accounts, managed care accounts and other similar accounts and government programs; activities related to reimbursement; market and product support; customer service; medical support, educational initiatives; product storage and distribution; order
entry; billing; collection; invoicing; returns; and other marketing, sales and distribution activities. 
 1.13
“Commercialization Plan” means, with respect to the US Profit Share Product, in each Calendar Year, the plan approved by the JSC for activities to be conducted by or on behalf of the Parties related to Commercialization of the US
Profit Share Product in the United States under this Agreement and the budget for the costs to be incurred in connection with such activities. 
 1.14 “Commercially Reasonable Efforts” means, with respect to a Party, such level of effort [***]. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 3 

 1.15 “Confidential Information” means all confidential Know-how of a Party
which is disclosed (whether in written, graphic, oral, electronic or other form) by or on behalf of such Party (the “Disclosing Party”) to the other Party (the “Receiving Party”) pursuant to this Agreement,
including: information regarding a Party’s technology, products, programs, business, financial status, biological or chemical substances, formulations, techniques, methodology, equipment, sources of supply, patent positioning, and business
plans. Notwithstanding the foregoing, after the Research Term, all Know-how related to any Target Compound or Returned Compound whether generated by or on behalf of Rib-X or Sanofi will be treated as the Confidential Information of Rib-X with Sanofi
treated as the Receiving Party, subject to (i) the licenses granted to Sanofi under Sections 4.1.1 and 4.2.1; (ii) Sanofi’s right to use such Confidential Information in accordance with Section 8.2; and (iii) the
restrictions imposed on Rib-X under Section 8.4. For purposes of this Agreement, Confidential Information of Rib-X will also include Confidential Information obtained under the Yale Agreement, which such Confidential Information will be subject
to the additional restrictions set forth in the Yale Agreement. 
 1.16 “Control” or
“Controlled” means, with respect to any Patent Rights or Know-how, possession (whether by ownership or license, other than a license or ownership granted pursuant to this Agreement) of the ability to grant the licenses or
sublicenses as provided for in this Agreement without violating the terms of any agreement or other arrangement with any Third Party. 
 1.17 “Cover”, “Covering” or “Covered” means, with respect to a product, composition, technology, process or method that, in the absence of ownership of,
or a license granted under, a Valid Claim, the manufacture, use, offer for sale, sale or importation of such product or composition or the practice of such technology, process or method would infringe such Valid Claim. 

1.18 “CPI” means l’indice des prix à la consommation (IPC) as published by the Institut National
de la Statistique et des Études Économiques  
 1.19 “Detail” or “Detailing”
means, with respect to a US Profit Share Product, an interactive in-person visit by a representative of either (or both) Party’s sales force, or other employee of either Party who may be deemed to be part of the Commercialization Plan with a
medical professional having prescribing authority (other than a microbiologist or pharmacist) where the relevant characteristics of such US Profit Share Product are described to such medical professional by the representative in a fair and balanced
manner consistent with the requirements of this Agreement and Applicable Law and in a manner that is customary in the industry for the purpose of promoting a prescription pharmaceutical product. A sample drop shall not constitute a Detail. When used
as a verb, “Detail” means to engage in a Detail. 
 1.20 “Development,” “Develop,”
or “Developing” means all preclinical and clinical drug development activities and regulatory affairs support conducted for the purpose of obtaining or maintaining Regulatory Approval of a product. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 4 

 1.21 “Development Costs” means all internal and external, direct
expenditures actually incurred by either Party in connection with the Development of a US Profit Share Product; provided that [***]. 
 1.22 “Development and Commercialization Option” has the meaning set forth in Section 2.8. 
 1.23 “Development Plan” means, with respect to the US Profit Share Product in each Calendar Year, the plan approved by the JSC for activities to be conducted in such year by or on behalf
of the Parties and their Affiliates and Sublicensees related to Development of the US Profit Share Product in the United States under this Agreement and the budget for such activities. 

1.24 “EMA” means the European Medicines Agency or any successor agency thereto. 

1.25 “Executives” means with respect to Rib-X, its Chief Executive Officer and, with respect to Sanofi, its President of
Global Research and Development or such other similar position designated by Sanofi from time to time. 
 1.26
“FDA” or “Food and Drug Administration” means the United States Food and Drug Administration and any successor agency. 
 1.27 “Field” means all therapeutic, prophylactic and palliative uses in humans. 
 1.28 “First Commercial Sale” means, with respect to a Licensed Product in a country in the Territory, the first bona fide arms-length sale of such Licensed Product sold to a Third Party
in such country by or on behalf of Sanofi, its Affiliates, or Sublicensees after Regulatory Approval has been obtained for such Licensed Product in such country or, if Regulatory Approval is not required, after the date on which sales are permitted
under Applicable Law. 
 1.29 “Follow-on Compounds” means any RX04 Compound identified by or on behalf of
Sanofi or any of its Affiliates during the Follow-on Period, excluding (i) any Licensed Compounds, and (ii) any RX04 Compounds identified by a Third Party during the Follow-on Period independent of any Know-how related to RX04 Compounds
provided to such Third Party by Sanofi or any of its Affiliates and either purchased or in-licensed by Sanofi or any of its Affiliates. 
 1.30 “Follow-on Period” means the twenty-four month period following the earlier to occur of (i) the end of the Research Term, or (ii) termination of this Agreement. 

1.31 “FTE” means a full-time equivalent person year of scientific, technical, regulatory or professional work. An FTE
shall consist of a total of One Thousand Eight Hundred Eighty (1,880) hours per year, with any portion of an FTE calculated based upon hours worked divided by such annual total. 

1.32 “FTE Cost” means, for any period, the product of (i) the actual total FTEs (and/or portion thereof) during
such period, and (ii) the FTE Rate. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 5 

 1.33 “FTE Rate” means €[***], increased or decreased at the end of
each Calendar Year by the cumulative increase or decrease in the level of CPI as of December 31st of such year over the level of the CPI as of December 31st of the prior Calendar Year. 

1.34 “Generic Product” means, with respect to any Licensed Product and any country in the Territory, any pharmaceutical
product that meets all of the following criteria: [***]. 
 1.35 “IFRS” means the International Financial
Reporting Standards adopted by the European Union, as consistently applied by Sanofi. 
 1.36 “IND” or
“Investigational New Drug Application” means an Investigational New Drug Application filed with the FDA in the United States or any equivalent counterpart in any country other than the United States, including all supplements and
amendments thereto. 
 1.37 “Indemnitee” means (i) with respect to Rib-X, each Rib-X Indemnitee, and
(ii) with respect to Sanofi, each Sanofi Indemnitee. 
 1.38 “Invention” means any method, process, means
of manufacture, compound, formulation, or composition of matter, whether or not patentable or copyrightable, or any improvement thereof. 
 1.39 “Joint Inventions” has the meaning set forth in Section 7.1. 
 1.40 “Joint Patent Rights” means any Patent Rights owned by both Parties or together with any of their Affiliates Covering Joint Inventions. 

1.41 “Joint Technology” means Joint Inventions and Joint Patent Rights. 

1.42 “Joint Commercialization Committee” or “JCC” shall have the meaning set forth in
Section 5.6.2. 
 1.43 “Joint Steering Committee” or “JSC” has the meaning set forth in
Section 3.1. 
 1.44 “Know-how” means any information, Inventions, know-how, data and materials, whether
patentable or not, including (i) ideas, discoveries, improvements and trade secrets; (ii) pharmaceutical, chemical and biological materials, products and compositions; (iii) tests, assays, techniques, methods, procedures, formulas and
processes; (iv) technical, medical, clinical, toxicological, and other data and other information, including the results of preclinical studies and Clinical Trials; and (v) drawings, plans, designs, diagrams, sketches, specifications, and
other documents containing or relating to such information, inventions, know-how, data or materials; but excluding Patent Rights Covering the foregoing. 
 1.45 “Licensed Compound” means any Candidate Compound as to which Sanofi has exercised its Development and Commercialization Option under Section 2.8, and the two (2) Back-up
Compounds to such Candidate Compound selected by Sanofi under Section 2.8, until such time as any such compound becomes a Returned Compound. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 6 

 1.46 “Licensed Product” means any product containing as an active
pharmaceutical ingredient a Licensed Compound, [***]. 
 1.47 “License Term” means, with respect to a Licensed
Product, the period commencing upon Sanofi’s exercise of its Development and Commercialization Option with respect to the relevant Licensed Compound and ending upon the earlier to occur of (i) expiration or earlier termination of this
Agreement pursuant to Article XI or (ii) termination of Sanofi’s rights with respect to such Licensed Product under Article XI. 
 1.48 “Major Countries” means: (i) the United States of America; [***]. 
 1.49 “Manufacture” or “Manufacturing” means all activities related to the manufacturing of a US Profit Share Product, for use in clinical studies and manufacturing for
commercial sale, including fill/finish, packaging, labeling, release of product, quality assurance/quality control testing (including in-process, in-process release and stability testing), shipping and storage of such product. 

1.50 “NDA” means a New Drug Application or a supplemental New Drug Application, as defined in 21 C.F.R.
§§314.50 and 314.70, respectively, filed with the FDA with respect to a Licensed Product, or an equivalent application filed with a Regulatory Authority of a country in the Territory other than the United States, including any application
for Regulatory Approval filed with the EMA. 
 1.51 “Net Profit/Loss” means, with respect to the US Profit
Share Product in a Calendar Quarter, Net Sales of such US Profit Share Product sold or otherwise disposed of by Sanofi and its Affiliates and/or Sublicensees during such Calendar Quarter in the United States less [***]. For purposes of clarity, it
is understood that no costs and expenses are to be double-counted in the calculation of Net Profit/Loss. 
 1.52 “Net
Sales” means the gross amount billed or invoiced for sales or other commercial disposition of a Licensed Product by Sanofi and its Affiliates and Sublicensees (each, a “Selling Party”), to Third Parties (other than a sale
to a Sublicensee for further resale) (the “Gross Sales”), less the following deductions with respect to the sale of such Licensed Product, to the extent actually allowed or taken: 

[***] 
 Such
amounts will be determined from the books and records of Sanofi, its Affiliates or Sublicensees, maintained in accordance with IFRS consistently applied by the Selling Party. Any of the items set forth above that would otherwise be deducted from the
invoice price in the calculation of Net Sales, but which are separately charged to, and paid by Third Parties will not be deducted from the invoice price in the calculation of Net Sales. 

In the case of any sale of the Licensed Product for consideration other than cash, such as barter or countertrade, Net Sales will be
calculated using the cash price that would be paid for Licensed Product in an arm’s length transaction between two unrelated parties, using the average per unit Net Sales price for all arm’s length transactions in the same country during
the relevant period or, if none, then as determined in the relevant period by mutual good faith agreement of both Parties. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 7 

 Notwithstanding anything in this Agreement to the contrary, the following dispositions will
not be included in the calculation of Net Sales: [***]. 
 [***]. 

The sale of a Licensed Product between or among Sanofi or its Affiliates or Sublicensees for resale will not be included in Net Sales;
provided, however, that the first sale or disposition to a Third Party who is not a Selling Party thereafter will be included in Net Sales. In the event an Affiliate or Sublicensee is the end-user of Licensed Product, the transfer of Licensed
Product to such Affiliate or Sublicensee shall be included in the calculation of Net Sales at the average selling price charged in an arm’s length sale to a Third Party who is not a Sublicensee in the relevant period. A sale of a Licensed
Product is deemed to have occurred upon invoicing. 
 If any Licensed Product is sold as a Combination Product (as defined
below), the Net Sales from the Combination Product, for the purposes of determining milestones and royalties, will be determined by multiplying [***], in each case during the applicable Calendar Quarter and in the relevant countries or, if sales of
both the Sole Compound Product and the other significantly active compounds did not occur in such period, then in the most recent Calendar Quarter in which sales of both occurred. If such [***] cannot be determined for both the Sole Compound Product
and the other significantly active compounds included in the Combination Product, Net Sales for the purposes of determining milestones and royalties will be calculated by multiplying [***]. In such event, the Parties will mutually agree in good
faith on the respective [***] of the Sole Compound Product and the other significantly active compounds included in the Combination Product. “Combination Product” means a Licensed Product that consists of (i) a Licensed
Compound and (ii) one or more other significantly active compounds that are not a Licensed Compound. “Sole Compound Product” means a Licensed Product containing no significantly active compounds other than a Licensed Compound.
Notwithstanding the foregoing, in the event a US Profit Share Product is sold as a Combination Product, Net Sales of such US Profit Share Product will not be [***] but instead [***]. 

1.53 “New [***]” shall mean a specific [***] differing from any of the [***] existing [***] described in Exhibit
C or any other specific [***] that cannot be classified within such other [***], and is invented by either Party during the Research Term. 
 1.54 “Option Exercise Fee” has the meaning set forth in Section 6.3. 
 1.55 “Party” or “Parties” means Rib-X and/or Sanofi, as the context requires. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 8 

 1.56 “Patent Rights” means any patents, including certificates of
correction, substitutions, extensions (including supplemental protection certificates), registrations, confirmations, reissues, re-examinations and renewals, and patent applications, including any provisional applications, divisionals, continuations
and continuations-in-part. 
 1.57 “Phase 1 Clinical Trial” means a human clinical trial (whether a phase 1a or
a phase 1b trial) in any country, the principal purpose of which is a preliminary determination of safety in individuals or patients, that would satisfy the requirements of 21 C.F.R. §312.21(a), or an equivalent clinical study required by a
Regulatory Authority outside of the United States. 
 1.58 “Phase 2 Clinical Trial” means a human clinical
trial (whether a phase 2a or phase 2b trial) conducted in any country, intended to explore multiple doses, dose response or duration of effect and to generate initial evidence of safety and activity in a target patient population, that would satisfy
the requirements of 21 C.F.R. §312.21(b), or an equivalent clinical study required by a Regulatory Authority outside of the United States. 
 1.59 “Phase 3 Clinical Trial” means a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. §312.21(c), or an equivalent clinical study required by a
Regulatory Authority outside of the United States. 
 1.60 “Phase 4 Clinical Trial” means a human clinical
trial which is conducted on a product after Regulatory Approval of the product has been obtained from an appropriate Regulatory Authority, and includes (a) trials conducted voluntarily for enhancing marketing or scientific knowledge of an
approved indication or (b) trials conducted after Regulatory Approval due to request or requirement of a Regulatory Authority or as a condition of a previously granted Regulatory Approval. 

1.61 “Pre-Opt-in Development Costs” means, with respect to the US Profit Share Product, the sum of (i) [***]
([***]%) of the Development Costs that are incurred by Sanofi or any of its Affiliates during the Pre-Opt-in Period for all Development activities required to conduct Clinical Trials or obtain Regulatory Approval of the US Profit Share Product in
the US, but only if the results of such Development activities will not be used in a substantial way to support Regulatory Approval of the US Profit Share Product in [***], the [***], and (ii) [***] percent ([***]%) of the Development Costs
that are incurred by Sanofi or any of its Affiliates during the Pre-Opt-in Period for all Development activities required to conduct Clinical Trials or obtain Regulatory Approval of the US Profit Share Product worldwide, but solely to the extent the
results of such Development activities will also be used in a substantial way to support Regulatory Approval of the US Profit Share Product in the U.S., and excluding any Development Costs included in subclause (i) of this definition.

 1.62 “Pre-Opt-in Period” means, with respect to the US Profit Share Product, the period commencing on the
date of the Option Exercise Notice and ending on the US Profit Share Option Exercise Date. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 9 

 1.63 “Profit/Loss Share Percentage” means, in the event Rib-X has exercised
the US Profit Share Option, [***] percent ([***]%) of Net Profit/Loss to Sanofi and [***] percent ([***]%) of Net Profit/Loss to Rib-X. 
 1.64 “Regulatory Approval” means the receipt of any and all approvals, licenses, registrations or authorizations by a Regulatory Authority that are necessary for the marketing and sale of
a pharmaceutical product in a country or group of countries, including all applicable pricing and reimbursement approvals. 

1.65 “Regulatory Authority” means any federal, national, multinational, state, provincial or local regulatory agency,
department, bureau or other governmental entity with authority over the marketing, pricing or sale of a pharmaceutical product in a country, including the FDA and the EMA. 
 1.66 “Research” means the research and preclinical activities conducted by or on behalf of the Parties and their Affiliates under the Research Plan. 

1.67 “Research Plan” means the Research Plan attached to this Agreement as Exhibit A, as modified from time to
time by the JSC during the Research Term in accordance with Section 2.3. 
 1.68 “Research Program” means
the conduct of the research and preclinical activities described in the Research Plan during the Research Term. 
 1.69
“Research Term” means the period commencing on the Effective Date and ending on the third anniversary of the Effective Date, unless extended by mutual agreement of the Parties or earlier terminated by mutual agreement of the Parties
or termination of this Agreement under Article XI. 
 1.70 “Returned Compounds” mean [***]. 

1.71 “Rib-X Internal Compound Modeling Criteria” means the modeling criteria set forth on Exhibit B. 

1.72 “Rib-X Existing Compounds” means RX04 Compounds that were identified as meeting Rib-X Internal Compound Modeling
Criteria by Rib-X prior to the Effective Date, in each case as specifically set forth on Schedule 1 to Exhibit B, and any Back-up Compounds to such compounds. 
 1.73 “Rib-X Know-how” means, subject to Section 13.8(b), any Know-How Controlled by Rib-X or any of its Affiliates as of the Effective Date or developed during the Research Term
which are related to or useful in the identification, development, manufacture, use or sale of RX04 Compounds. 
 1.74
“Rib-X Licensed Technology” means the Rib-X Patent Rights and Rib-X Know-how. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 10 

 1.75 “Rib-X Patent Rights” means, subject to Section 13.8(b), all
Patent Rights Controlled by Rib-X or any of its Affiliates as of the Effective Date or at any time during the Term of this Agreement which are related to or useful in the identification, development, manufacture, use or sale of RX04 Compounds;
provided that “Rib-X Patent Rights” shall not cover any Patent Rights Controlled by Rib-X that cover Inventions conceived of after the Research Term which are not necessary for (or the absence of which would not make the following
impracticable) the identification, development, manufacture, use or sale of RX04 Compounds by Sanofi, its Affiliates and Sublicenses. 
 1.76 “Royalty-bearing Product” means any Licensed Product other than the US Profit Share Product with respect to sales of such US Profit Share Product in the United States. For the sake
of clarity a Licensed Product that is a US Profit Share Product in the United States will be deemed a Royalty-bearing Product outside the United States. 
 1.77 “RX04 Compound” any compound that [***] on the [***] of the large ribosomal subunit, defined more specifically as a [***]. 

1.78 “Sanofi Compound Specific Patent Rights” means those Sanofi Patent Rights that (i) Cover the composition of
matter or method of manufacture or use of a specific RX04 Compound and (ii) do not Cover the composition of matter or method of manufacture or use of any other compound. 
 1.79 “Sanofi Know-how” means, subject to Section 13.8(b), (i) with respect to the license granted to Rib-X and its Affiliates under Section 4.1.2, any Know-How Controlled
by Sanofi or any of its Affiliates as of the Effective Date or at any time arising from activities performed by Sanofi or any of its Affiliates or Sublicensees under the Research Plan during the Research Term which are used by Sanofi or any of its
Affiliates or permitted Sublicensees in the identification, development, manufacture, use or sale of RX04 Compounds; and (ii) with respect to the licenses granted to Rib-X under Section 4.2.2, 4.2.3 and 11.3.1 as to a specific US Profit
Share Product, Licensed Product or Returned Compound, any Know-how Controlled by Sanofi or any of its Affiliates during the Term and incorporated into such US Profit Share Product, Licensed Product or Returned Compound, as the case may be, or its
manufacturing process or which has been generated or applied in a substantial way by Sanofi or any of its Affiliates or Sublicensees in the development, manufacture, use or commercialization of such US Profit Share Product, Licensed Product or
Returned Compound, as the case may be, or that relates to the composition of matter or a use of any such US Profit Share Product, Licensed Product or Returned Compound, as the case may be. 

1.80 “Sanofi Licensed Technology” means the Sanofi Patent Rights and Sanofi Know-how. 

1.81 “Sanofi Patent Rights” means all Patent Rights Controlled by Sanofi or any of its Affiliates as of the Effective
Date or at any time during or after the Term of this Agreement which (i) Cover any Invention arising from activities performed by Sanofi or any of its Affiliates or Sublicensees under the Research Plan during the Research Term; or
(ii) Cover an Invention used by Sanofi or any of its Affiliates or Sublicensees in the development, manufacture, use or sale of RX04 Compounds. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 11 

 1.82 “[***]” means (i) any of the [***] specific [***] for molecules
designated in Exhibit C through which variable [***] can be attached through standard organic chemical transformations; and (ii) any New [***]. Molecules sharing a [***] differ only by [***] of one or more [***]. [***] variations in the
[***] will be considered [***]. 
 1.83 “Shared Development Costs” means those Development Costs incurred by
either Party or any of its Affiliates after exercise by Rib-X of its US Profit Share Option to the extent directly attributable to activities specifically required to conduct Clinical Trials and regulatory activities required to obtain Regulatory
Approval of the US Profit Share Product anywhere in the world, but solely to the extent (i) such activities will be used in a substantial way to support regulatory filings in the United States and (ii) such costs are consistent with the
then current Development Plan and the related budget contained therein 
 1.84 “Sublicensee” means a Third
Party to whom Sanofi or one of its Affiliates has granted an express or implied license or sublicense under the licenses granted under Section 4.2.1 or otherwise with respect to the development, manufacture, use or sale of Licensed Product, but
not including distributors who purchase Licensed Product in final finished form from Sanofi, its Affiliates or a Sublicensee for resale and do not market, such Licensed Product or perform any manufacturing, development or marketing activities.

 1.85 “Target Compounds” means Collaboration Compounds and Rib-X Existing Compounds. 

1.86 “Target Profiles” mean the parameters of compound activity set forth in Exhibit D. 

1.87 “Term” has the meaning set forth in Section 11.1. 

1.88 “Territory” means all countries of the world. 

1.89 “Third Party” means any person or entity other than Rib-X or Sanofi or any of their respective Affiliates.

 1.90 “Third Party and Other Permitted Sales and Marketing Expenses” means, with respect to any US Profit
Share Product, the aggregate of the following incurred by either Party or any of its Affiliates with respect to such US Profit Share Product in the relevant Calendar Quarter to the extent attributable to activities in the United States and shown on
the then applicable Commercialization Plan approved by the JSC or otherwise [***]. All the foregoing will be determined from the books and records of the applicable Party or its Affiliates, maintained in accordance with IFRS as consistently applied
by the applicable Party and no such amounts will be counted twice. 
 1.91 “United States” or
“US” or “U.S.” means the United States of America, its territories and possessions. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 12 

 1.92 “US Profit Share Option” has the meaning set forth in
Section 5.1. 
 1.93 “US Profit Share Option Exercise Date” has the meaning set forth in Section 5.2.

 1.94 “US Profit Share Product” means the Licensed Product, if any, as to which Rib-X has exercised its US
Profit Share Option under Section 5.2. 
 1.95 “Valid Claim” means any claim in any unexpired and issued
patent that has not been disclaimed, revoked or held invalid or unenforceable by a decision of a court or other governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not taken within
the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. 
 1.96 “Value Added Compound” means any Returned Compound that was either (i) a Rib-X Existing Compound which was resynthesized as part of the Research Program after completion of
mouse pharmacokinetic studies; or (ii) a Collaboration Compound. 
 1.97 “Yale” means Yale University.

 1.98 “Yale Agreement” means a certain Yale Exclusive License Agreement between Rib-X and Yale, dated as of
December 6, 2001. 
 1.99 Additional Definitions. Each of the following definitions is set forth in the section of
this Agreement indicated below: 
  

			
	 Definition
	  	Section
		
	 Bankruptcy Code
	  	4.8
	 Breaching Party
	  	11.2.2
	 Change of Control
	  	13.8(d)
	 Combination Product
	  	1.52
	 Data Package
	  	5.2
	 Development Loan
	  	5.3.1(a)
	 Development Plan Guidelines
	  	5.3
	 Exchange Act
	  	13.8(d)
	 Face-to-Face Customer Activities
	  	5.6.1
	 Flow Chart
	  	6.2(i)
	 Gross Sales
	  	1.52
	 IFRS
	  	1.35
	 Indemnified Party
	  	10.3
	 Indemnifying Party
	  	10.3.1
	 Initial Development Plan
	  	5.2
	 Knowledge
	  	9.2
	 Non-Breaching Party
	  	11.2.2
	 Option Exercise Date
	  	2.8
	 Option Exercise Notice
	  	2.8
	 Paragraph IV Certification
	  	7.6

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 13 

			
	 Definition
	  	Section
		
	 Percentage Reduction of Net Sales
	  	6.7.2(c)
	 Phase 3 Notice
	  	5.2
	 Recovery
	  	7.3.5
	 Reduction in Royalty
	  	6.7.2(c)
	 Rib-X In-License Agreement
	  	6.7.3(b)
	 Representatives
	  	8.1
	 Rib-X Indemnitees
	  	10.1
	 Royalty Term
	  	6.7.2
	 Sanofi Indemnitees
	  	10.2
	 Selling Party
	  	1.52
	 Sole Compound Product
	  	1.52
	 Standard Increase
	  	5.3.1(a)
	 Third Party Research Costs
	  	2.4
	 [***]
	  	5.3.1(a)

 ARTICLE II - RESEARCH PROGRAM 

2.1 Overview. The objective of the Research Program is to identify [***] Candidate Compounds. 

2.2 Conduct of Research Program. During the Research Term, each Party will use Commercially Reasonable Efforts to conduct the
activities which are assigned to such Party under the then-current Research Plan. During the course of the Research Program, subject to the requirements of the Research Plan and this Agreement, each Party will have sole decision-making authority
with respect to day-to-day conduct of the Research activities allocated to it under the Research Plan. 
 2.3 Research
Plans. The initial Research Plan is attached hereto as Exhibit A. Periodically, during the Research Term, the JSC will review the Research Plan, and prepare and approve updates to the Research Plan. If the JSC cannot agree on a revised
Research Plan, then the dispute will be resolved in accordance with the mechanism of Article XII. 
 2.4 Costs. Each
Party will pay its own internal costs associated with the activities allocated to it under the Research Plan. Each Party will be responsible for Third Party costs it incurred in the conduct of the Research Program (“Third Party Research
Costs”) in accordance with the Research Plan. 
 2.5 Know-how Exchange. Rib-X will make available to Sanofi all
Rib-X Know-how listed in Exhibit E as well as any other Rib-X Know-how reasonably requested by Sanofi. In addition, during the Research Term, each Party will share with the other Party such Rib-X Know-how or Sanofi Know-how, as the case may
be, as is specifically related to Target Compounds and is developed, acquired or generated by or on behalf of such Party in the course of the Research Program, such Know-how to be provided in such format as the Parties will mutually agree. Results
of Research will also be exchanged via status reports and JSC reporting 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 14 

 
as set forth in Section 3.6. Notwithstanding anything in this Agreement to the contrary, Rib-X will not have any obligation to transfer to Sanofi any Rib-X Know-how or any other Know-how
Controlled by Rib-X related to or arising from the methodology necessary for crystallization and analysis of the crystal structure of the ribosome. For the sake of clarity, Rib-X will have no obligation to share any Know-how with Sanofi after the
JSC has been disbanded and all Development and Commercialization Options have expired unexercised. 
 2.6
Record-keeping. All Research activities conducted by either Party under the Research Plan will be completely and accurately recorded in separate laboratory notebooks, in sufficient detail and in good scientific manner appropriate for patent
and regulatory purposes. Upon reasonable advance notice, and at reasonable intervals, each Party will have the right to inspect and copy such records of the other Party reflecting work done under the Research Plan, to the extent reasonably required
to carry out its respective obligations and to exercise its respective rights under this Agreement.  
 2.7 Nomination
of Candidate Compound. 
 2.7.1 By JSC. At such time as a Target Compound is shown in the course of the Research
Program to meet or exceed one or more of the Target Profiles, the JSC will review the data generated under the Research Program with respect to such compound, and will nominate such Target Compound as a Candidate Compound. 

2.7.2 By Sanofi. Notwithstanding anything to the contrary set forth in Section 2.7.1, Sanofi will have the right at any time
during the Research Term to nominate as a Candidate Compound any Target Compound that has met or exceeds one or more Target Profiles or otherwise has antibacterial activity, whether or not the JSC has agreed to take such actions. 

2.8 Development and Commercialization Option. Rib-X hereby grants to Sanofi an exclusive right, but not the obligation,
exercisable during the Research Term to acquire from Rib-X the license set forth in Section 4.2.1 with respect to each Candidate Compound, subject to the terms and conditions of this Agreement (each, a “Development and Commercialization
Option”). Each Development and Commercialization Option will be exercisable as to a particular Candidate Compound during the Research Term. In the event Sanofi elects to exercise its Development and Commercialization Option as to a
particular Candidate Compound, Sanofi will, no later than the close of business on the last day of the Research Term, deliver to Rib-X (i) a written notice specifying that Sanofi has elected to exercise its Development and Commercialization
Option as to such Candidate Compound (the “Option Exercise Notice”) and (ii) payment in full of the Option Exercise Fee for such Candidate Compound. In addition, for each Candidate Compound as to which Sanofi has exercised its
Development and Commercialization Option under the preceding sentence, Sanofi will be entitled to designate two Back-up Compounds to such Candidate Compound to include as Licensed Compounds, such designation to be made by written notice given to
Rib-X at any time during the Research Term or Follow-on Period. For the sake of clarity, no additional Option Exercise Fee will be due for the [***] ([***]) designated Back-up Compounds to a Candidate Compound as to which Sanofi exercises its
Development and Commercialization Option, and these [***] ([***]) designated Back-up Compounds will be treated as Licensed Compounds as long as the Option Exercise Fee 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 15 

 
has been paid with respect to the corresponding Candidate Compound. The date, if any, on which Sanofi has properly exercised its Development and Commercialization Option in accordance with the
preceding sentence will be the “Option Exercise Date” for such Licensed Compound for purposes of this Agreement. On the Option Exercise Date, the License Term will be deemed to have commenced as to the relevant Licensed Compounds.
In addition to the rights set forth above in this Section 2.8, during the [***] of the Research Term, all Target Compounds shall be deemed Candidate Compounds, thereby allowing Sanofi to exercise its Development and Commercialization Option on
all such compounds and receive the license set forth in Section 4.2.1 for any such Target Compound as to which Sanofi exercises its Development and Commercialization Option prior to the end of the Research Term. 

2.9 Limitation on Activities During Option Period. Notwithstanding anything in this Agreement to the contrary, Sanofi will not
have the right to conduct, or have conducted, GLP toxicology studies, or any clinical studies with respect to any Target Compound unless such Target Compound has become a Licensed Compound in accordance with Section 2.8. 

2.10 Effectiveness of License. Commencing on the Option Exercise Date with respect to each Licensed Compound, the provisions set
forth in Article I and Articles III - XIII of this Agreement will constitute the terms and conditions of the license granted by Rib-X to Sanofi with respect to Licensed Products based on such Licensed Compound in the Field. 

2.11 Returned Compounds. Notwithstanding anything in this Agreement to the contrary, the right of the JSC and Sanofi to nominate
Candidate Compounds and the right of Sanofi to exercise a Development and Commercialization Option with respect to any Candidate Compound will terminate at the end of the Research Term. At the end of the Research Term, all rights to all Target
Compounds, including Collaborations Compounds, that have not become Licensed Compounds, will belong to Rib-X, including through the assignment provisions set forth in Section 4.2.3 subject to Sanofi’s right of first negotiation under
Section 4.7 and the restrictions on Rib-X under Section 4.6. 
 2.12 Use of Third Parties. Neither Party nor
any of its Affiliates will use any Third Party to perform Research activities under the Research Program unless specifically authorized in the Research Plan or otherwise authorized by the JSC. In the event a Party is permitted to use a Third Party
to perform Research activities under the preceding sentence, such Party will ensure that any Know-how or Patent Rights related to Target Compounds arising from the activities of such Third Party are assigned to the contracting Party with no rights
retained by the Third Party. 
 ARTICLE III - GOVERNANCE; DECISION-MAKING 

3.1 Formation and Membership. Within twenty (20) Business Days after the Effective Date, Sanofi and Rib-X will establish a
joint steering committee (the “JSC” or “Joint Steering Committee”). The JSC will be comprised of three (3) members from Sanofi and three (3) members from Rib-X, or such other number, maintaining equal
representation, as the Parties mutually agree, each such member appointed by a Party to have an appropriate level of decision making authority within such Party’s organization. Each Party may change any one or more of its representatives to the
JSC at any time upon written notice to the other Party. From time to 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 16 

 
time, the JSC may, in its discretion, establish one or more subcommittees or project teams to coordinate and monitor particular projects or activities over which the JSC has authority, as the JSC
deems necessary or advisable, each of which will report to the JSC and, unless otherwise agreed upon by the JSC, the provisions of this Article III will apply to such subcommittee to the same extent as such provisions apply to the JSC. 

3.2 Responsibilities. The JSC will have the following responsibilities: 

(i) review, coordinate, monitor and provide overall strategic direction to the Parties’ activities under the
Research Program; 
 (ii) serve as a forum for an exchange and discussion of the results of the Research
Program; 
 (iii) serve as a forum for updates from Sanofi on its Development and commercialization activities
related to Licensed Products; and 
 (iv) if Rib-X exercises its US Profit Share Option, then the JSC shall
oversee the Development and Commercialization of the US Profit Share Product in the United States, including the approval of Development Plans, Commercialization Plans, related budgets, the design of clinical studies, and the content of proposed
regulatory filings, and to serve as a forum for review of all results of clinical studies and for updates on activities outside the United States, in each case with respect to the US Profit Share Product. 

For the sake of clarity, it is expected that, with respect to the sharing of information regarding the US Profit Share Product, each
Party will, through the JSC, and through regular communication between each Party’s designated Alliance Manager, keep the other Party informed, at a detail level, about all activities related to the Development, Manufacture and
Commercialization of the US Profit Share Product in the United States, including those activities related to Development, Manufacture or commercialization of the US Profit Share Product outside the United States that are relevant to or may affect
Development, Manufacture or Commercialization of the US Profit Share Product in the United States. 
 3.3 Administrative
Matters. The JSC will appoint a chairperson from among its members, who will be designated by Rib-X during the Research Term and thereafter will be designated by Sanofi. The chairperson will be responsible for calling meetings of the JSC and for
leading the meetings, but will otherwise have no greater authority on the JSC than any other member. A JSC member of the non-chairing Party will serve as secretary of such meetings. The secretary will promptly prepare and distribute to all members
of the JSC draft minutes of the meeting for review and comment, including a list of any actions or decisions approved by the JSC, with the goal of distributing final approved minutes of each JSC meeting within fifteen (15) days after the
meeting. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 17 

 3.4 Meetings. 

3.4.1 Schedule. The JSC will meet at least once per Calendar Quarter during the Research Term, and twice per Calendar Year
thereafter. The location of JSC meetings will be as agreed by the Parties, and may be held in person, alternating locations between the Parties, or by telephone conference call or by videoconference. In addition, within fifteen (15) days after
the end of the Research Term, the JSC shall meet to discuss, exchange and finalize the following information: (i) status of wind-up activities; and (ii) a list of all then existing Returned Compounds indicating which of such Returned
Compounds are Value Added Compounds, as well as a list of related Sanofi Patent Rights. 
 3.4.2 Attendance and Expenses.
Each Party will use reasonable efforts to cause its representatives to attend the meetings of the JSC. In addition, each Party may, at its discretion, invite a reasonable number of non-member employees, and, with the consent of the other Party,
consultants or scientific advisors, to attend meetings of the JSC or the relevant portion thereof; provided, that any such consultants or scientific advisors are bound by written obligations of confidentiality and restrictions on use of Confidential
Information that are at least as stringent as those set forth in Article VIII. Each Party shall be responsible for all travel and related costs for its representatives to attend meetings of, and otherwise participate on, the JSC or any subcommittee
thereof. 
 3.4.3 Special Meetings. Either Party may also request that a special meeting of the JSC be convened for the
purpose of reviewing or making a decision pertaining to any matter within the purview of the JSC, or resolving any dispute related to any such matter, by providing written notice to the other Party. Such meeting will be convened at such time as may
be mutually agreed upon by the Parties, but in any event will be held within fourteen (14) days after the date of such notice. 
 3.5 Decision Making. Each Party will have one (1) vote on the JSC. Any action by the JSC will require unanimous vote. No vote will be taken without at least one member from each Party being
present. Action on any matter may be taken at a meeting, by teleconference, videoconference or by written agreement. In the event of any dispute at the JSC, the terms of Article XII will apply, except that, in the event the JSC cannot agree on an
amendment to the Research Plan and the dispute is not resolved by agreement of the Executives under Section 12.1 [***]. 

3.6 Status Reports. During the Research Term, prior to each quarterly meeting of the JSC, each Party will prepare and deliver to
the members of the JSC a written report describing the status and results of such Party’s Research and Development activities since the last report. After first exercise by Sanofi of a Development and Commercialization Option, Sanofi’s
report to the JSC will also include a summary of the status and results of Sanofi’s development and manufacturing activities, including those of its Affiliates and Sublicensees, with respect to each Licensed Product. After the Research Term and
until exercise by Rib-X of its US Profit Share Option, Sanofi will also provide as part of the foregoing status report a then-current budget for the projected costs of Development activities related to each Licensed Product. In the event Rib-X
exercises its US Profit Share Option, each Party’s report to the JSC will also include the status 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 18 

 
and results of its activities related to Development, Manufacture and Commercialization of the US Profit Share Product. Each report given under this Section may be provided in any reasonable
written form as determined by the reporting Party. Each Party will provide the members of the JSC with copies, which may be in electronic format, of all materials it intends to present at a JSC meeting. The JSC may also request at any time specific
data or information related to activities contemplated under this Agreement, and the Party or appropriate committee to whom such request is made will promptly provide to the other Party or the JSC such data or information. All data provided pursuant
to this Section 3.6 shall be in a reasonable format specified by Sanofi. 
 3.7 Alliance Managers. 

3.7.1 Appointment. Each of the Parties will appoint a single point of contact for coordination of activities and to facilitate the
effective exchange of information between the Parties related to the Research Program (each, a “Alliance Manager”). Each Party may change its designated Alliance Manager from time to time upon written notice to the other Party.

 3.7.2 Responsibilities. The Alliance Managers will: (i) coordinate the interactions between the relevant
functional representatives of the Parties; (ii) identify and bring disputes to the attention of the JSC in a timely manner; (iii) assist with governance activities, such as the conduct of required JSC meetings and drafting of meeting
minutes; (iv) ensure that relevant action items resulting from such meetings are appropriately carried out or otherwise addressed; and (v) serve as the initial point of contact to resolve any disputes between the Parties. The Alliance
Managers may also be members of the JSC. 
 ARTICLE IV - LICENSES AND ASSIGNMENTS 

4.1 Research Licenses. 
 4.1.1 To Sanofi. Subject to the terms and conditions of this Agreement, Rib-X hereby grants to Sanofi and its Affiliates a co-exclusive (with Rib-X) worldwide, fully paid-up right and license,
without the right to grant sublicenses except as specifically authorized in the Research Plan, under the Rib-X Licensed Technology and Rib-X’s interest in Joint Technology, solely to enable Sanofi and its Affiliates to conduct the activities
allocated to Sanofi under the Research Plan during the Research Term. 
 4.1.2 To Rib-X. Subject to the terms and
conditions of this Agreement, Sanofi hereby grants to Rib-X and its Affiliates a co-exclusive (with Sanofi), worldwide, fully paid-up right and license, without the right to grant sublicenses except as specifically authorized in the Research Plan,
under the Sanofi Licensed Technology, solely to enable Rib-X and its Affiliates to perform the activities allocated to Rib-X under the Research Plan during the Research Term. 
 4.1.3 Limitation on Know-how transfer. For the sake of clarity, notwithstanding anything in this Agreement to the contrary, Rib-X will not have any obligation to transfer to Sanofi any Rib-X
Know-how related to or arising from the methodology necessary for crystallization and analysis of the crystal structure of the ribosome. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 19 

 4.2 Development and Commercialization Licenses. 

4.2.1 To Sanofi. Subject to the terms and conditions of this Agreement, including Section 4.2.2, Rib-X hereby grants to
Sanofi an exclusive (even as to Rib-X), worldwide, royalty-bearing right and license, in the Field and throughout the Territory, with the right to grant sublicenses (solely in accordance with Section 4.3), under the Rib-X Licensed Technology
and Rib-X’s interest in Joint Technology to develop, make, have made, use, market, import, sell and have sold, Licensed Compounds and Licensed Products. 
 4.2.2 To Rib-X With Respect to US Profit Share Product. In the event, Rib-X exercises its US Profit Share Option, Sanofi hereby grants to Rib-X a co-exclusive (with Sanofi), royalty-free (subject
to the Profit/Loss Share Percentage) right and license, during the Term in the United States, with the right to grant sublicenses (solely in accordance with Section 4.3) under the Sanofi Licensed Technology solely to perform the activities
allocated to Rib-X with respect to such US Profit Share Product in accordance with the applicable Development Plan and Commercialization Plan. 
 4.2.3 Assignment to Rib-X of Sanofi Compound Specific Patent Rights and License Grant under Sanofi Licensed Technology. Effective at the end of the Research Term, Sanofi (i) assigns to Rib-X
all right, title and interest of Sanofi and its Affiliates in all Sanofi Compound Specific Patent Rights Covering Returned Compounds and (ii) will be deemed to have granted to Rib-X an exclusive worldwide, fully paid-up, royalty-bearing (to the
extent specified in Section 6.9) right and license, with the right to grant sublicenses, under the relevant Sanofi Licensed Technology to develop, make, have made, use, market, import, sell and have sold products comprising or incorporating
Returned Compounds. Upon assignment under this Section the relevant Sanofi Compound Specific Patent Rights shall become Patent Rights or Know-how, as the case may be, of Rib-X. Sanofi agrees to take, and to cause its employees, Affiliates or
Sublicensees, to take, all such reasonable actions and execute all such documents, as Rib-X may from time to time reasonably request to effect the provisions of this Section. Promptly following the end of the Research Term and during the Follow-on
Period, Sanofi shall provide to Rib-X any Sanofi Know-how that is related to the Returned Compounds to the extent not previously shared with Rib-X, provided that the foregoing obligation will be limited to transfer of documented Sanofi Know-how in
the possession of Sanofi and its Affiliates and Sublicensees, and will not be deemed to create an obligation on the part of Sanofi to teach or train Rib-X in the practice of such Know-how. 

4.3 Sublicensing Rights. 
 4.3.1 Research Period. Neither Party may grant sublicenses under the rights granted to it by the other Party under Sections 4.1 except as expressly set forth in the Research Plan or otherwise with
the prior written consent of the other Party. 
 4.3.2 Licensed Products. Except as set forth in Section 4.3.3,
Sanofi will, have the right to grant sublicenses under the rights granted to it under Section 4.2.1 with respect to such Licensed Product, to develop, manufacture, have manufactured, use, commercialize or import such Licensed Product in the
Field in the Territory (i) to its Affiliates (with the right to 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 20 

 
further sublicense) and (ii) to a Sublicensee without the right to grant further sublicenses. Sanofi and its Affiliates will provide to Rib-X written notice of any agreement with a
Sublicensee reflecting each such license or sublicense promptly after the execution thereof. If Sanofi or any of its Affiliates grants such a license or sublicense, all of the relevant terms and conditions of this Agreement will apply to each such
Affiliate or Sublicensee to the same extent as they apply to Sanofi, and Sanofi will require each such Affiliate and Sublicensee to agree in writing to the foregoing. Without limiting the foregoing, each sublicense agreement will contain the
following provisions: (i) an obligation of the Sublicensee to assign to Sanofi at the end of the Research Term, with the right to further assign to Rib-X, any Patent Rights Covering the composition of matter or method of manufacture or use of
any Returned Compounds, provided such Patent Rights do not also Cover the composition of matter or method of manufacture or use of any other compound; and (ii) a license grant to Sanofi with respect to Know-how and Patent Rights Controlled by
such Sublicensee, with the right to grant a sublicense to Rib-X, such license from the Sublicensee to be triggered automatically by an obligation of Sanofi to grant a license to Rib-X under this Agreement, but solely to the extent such Know-how and
Patent Rights of the Sublicensee will fall within the Sanofi Know-how and Sanofi Patent Rights being licensed to Rib-X once Sanofi obtains Control from such Sublicensee. Sanofi assumes full responsibility for the performance of all obligations so
imposed on each Affiliate and Sublicensee and will itself pay and account to Rib-X for all payments due under this Agreement by reason of operation of any such sublicense. 
 4.3.3 US Profit Share Products. Neither Party will have the right to grant sublicenses with respect to US Profit Share Products in the United States unless mutually agreed upon by the Parties.

 4.4 Rights Retained by the Parties. 
 4.4.1 By the Parties. Any rights of Rib-X or Sanofi, as the case may be, not expressly granted to the other Party pursuant to this Agreement will be retained by the Party that owns such rights.

 4.4.2 Yale Retained Rights. All licenses granted by Rib-X under this Agreement are subject to the rights retained by
Yale and Howard Hughes Medical Institute under Section 3.3 of the Yale Agreement. 
 4.4.3 Government Rights. All
licenses granted by Rib-X under this Agreement are subject to a nonexclusive, irrevocable, royalty-free license previously granted by Yale to the U.S. Government, a copy of which is attached to the Yale Agreement. 

4.5 Diligence. Sanofi will use Commercially Reasonable Efforts to Develop, obtain Regulatory Approval for, and commercialize each
Licensed Compound in the Field in the Major Countries. 
 4.6 Exclusivity. 

(a) During Research Term. Subject to Sections 4.6(d) and 13.8(c) and except as contemplated by the Research Plan,
during the Research Term, neither Party 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 21 

 
nor any of its Affiliates will conduct any research or development activities, fund any such activities by a Third Party, or grant any rights to a Third Party to the extent directed at the
research, development, manufacture, commercialization or use of a RX04 Compound. 
 (b) During the Follow-on
Period. Subject to Sections 4.6(d) and 13.8(c), during the Follow-on Period, neither Party nor any of its Affiliates will conduct any research or development activities, fund any such activities by a Third Party, or grant any rights to a Third
Party, to the extent directed at the research, development, commercialization or use of any RX04 Compound other than Licensed Compounds. 
 (c) During the Term. Notwithstanding anything to the contrary, during the Term, Rib-X shall not, directly or indirectly, either by itself or with another party, commercialize, seek to
commercialize, or grant another party any rights to commercialize, any compound which otherwise satisfies the criteria set forth in (i), (ii), (iii) and (iv) of the definition of “Back-up Compound” with respect to a Licensed
Compound, including any prodrugs of such compounds. 
 (d) Effect of Termination for Breach.
Notwithstanding anything in this Agreement to the contrary, in the event of a termination of this Agreement for breach under Section 11.2.2 or for bankruptcy of the other Party under Section 11.2.4 or a termination of this Agreement by
either Party under Section 11.2.5, the provisions of this Section 4.6 shall not apply to the terminating Party, but shall apply only as to the breaching Party in the case of a termination under Section 11.2.2, or the Party subject to
bankruptcy proceedings in the case of a termination under Section 11.2.4 or Sanofi, in the case of termination of this Agreement under Section 11.2.5. 
 4.7 Right of First Negotiation. During the Follow-on Period, Sanofi will have the first right to negotiate for a license to any RX04 Compound owned or Controlled by Rib-X. In the event Sanofi
desires to exercise its right of first negotiation as to any RX04 Compound during the Follow-on Period, Sanofi shall provide written notice to Rib-X of Sanofi’s desire to enter into negotiations for a license to a specified RX04 Compound (the
“Exercise Notice”). In the event Sanofi exercises its right of first negotiation by delivering the Exercise Notice to Rib-X during the Follow-on Period, the Parties shall enter into good faith negotiations on the mutually agreeable
terms of a definitive agreement. In the event the Parties cannot reach agreement on the terms of a definitive agreement despite good faith negotiations within ninety (90) days from the date of delivery of the Exercise Notice, Sanofi’s
right of first negotiation shall terminate as to such RX04 Compound. Upon expiration of the restrictions set forth in Section 4.6, Rib-X shall thereafter be free to license to any Third Party Rib-X’s rights with respect to any RX04
Compound which is not the subject of a further definitive agreement between the Parties executed in connection with this Section. 
 4.8 Section 365(n) of the Bankruptcy Code. All rights and licenses expressly granted pursuant to any section of this Agreement are rights and licenses to “intellectual property” (as
defined in Section 101(35A) of title 11 of the United States Code (the “Bankruptcy Code”)). Each Party will retain and may fully exercise all of its rights and elections under the Bankruptcy

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 22 

 
Code. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party or its Affiliates under the Bankruptcy Code or analogous provisions of
Applicable Law outside the United States, the other Party, as a licensee under such bankrupt Party’s intellectual property, will be entitled to a complete duplicate of (or complete access to, as appropriate) such specifically licensed
intellectual property and all embodiments of such intellectual property, which, if not already in such licensee Party’s possession, will be promptly delivered to it upon such licensee Party’s request therefor. For clarity, so long as this
Agreement has not expired or terminated by its terms prior to the date on which a case under the Bankruptcy Code is commenced, and so long as both Parties remain subject to material obligations hereunder (i.e., Rib-X’s obligation to license the
Rib-X Licensed Technology and Sanofi’s obligation to make royalty payments on Licensed Products), this Agreement shall be recognized as an executory contract. 
 ARTICLE V - PROFIT-SHARE OPTION 
 5.1 US Profit Share Option. Rib-X
will have the option to co-develop and co-promote one Licensed Product with Sanofi, in the United States, under a single trademark approved by Sanofi, in accordance with a joint Development Plan and Commercialization Plan for such Licensed Product.
(the “US Profit Share Option”). 
 5.2 Data Package and Option Period. Rib-X will have a US Profit Share
Option with respect to each Licensed Product until Rib-X has exercised its US Profit Share Option for one Licensed Product, after which such exercise Rib-X will no longer have a US Profit Share Option for any other Licensed Product. Until Rib-X has
exercised its US Profit Share Option, Sanofi will provide Rib-X with a written notice (the “Phase 3 Notice”) that a Phase 3 Clinical Trial is planned along with the following information (the “Data Package”) at
least [***] ([***]) days prior to the commencement of the first Phase 3 Clinical Study of each Licensed Product: (i) a statement of [***] as of such date; (ii) a proposed Development Plan for Development of such Licensed Product through
First Commercial Sale, which such Development Plan will include a detailed Clinical Trial plan, a proposed description of activities, [***] (the “Initial Development Plan”); (iii) the following data and documentation regarding
non-clinical (including preclinical) and clinical Development activities: (a) the table and listings from the locked database for the most recently completed Phase 2 Clinical Trial; (b) a report describing the data and results of all other
Phase 2 Clinical Trials for such Licensed Product; and (c) all other significant data with respect to such Licensed Product which is equivalent, in all material respects, to that data which [***]; and (iv) the most recent market research
report, if any, prepared by or for Sanofi related to such Licensed Product. Rib-X understands that the Development Plans and [***] provided under clause (ii) of the preceding sentence are projections and estimates provided for informational
purposes only and are subject to modification and amendment by Sanofi. Sanofi will also provide Rib-X the opportunity to discuss the foregoing information with Sanofi in a face-to-face meeting to occur within twenty (20) days of Sanofi’s
receipt of written request from Rib-X, which such written request will be delivered to Sanofi no later than thirty (30) days after Rib-X’s receipt of the Data Package. Rib-X may exercise its US Profit Share Option as to the Licensed
Product that is the subject of the “Phase 3 Notice”, by, no later than [***] ([***]) days after Rib-X’s receipt of the Data Package (the “US Profit Share Option Exercise Date”), delivering to Sanofi the following:
(1) written notice of such exercise; (2) [***] (3) [***] 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 23 

 
percent ([***]%) of the Commercialization efforts in the U.S. involving interface with customers, as described in Section 5.6.1; provided, however that if Rib-X’s sales force is not
fully operational [***], then (i) all rights granted to Rib-X upon the exercise of such US Profit Share Option shall be null and void with no further effect, and (ii) Sanofi shall reimburse Rib-X for [***]% of the Pre-Opt-in Development
Costs. 
 5.3 Development of US Profit Share Product. 

5.3.1 For the United States. In the event Rib-X exercises its US Profit Share Option, Sanofi will continue to have responsibility
for conduct of the Development activities, but will, after the US Profit Share Option Exercise Date, perform Development activities under the relevant Development Plan and subject to the oversight of the JSC. The Initial Development Plan, as
included in the Data Package, will be the initial Development Plan governing activities after the US Profit Share Option Exercise Date, provided that the JSC will meet within thirty (30) days of the US Profit Share Option Exercise Date to
update the Initial Development Plan and the accompanying [***], based on proposed substantive amendments submitted by both Parties with the goal of minimizing costs while achieving Regulatory Approval of the US Profit Share Product as soon as
possible and ultimately maximizing the profitability of such US Profit Share Product (the “Development Plan Guidelines”). Thereafter the JSC will review the Development Plan not less frequently than annually at least ninety
(90) days prior to the beginning of any Calendar Year, and shall develop updates with the input of both Parties, such updates to include an overall description of Development activities; and a [***] using a level of detail consistent with
Sanofi’s then current practices. Notwithstanding anything in this Agreement to the contrary, and subject to 5.3.1(a), if the JSC cannot agree on an update to a Development Plan ([***]), including an update to the Initial Development Plan, then
the Executives shall use reasonable efforts to resolve the matter within ten (10) Business Days after the matter is referred to them, and if the Executives cannot resolve any such matter within ten (10) Business Days, the matter shall be
decided by the Executive of Sanofi. 
 (a) If Sanofi, in its reasonable judgment, would like to increase the
[***] plus [***] percent ([***]%). The Development Loan shall be fully creditable by Sanofi against any future payments to Rib-X under this Agreement, including payments then due but not yet paid, and including profit sharing payments under
Section 6.8. For purposes hereof, “Standard Increase” means an increase in then current approved budget for Shared Development Costs (i) for the then current Calendar Year in excess of [***] percent ([***]%), (ii) for
the first Calendar Year after the current Calendar Year in excess of [***] percent ([***]%). Sanofi’s “[***]” shall equal the [***]. For purposes of clarity, Sanofi shall have no obligation to loan Rib-X any funds for increases in
budgeted Shared Development Costs of Year 3 or Year 4 of any Development Plan. 
 5.3.2 Outside the United States. Sanofi
will have sole decision-making authority with respect to Development, Manufacture or commercialization of a US Profit Share Product outside the United States. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 24 

 5.3.3 Safety Information Sharing. Sanofi will be responsible for maintaining the
global safety database for the US Profit Share Product in compliance with all Applicable Laws. 
 5.4 Shared Development
Costs. Rib-X will pay [***] percent ([***]%) and Sanofi will pay [***] percent ([***]%) of all Shared Development Costs to the extent incurred after the US Profit Share Option Exercise Date. Commencing upon the US Profit Share Option Exercise
Date, each Party will report its actual Shared Development Costs to the other Party within thirty (30) Business Days after the end of each Calendar Quarter in each case tracked by activity to the amounts for such activities shown on the then
current Development Plan. Notwithstanding the foregoing, within fifteen (15) Business Days after the end of the third month of each Calendar Quarter, Rib-X and Sanofi will each provide to the other an estimate of Shared Development Costs for
such Calendar Quarter. The Parties will seek to resolve any questions related to any such reports within ten (10) Business Days after receipt. If a balancing payment is due to ensure that the Shared Development Costs have been allocated in
accordance with the first sentence of this Section, the Party due the payment will invoice the other Party at the end of each Calendar Quarter for such other Party’s share of Shared Development Costs for such Calendar Quarter calculated in
accordance with this Section, and such paying Party will pay amounts due with respect to Shared Development Costs under this Section within forty-five (45) days after receipt of the corresponding invoice. 

5.5 Record-Keeping. All Development activities conducted by either Party with respect to a US Profit Share Product will be
completely and accurately recorded, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes. Upon reasonable advance notice, and at reasonable intervals, each Party will have the right to inspect and copy
such records of the other Party reflecting on work done under the Development Plan, to the extent reasonably required to carry out its respective obligations and to exercise its respective rights hereunder. 

5.6 Commercialization of US Profit Share Product. 
 5.6.1 Co-commercialization Right. In the event Rib-X exercises its US Profit Share Option, Rib-X must participate equally in those Commercialization efforts with respect to the US Profit Share
Product in the U.S. that involve interfacing with customers, including Detailing, use of medical science liaisons (collectively, “Face-to-face Customer Activities”). Sanofi shall determine and establish the price and terms of sale
for the US Profit Share Product in the US, including any rebates and discounts, and will maintain control of all managed care interactions. Rib-X shall have the right to participate in any material meetings or the preparation of any material
meetings or the preparation of and material submissions to governmental authorities or managed care organizations relating to pricing in the US for the US Profit Share Product. At least [***] ([***]) days prior to the filing for Regulatory Approval
of a US Profit Share Product the JSC (or its designate the JCC) shall prepare an initial Commercialization Plan allocating to Rib-X and its Affiliates [***] percent ([***]%) of the Face-to-face Customer Activities related to Commercialization of the
US Profit Share Product in the U.S. Prior to Regulatory Approval of the US Profit Share Product in the U.S., the Parties will execute a Co-promotion Agreement that describes in more detail the roles and responsibilities of the Parties for
Commercialization of the US Profit Share Product under this Section. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 25 

 5.6.2 US Profit Share Commercialization Plans. The JSC shall appoint a Joint
Commercialization Committee (“JCC”) whose purpose is to propose the US Profit Share Product Commercialization Plan to the JSC. Notwithstanding anything in this Agreement to the contrary, if the JCC cannot agree on Commercialization
Plan (and budget), then the Executives shall use reasonable efforts to resolve the matter within ten (10) Business Days after the matter is referred to them, and if the Executives cannot resolve any such matter within ten (10) Business
Days, the matter shall be decided by the Executive of Sanofi, subject to Section 12.2.2. The JCC shall consist of at least two executives from each Party and their responsibilities shall consist of 

(a) Developing the commercialization strategy of the US Profit Share Product in the US; 

(b) Developing the forecasts for the supply requirements and allocating the Face-to-face Customer Activities; 

(c) Reviewing any post marketing clinical development or investigator initiated trials; and 

(d) Validating plans and policies regarding journal and other publications in concert with the JSC. 

5.6.3 Costs. Each Party will bear its own promotion costs associated with its Commercialization activities under the
Commercialization Plan except that each Party’s [***] will be factored into the calculation of Net Profit/Loss. 
 5.6.4
Net Profit/Profit Sharing. The Parties will share Net Profit/Losses in accordance with their respective Profit/Loss Share Percentage, subject to the terms of Section 6.8. 

5.6.5 Labeling and Trademark. To the extent permitted by Applicable Law, Sanofi will include the Rib-X name and logo on all
secondary packaging, literature, labels and other printed matter for the US Profit Share Product used in clinical Development in the U.S. or Commercialization in the U.S. Sanofi remains the owner of any trademark in the US for the US Profit Share
Product. 
 5.7 Sales and Distribution. Regardless of whether Rib-X exercises its US Profit Share Option, Sanofi will be
responsible for selling and booking all sales and for warehousing and distribution of US Profit Share Products in the Field in the U.S. 
 5.8 Promotional Materials. Sanofi shall be responsible for the creation, preparation and reproduction of all promotional materials, and Rib-X may review and comment on such materials prior to their
distribution through the JCC/JSC. Sanofi shall maintain all rights to promotional materials, including copyrights. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 26 

 ARTICLE VI - FINANCIAL PROVISIONS 

6.1 Initial License Payment. Sanofi will, within ten (10) Business Days of the Effective Date, make a non-refundable,
non-creditable payment to Rib-X of Ten Million Dollars ($10,000,000). 
 6.2 Research Milestone. Sanofi shall pay Rib-X
the following research milestone payments based on the progression of each [***] with each payment to be made on a per [***] basis. Each payment will be payable once for each [***] if the corresponding activity is completed with a [***] covered by
such [***] in accordance with Exhibit A. The payments will be due within ten (10) Business Days of receipt of written notice from Rib-X to Sanofi of the first completion of the corresponding activity with respect to each [***], as
follows: 
  

					
	 Research Milestone
	  	Research Milestone
Payment per [***]	 
		
	 (i)       First successful completion of a [***], provided that (i) with respect to a
[***] from any of the [***] described in Exhibit C, the steps set forth in the “Current Leads to Candidates: Flow Chart” of the Research Plan (the “Flow Chart”) that precede the [***] have been successfully
completed with respect to the same [***] or a different [***] in the same [***]; and (ii) with respect to a [***] from a New [***], the steps set forth in the Flow Chart that precede the [***] have been successfully completed with respect to
the same [***].
	  	US$	[***	] 
		
	 (ii)      First successful completion of a [***], provided that the steps set forth and highlighted
as “required” in the Flow Chart that precede such activity have been completed and the results of such highlighted steps would not block further development with respect to the same [***].
	  	US$	[***	] 

 6.3 Option Exercise Fee. Within ten (10) Business Days of each exercise by Sanofi of a
Development and Commercialization Option, Sanofi will pay to Rib-X an option exercise fee in the amount of US $[***] per [***] (and the [***]) as to which the relevant Development and Commercialization Option was exercised (the “Option
Exercise Fee”). By way of example, if Sanofi exercises its Development and Commercialization Option with respect to five (5) [***], the total amount of the Option Exercise Fee paid by Sanofi to Rib-X will be US $[***]. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 27 

 6.4 Milestone Payments. Sanofi will make the following non-refundable, non-creditable
payments to Rib-X upon the first achievement of each of the events set forth below with respect to each [***]: 
  

					
	 Milestone Event
	  	Payment	 
		
	 (i)       [***]:
	  	$	[***	] 
		
	 (ii)      [***]:
	  	$	[***	] 
		
	 (iii)     [***]:
	  	$	[***	] 
		
	 (iv)     [***]:
	  	$	[***	] 
		
	 (v)      [***]:
	  	$	[***	] 
		
	 (vi)     [***]:
	  	$	[***	] 

 For the sake of clarity, if a milestone related to a Clinical Trial or Regulatory Approval is reached
with respect to a Licensed Product, then, upon such event (if not earlier), any earlier stage Clinical Trial milestones will also be deemed to have been reached with respect to such Licensed Product for purposes of this Section, whether or not such
earlier milestone has actually occurred. For example, if Regulatory Approval for a Licensed Product is approved based on a Phase 2b Clinical Trial without a Phase 3 Clinical Trial, then upon Regulatory Approval, both the Regulatory Approval
milestone and the initiation of a Phase 3 Clinical Trial milestone will be paid. Notwithstanding the foregoing, if any of the above milestones have been met with respect to a Licensed Product as to which Development is subsequently terminated in
favor of [***] to such Licensed Compound, then Sanofi will not have any payment obligation with respect to achievement of those same completed milestones with respect to such Back-up Compound, but will be obligated to make milestone payments with
respect to those milestones that were not reached with the original Licensed Compound. 
 6.5 Sales Milestones Payments.
Sanofi will make the following non-refundable, non-creditable payments to Rib-X upon the first achievement of the events set forth below for each Licensed Product: 
  

					
	 Milestone Event
	  	Payment	 
		
	 (i)       Worldwide annual Net Sales of a single Licensed Product exceed
$[***]
	  	$	[***	] 
		
	 (ii)      Worldwide annual Net Sales of a single Licensed Product exceed $[***]
	  	$	[***	] 
		
	 (iii)     Worldwide annual Net Sales of a single Licensed Product exceed $[***]
	  	$	[***	] 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 28 

 Annual Net Sales for purposes of determining whether the milestones under this
Section 6.5 have been met will be based on Net Sales in the applicable Calendar Year. 
 6.6 Notification of
Achievement. Sanofi will notify Rib-X of achievement of any of the foregoing milestone events set forth in Section 6.4 or 6.5, and, except as otherwise specified, will pay to Rib-X the corresponding milestone payment, within thirty
(30) days of the date of achievements of such milestone event. 
 6.7 Licensed Product Royalties. 

6.7.1 Royalty Payment. Subject to adjustment as set forth in Section 6.7.2, and 6.7.3, Sanofi will pay to Rib-X royalties on
a Royalty-Bearing Product-by-Royalty-Bearing Product basis on the aggregate worldwide Net Sales of such Royalty-Bearing Products in a Calendar Year as follows: 
  

					
	 Portion of Aggregate Worldwide Net Sales of each Royalty-Bearing Product in a Calendar Year
	  	Royalty Rate	 
		
	 Less than $[***]
	  	 	[***	]% 
		
	 Equal to or greater than $[***] but less than $[***]
	  	 	[***	]% 
		
	 Equal to or greater than $[***] but less than $[***]
	  	 	[***	]% 
		
	 Equal to or greater than $[***]
	  	 	[***	]% 

 6.7.2 Royalty Term and Adjustments. 

(a) Royalty Term. Royalties under Section 6.7.1 will be payable, on a country-by-country and Licensed
Product-by-Licensed Product basis, commencing on the First Commercial Sale in such country of such Licensed Product and will expire, on a country-by-country basis, and Licensed Product-by-Licensed Product basis, on the later of: (i) the
expiration of the last Valid Claim within those Rib-X Patent Rights or Joint Patent Rights Covering the sale of such Licensed Product in the Field in such country; or (ii) the tenth (10th) anniversary of the date of the First Commercial
Sale of such Licensed Product in such country by or on behalf of Sanofi or any of its Affiliates or Sublicensees to a Third Party who is not a Selling Party (the “Royalty Term”). Thereafter, the license granted to Sanofi pursuant to
Section 4.2.1 will be fully-paid and royalty-free with respect to such Licensed Product in such country, on a Licensed Product-by-Licensed Product and country-by-country basis. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 29 

 (b) No Protection. Notwithstanding the foregoing, the royalty rate
applicable to Licensed Product will be reduced on a country-by-country and Licensed Product-by-Licensed Product basis by [***] percent ([***]%) during any portion of the applicable Royalty Term when there is no Valid Claim within the Rib-X Patent
Rights or Joint Patent Rights Covering such Licensed Product in the Field in the country of sale or country of manufacture and no other protective data or marketing exclusivity applies to such Licensed Product in the country of sale. 

(c) Generic Competition. Notwithstanding anything to the contrary, if a Generic Product corresponding to a Licensed
Product is launched in such particular country, then [***]. 
  

					
	 [***]
	  	[***]	 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 

 6.7.3 Third Party Payments. 

(a) Yale Agreement and Other Existing Rib-X Agreements. Rib-X will pay all amounts due under any agreements it has
entered into as of the Effective Date, including, but not limited to all payments Yale University under the Yale Agreement, provided that any amounts paid under the Yale Agreement with respect to Net Sales in the U.S. for the US Profit Share Product
will be treated as a Third Party and other Permitted Sales and Marketing Expense of Rib-X. 
 (b) Other Rib-X
In-licenses. [***]. 
 (c) Other Third Party Payments. [***]. 

6.7.4 Report and Payment. Sanofi will pay royalties pursuant to this Section 6.7 within forty-five (45) days after the
end of each Calendar Quarter with respect to applicable Net Sales received in such Calendar Quarter, along with a written report setting forth the Gross Sales, Net Sales and adjustments made pursuant to Sections 6.7.2 and 6.7.3 (if applicable), on a
Licensed Product-by-Licensed Product and country-by-country basis, and the total royalty payments payable to Rib-X. The report for the fourth (4th) Calendar Quarter in each Calendar Year will include a list of all countries in which a Licensed
Product has been sold in the Territory for the applicable Calendar Year. 
 6.8 Net Profit/Loss. The following provisions
of this Section 6.8 will apply with respect to the US Profit Share Product, if any. 
 6.8.1 Profit/Loss Share. Each
Party will share in Net Profit/Loss according to such Party’s Profit/Loss Share Percentage, continuing for as long as such Licensed Product is being Commercialized in the U.S. Exhibit F sets forth an example of the calculation of Net
Profit/Loss and of a Party’s Profit/Loss Share Percentage, and is provided solely for illustrative purposes. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 30 

 6.8.2 Accounting. Each Party will provide to the other Party within ten
(10) Business Days after the end of each month during a Calendar Quarter a reasonably detailed written report of the actual [***] for the US Profit Share Product incurred by such Party or its Affiliates during such month, and Sanofi will report
to Rib-X the total Net Sales for such month. Notwithstanding the foregoing, within four (4) Business Days after the end of the third month of each Calendar Quarter, Rib-X and Sanofi will each provide to the other an estimate of such amounts for
such third month. The Parties will seek to resolve any questions related to any such report within ten (10) Business Days after receipt thereof. Within twenty (20) Business Days after receipt of Rib-X’s report of actual amounts for
the third month of each Calendar Quarter, Sanofi will submit to Rib-X a written report setting forth in reasonable detail the calculation of Net Profit/Loss with respect to the US Profit Share Product and the calculation of the net amount owed by
Sanofi to Rib-X, taking into account [***] incurred by Rib-X, in order to ensure that the sharing of Net Profit/Loss is in accordance with each Party’s respective Profit/Loss Share Percentage. Sanofi’s written report will include the
following with respect to such Calendar Quarter for such Licensed Product: (i) [***] with respect to such Licensed Product, on a country-by-country basis, during such Calendar Quarter; (ii) a reasonably detailed written report [***]; and
(iii) [***] reported by both Parties. The net amount payable will be paid by Sanofi or Rib-X, as the case may be, within thirty (30) days after the end of the applicable Calendar Quarter. 

6.9 Royalty Payment by Rib-X. Rib-X shall pay to Sanofi a royalty of [***] percent ([***]%) on Net Sales by Rib-X and its
Affiliates and sublicensees of any product in the Field incorporating a “Value Added Compound”, in each case with the applicable definitions and the provisions of Section 6.7.2, 6.7.3, 6.7.4, 6.11 and 6.12 applying to such royalty
payments after making the necessary revisions to reflect the respective roles of the Parties. 
 6.10 Accounting.

 6.10.1 Late Payment. Each Party will pay interest on the aggregate amount of any payments that are owed to the other
Party under this Agreement and not paid on or before the tenth (10th) Business Day after which such payments are due under this Agreement at a rate per annum equal to the lesser of (a) the [***] for United States dollars, as reported by
The Wall Street Journal, Eastern Edition, plus [***], or (b) the highest rate permitted by Applicable Law, calculated on the number of days such payments are paid after the date such payments are due. 

6.10.2 Method of Payment. Royalties on Net Sales and all other amounts payable by either Party hereunder will be paid by or on
behalf of such Party in U.S. Dollars by electronic funds transfer to an account specified by the Party entitled to such payment. 
 6.10.3 Currency. All dollar ($) amounts specified in this Agreement are in U.S. dollars. In the case of sales outside the United States calculations of Net Sales to determine the payment of
sales milestones and royalties due hereunder shall first be determined in the currency of the country in which the Licensed Products in question were sold and then converted into 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 31 

 
equivalent U.S. funds. Any currency conversion will be made in a manner consistent with Sanofi’s normal practices used to prepare its audited financial statements for internal and external
reporting purposes, which uses a widely accepted source of published exchange rates. 
 6.11 Taxes. Rib-X shall bear any
and all taxes levied on account of any payment received under this Agreement. In the event that Sanofi is required, under Applicable Laws, to withhold any deduction or tax from any payment due to Rib-X under this Agreement, such amount shall be
deducted from the payment to be made by Sanofi, paid to the proper taxing authority, provided that Sanofi shall take reasonable and lawful actions to avoid and minimize such withholding and promptly notify Rib-X so that Rib-X may take lawful actions
to avoid and minimize such withholding. Sanofi shall promptly furnish Rib-X with copies of any tax certificate or other documentation evidencing such withholding as necessary to satisfy the requirements of the relevant governmental authority related
to any application by Rib-X for foreign tax credit for such payment. Each Party agrees to cooperate with the other Party in claiming exemptions from such deductions or withholdings under any agreement or treaty from time to time in effect.

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 32 

 6.12 Records and Inspection. 

6.12.1 Audit Rights. 
 (a) Each Party will keep, and will require its Affiliates and, with respect to Sanofi, its Sublicensees, to keep, full, true and accurate books of account containing all particulars that may be necessary
for the purpose of calculating the amounts payable by the other Party under this Agreement, including records underlying COGS, Third Party and Other Permitted Sales and Marketing Expenses, Pre-Opt-In Development Costs, Shared Development Costs, Net
Sales and the calculation of Net Profit/Loss, and, in the case of Sanofi, to enable Rib-X to confirm compliance with diligence obligations or to determine whether payment events have occurred. Such books of accounts will be kept at each Party’s
principal place of business for a period of at least three (3) full Calendar Years after the date on which the relevant cost was incurred or Net Sales was received or the relevant activity occurred. Each Party has the right to engage an
independent, certified public accountant selected by such Party and reasonably acceptable to the other Party to perform, on behalf of the auditing Party, an audit of such books and records of the audited Party and its Affiliates and, as applicable,
Sublicensees, that are deemed necessary by such accountant to report on the correctness of any report or payments made or to have been made under this Agreement. 

(b) The auditing Party will provide reasonable notice to the audited Party of any requested audit and will conduct such
audit during regular business hours in such a manner as to not unnecessarily interfere with the audited Party’s normal business activities. Any audit will be limited to records for the three (3) full Calendar Years prior to audit
notification. 
 (c) An auditing Party will not perform an audit more frequently than once per Calendar Year nor
more frequently than once with respect to records covering any specific period of time. 
 (d) The auditing Party
will use all such records of the audited Party only for the purpose of verifying payments due hereunder, and will treat such records as Confidential Information of the audited Party. The independent certified public accountant will only share the
results of the audit with the auditing party, not the underlying records. 
 (e) Any final audit report will be
shared by the auditing Party with the audited Party. 
 (f) Notwithstanding anything in this Agreement to the
contrary, Sanofi shall permit Yale to audit the books and records maintained by Sanofi and its Affiliates and Sublicensees under Section 6.12.1, to the same extent as Rib-X is entitled to conduct any such audit, and shall permit Rib-X to share
with Yale information obtained from Sanofi or any of its Affiliates or Sublicensees in connection with any audit. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 33 

 6.12.2 Over- or Underpayment. If the audit reveals an underpayment by a Party, such
Party will reimburse the other Party for the amount of the underpayment within thirty (30) days, with interest as set forth in Section 6.10.1 if such underpayment is by the audited Party and was due to an inaccuracy by the underpaying
Party. If the audit reveals an overpayment, the Party who received the overpayment will, as instructed by the other Party, either credit the amount of such overpayment against the next payment owed by it to such other Party, or refund such amount to
such other Party, in each case within thirty (30) days of receipt of instructions from the other Party, along with interest as set forth in Section 6.10.1 if such overpayment was due to an inaccuracy by the Party who received the
overpayment. 
 6.12.3 Costs. The costs of any audit will be paid by the auditing Party unless the underpayment of
amounts by the audited Party is determined to be greater than ten percent (10%) of the amount due for the entire period being audited, in which case the auditing Party will reimburse the audited Party for the audited Party’s reasonable
costs incurred in such audit. 
 ARTICLE VII - INTELLECTUAL PROPERTY MATTERS 

7.1 Ownership. Except as provided in the assignment provisions of Section 4.2.3, each Party will exclusively own all
inventions conceived or reduced to practice solely by employees, agents and consultants of such Party or its Affiliates, subject to the licenses granted under Article IV. Inventions conceived or reduced to practice jointly by employees, agents, or
consultants of the Parties or their Affiliates will be jointly owned, subject to the licenses granted under Article IV and the assignment provisions of Section 4.2.3 (the “Joint Inventions”). Inventorship will be determined in
accordance with U.S. patent laws. 
 7.2 Prosecution and Maintenance of Patent Rights. 

7.2.1 General. Except as set forth in Section 7.2.3, each Party shall be responsible for preparing, filing, prosecuting and
maintaining (including the defense of any interference or opposition proceeding) its own Patent Rights, at its expense and Rib-X shall be responsible for preparing, filing, prosecuting and maintaining Patent Rights describing and claiming Joint
Inventions, at Rib-X’s expense. Each Party shall file the Patent Rights within the scope of its authority related to composition of matter, method of use or method of manufacture of Target Compounds, and Rib-X shall file Patent Rights
describing and claiming Joint Inventions related to composition of matter, method of use or method of manufacture of Target Compounds, in each case in at least the countries and jurisdictions listed in Exhibit G. 

7.2.2 During the Research Term. During the Research Term, with respect to (i) Rib-X Patent Rights, (ii) Sanofi Patent
Rights; and (iii) Patent Rights that describe and claim Joint Inventions, in each case that describe and claim the composition of matter, or method of manufacture or use, of RX04 Compounds and are not otherwise covered by the provisions of
Section 7.2.3, each Party will provide to the other Party copies of all filings and material submissions and correspondence sent to or received from patent offices or Third Parties, and will provide the other Party with a draft of each such
filing or material submission or correspondence reasonably in advance of its submission or following its receipt. Each Party will consider in good faith any comments that the other Party may timely provide with respect to such filings and

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 34 

 
material submissions and correspondence and Rib-X will give effect to or, in the event of a disagreement with Sanofi’s comments, bring to the attention of the JSC, any comments that Sanofi
may timely provide with respect to Patent Rights describing and claiming Joint Inventions. In addition, each Party will provide to the other Party such other information related to prosecution of Patent Rights hereunder as the other Party may from
time to time reasonably request to allow the other Party to track prosecution and maintenance of such Patent Rights. Neither Party will discontinue prosecution or maintenance of any such Patent Rights without at least ninety (90) days prior
written notice to the other Party. On a country-by-country basis, if a Party decides to discontinue prosecution or maintenance of any subject matter claimed or disclosed in any such Patent Right prosecuted by such Party hereunder, then, unless such
subject matter is being abandoned in one application in favor of another application within the same group of Patent Rights, such Party will, at the written request of the other Party, made within thirty (30) days of receipt of written notice
from the prosecuting Party of such intended abandonment, transfer to the other Party all patent files, and execute any document, including relevant powers of attorney forms related to such Patent Rights, sufficiently in advance of any loss of rights
so that the other Party may, at its option, continue to prosecute and maintain such subject matter, in such other Party’s name, at such other Party’s sole expense. 
 7.2.3 During License Term. Following exercise by Sanofi of its Development and Commercialization Option as to a Licensed Compound, the following provisions will apply with respect to (i) Rib-X
Patent Rights, (ii) Sanofi Patent Rights; and (iii) Patent Rights that describe and claim Joint Inventions, in each case that specifically describe and claim the composition of matter, or method of manufacture or use, of such Licensed
Compound and at Sanofi’s cost: 
 (a) Promptly following the relevant Option Exercise Date, Sanofi will, at
its sole expense, have, and Rib-X will transition to Sanofi, the responsibility for, and control over, preparing, filing, prosecuting, and maintaining (including the defense of any interference or opposition proceeding) such Patent Rights, including
by obtaining power of attorney forms and other documentation required by the relevant patent offices for Sanofi to assume prosecution of such Patent Rights, in Sanofi’s name. 

(b) Sanofi will provide to Rib-X copies of all prosecution filings and material submissions and correspondence related to
Patent Rights being prosecuted by Sanofi under this Section 7.2.3(a) sent to or received from patent offices, and, with respect to patent applications, and material submissions, will use reasonable efforts to provide Rib-X with a draft of each
such filing or material submission reasonably in advance of submission, and will consider in good faith any comments that Rib-X may timely provide. In addition, Sanofi will provide to Rib-X such other information related to prosecution and
maintenance of such Patent Rights hereunder as Rib-X may from time to time reasonably request to allow Rib-X to track prosecution and maintenance of such Patent Rights. Sanofi will not discontinue prosecution or maintenance of any such Patent Rights
without at least ninety (90) days prior written notice to Rib-X. On a country-by-country basis, if Sanofi decides to discontinue prosecution or maintenance of any subject matter claimed or disclosed in any such Patent Right prosecuted by such
Party hereunder then, unless such subject matter is being abandoned in one application in favor of another 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 35 

 
application within the same group of Patent Rights, Sanofi will, at Rib-X’s written request made within thirty (30) days of receipt by Rib-X of written notice from Sanofi of such
intended abandonment, transfer to Rib-X all patent files, including relevant powers of attorney forms related to such Patent Rights, sufficiently in advance of any loss of rights so that Rib-X will have the option to continue to prosecute and
maintain such subject matter, at Rib-X’s sole expense, and, in such event, any Valid Claims directed to such subject matter will be assigned to Rib-X and thereafter will be excluded from Rib-X Patent Rights for purposes of the licenses and
rights granted to Sanofi and the royalties payable to Rib-X under this Agreement. 
 7.2.4 Patent Term Extensions. Rib-X
and Sanofi will discuss together whether and on which patent(s) to seek patent term extensions or supplemental patent protection, including supplemental protection certificates, in any country in the Territory in relation to the Licensed Products
described and claimed by Rib-X Patent Rights. Rib-X and Sanofi will cooperate in connection with all such activities. Notwithstanding the foregoing, if the Parties cannot agree, Sanofi will determine whether and on which patent(s) Rib-X or Sanofi
will seek patent term extensions or supplemental patent protection in relation to the relevant Licensed Product, except that in the case of US Patent Rights that describe and claim a Profit Share Product, the final decision will be made by the JSC.

 7.3 Third Party Infringement. 
 7.3.1 Notice. Each Party will promptly report in writing to the other Party during the Term any known or suspected infringement of any of (i) Rib-X Patent Rights, (ii) Sanofi Patent
Rights and (iii) Patent Rights that describe and claim Joint Inventions, in each case, that Cover a Licensed Product, or known or suspected unauthorized use or misappropriation of any existing Rib-X Know-how used in the development, manufacture
or commercialization of Licensed Product, of which such Party becomes aware, and will provide the other Party with all available evidence of such known or suspected infringement or unauthorized use or misappropriation. 

7.3.2 Right to Enforce Patent Rights. 
 (a) With respect to the Patent Rights prosecuted by Sanofi pursuant to Section 7.2.3(a): Sanofi will have the first right, but not the obligation, to initiate a suit or take other appropriate
action that it believes is reasonably required to prevent or abate actual or threatened infringement or misappropriation of, or otherwise protect or enforce any such Patent Rights against a Third Party who is researching, developing, making, using
or selling a product that contains the relevant Licensed Compound in the Field. Rib-X and its Affiliates will join such suit if the relevant court would lack jurisdiction if Rib-X or such Affiliate were absent from such suit and Rib-X and such
Affiliates will execute such legal papers and cooperate in the prosecution of such suit as may be reasonably requested by Sanofi; provided, that Sanofi will promptly reimburse all out-of-pocket expenses (including reasonable attorneys’ fees and
expenses) incurred by Rib-X and such Affiliates in connection with such cooperation. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 36 

 (b) With respect to the Patent Rights prosecuted by Rib-X pursuant to
Section 7.2.3(b): Rib-X will have the first right, but not the obligation, to initiate a suit or take other appropriate action that it believes is reasonably required to prevent or abate actual or threatened infringement or misappropriation
of, or otherwise protect or enforce any such Patent Rights against a Third Party who is researching, developing, making, using or selling a product that contains the relevant Licensed Compound in the Field. Sanofi and its Affiliates will join such
suit if the relevant court would lack jurisdiction if Sanofi or such Affiliate were absent from such suit and Sanofi and such Affiliates will execute such legal papers and cooperate in the prosecution of such suit as may be reasonably requested by
Rib-X; provided, that Rib-X will promptly reimburse all out-of-pocket expenses (including reasonable attorneys’ fees and expenses) incurred by Sanofi and such Affiliates in connection with such cooperation. 

(c) Other Party’s Rights. If the Party having the first right to initiate an action under either (a) or
(b) above, does not initiate a suit or take other appropriate action pursuant to Section 7.3.2(a) or Section 7.3.2(b) within sixty (60) days (fifteen (15) days in the case of a Paragraph IV Certification) after receipt of a
written notice from the other Party, then the other Party will have the right to initiate a suit or take other appropriate action that it believes is reasonably required to protect the relevant Patent Rights and the Party not initiating such suit
and its Affiliates will join such suit if the relevant court would lack jurisdiction if such Party or such Affiliates were absent from such suit and such Party and such Affiliates will execute such legal papers and cooperate in the prosecution of
such suit as may be reasonably requested by the initiating Party; provided, that the initiating Party will promptly reimburse all out-of-pocket expenses (including reasonable attorneys’ fees and expenses) incurred by the Party not initiating
such suit and such Affiliates in connection with such cooperation. Notwithstanding the foregoing, Sanofi will have no right to initiate an action with respect to any Patent Rights that have been excluded from Rib-X Patent Rights under
Section 7.2.3(b). 
 7.3.3 Right to Enforce Know-how. Responsibility for protecting (i.e., preventing or abating
actual or threatened infringement or misappropriation of) or otherwise enforcing Know-how will be determined in the same manner as the relevant Patent Rights. 
 7.3.4 Conduct of Certain Actions; Costs. The Party initiating suit pursuant to this Section 7.3 will have the sole and exclusive right to select counsel for any such suit initiated by it. The
initiating Party will assume and pay all of its own out-of-pocket costs incurred in connection with any litigation or proceedings initiated by it pursuant to this Section 7.3, including the fees and expenses of the legal counsel selected by it,
except that, in the event the Licensed Product is a US Profit Share Product, such costs of outside counsel and court costs will be treated as Third Party and Other Permitted Sales and Marketing Expenses. 

7.3.5 Recoveries. 
 (a) If Sanofi initiates suit as permitted in accordance with Section 7.3.2(a) or Section 7.3.2(c) or, with respect to Know-how, in the same manner as set forth in Section 7.3.2.(a) or
Section 7.3.2(c), any damages, settlements, accounts of profits, or 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 37 

 
other financial compensation recovered by Sanofi from a Third Party based upon such suit, after deducting Sanofi’s actual out-of-pocket expenses (including reasonable attorneys’ fees
and expenses) incurred in pursuing such suit (such net amount, the “Recovery”), will be treated as Net Sales (and will be subject to the milestone and royalty payment obligations or US Profit Share calculation hereunder, as the case
may be). 
 (b) If Rib-X initiates suit pursuant to Section 7.3.2(b) or Section 7.3.2(c) or, with
respect to Know-how, in the same manner as set forth in Section 7.3.2(b) or Section 7.3.2(c), Rib-X may retain any damages, settlements, accounts of profits, or other financial compensation recovered from a Third Party based upon such
suit. 
 7.4 Patent Invalidity Claim. Each of the Parties will promptly notify the other in the event of any legal or
administrative action by any Third Party against (i) Rib-X Patent Rights, (ii) Sanofi Patent Rights and (iii) Patent Rights that describe and claim Joint Inventions, in each case that Covers a Licensed Product of which it becomes
aware, including any nullity, revocation, reexamination or compulsory license proceeding or, in accordance with Section 7.6, any Paragraph IV Certification. Responsibility for defending against any such action or Paragraph IV Certification will
be determined in the same manner as enforcement of the relevant Patent Rights pursuant to Section 7.3. 
 7.5 Patent
Marking. Sanofi will comply with the patent marking statutes in each country in which the Licensed Product is sold by Sanofi, its Affiliates, and Sublicensees. 
 7.6 Paragraph IV Certification. If a Party becomes aware of any certification filed pursuant to 21 U.S.C. §355(b)(2)(A)(iv) or 355(j)(2)(A)(vii)(IV), or any notice under any future analogous
provisions of United States law relating to regulation or approval of pharmaceutical products (or any amendment or successor statute thereto), or any comparable law under any other jurisdiction, claiming that any Rib-X Patent Rights or Joint Patent
Rights, in each case Covering a Licensed Product in the Field, is invalid or otherwise unenforceable, or that infringement will not arise from the manufacture, use, import, sale or offer of sale of a product by a Third Party (a “Paragraph IV
Certification”), such Party will promptly notify the other Party in writing within one (1) Business Day after its receipt thereof, in accordance with Section 13.4. 

7.7 Settlement. Notwithstanding anything in this Agreement to the contrary, in no event may (i) Sanofi settle or compromise
any claim or proceeding relating to the Rib-X Know-how or Rib-X Patent Rights or Patent Rights that describe and claim Joint Inventions without first providing prior written notice to Rib-X, and (ii) Rib-X settle or compromise any claim or
proceeding relating to the Sanofi Know-how or Sanofi Patent Rights or Patent Rights that describe and claim Joint Inventions without first providing prior written notice to Sanofi. 

7.8 Yale Agreement. Notwithstanding anything in this Agreement to the contrary, in the event of any inconsistency between the
rights granted to Sanofi under this Article VII and the rights of Yale under the Yale Agreement, the provisions of the Yale Agreement shall control. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 38 

 ARTICLE VIII - CONFIDENTIAL INFORMATION 

8.1 Treatment of Confidential Information. During the Term of this Agreement and for ten (10) years thereafter, each Party
will maintain the Confidential Information of the other Party in confidence, will not disclose, divulge, or otherwise communicate such Confidential Information to others and will not use it for any purpose other than in performance of its
obligations or exercise of its rights pursuant to this Agreement, except that each Receiving Party may disclose the Disclosing Party’s Confidential Information to the Receiving Party’s directors, officers, employees, consultants,
subcontractors, Affiliates, agents and advisors (collectively, “Representatives”) who are bound by written or professional obligations of confidentiality and restrictions on use at least as stringent as those set forth in this
Article VIII and who have a need to know such information to perform obligations or exercise rights on behalf of the Receiving Party under this Agreement. Each Receiving Party will exercise efforts that are at least as diligent as those generally
used by such Party in protecting its own confidential and proprietary information of a similar nature (but no less than reasonable efforts), to prevent and restrain the unauthorized disclosure or use of the Disclosing Party’s Confidential
Information by any of the Receiving Party’s Representatives. Each Party will be responsible for a breach of this Article VIII by its Representatives. Notwithstanding anything in this Agreement to the contrary, Sanofi agrees to comply with
the obligations of Rib-X under Article 8 of the Yale Agreement with respect to Confidential Information marked “Confidential Information of Yale.” 
 8.2 Permitted Uses. Notwithstanding anything in this Section to the contrary, the Receiving Party may disclose Confidential Information of the Disclosing Party (i) to Regulatory Authorities,
to the extent necessary to obtain or maintain INDs or Regulatory Approvals for any Licensed Product (or, in the case of Rib-X, products incorporating any Returned Compound), as permitted under this Agreement; (ii) to outside consultants,
service providers, scientific advisory boards, managed care organizations, non-clinical and clinical investigators and, in the case of Sanofi as the Receiving Party, to Sublicensees and potential Sublicensees, in each case to the extent necessary to
research, develop, manufacture or commercialize any Licensed Product in the Field (or, in the case of Rib-X, products incorporating any Returned Compound) in accordance with this Agreement, provided, that such Receiving Party will bind such Third
Parties other than Regulatory Authorities to written obligations of confidentiality and restrictions on use at least as stringent as those set forth in this Article VIII; (iii) under written obligations of confidentiality and restrictions on
use no less stringent than the terms set forth in this Article VIII, to bona fide potential or actual acquirers, investors, lenders, investment bankers or other potential financial partners in connection with such Party’s proposed financing or
business combination activities and to advisors and consultants advising such Party in connection with such activities; and (iv) to the extent necessary to prosecute and enforce Rib-X Patent Rights in accordance with the terms of Article VII,
and; in each of the foregoing cases, solely in accordance with this Agreement, provided, that, in each case under clauses (ii)-(iv), if Sanofi provides notice to Rib-X that certain Confidential Information of Sanofi is or may be, in Sanofi’s
reasonable determination, material to an investor making an investment decision in Sanofi, Rib-X will not disclose such Confidential Information to a Third Party until Sanofi has made a public disclosure of such information; provided, however, that,
if Rib-X provides written notice to Sanofi that Rib-X has determined in good faith that Rib-X’s interests would be materially adversely affected if Rib-X could not make such disclosure, then Sanofi will either make the applicable Sanofi
Confidential 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 39 

 
Information public within ten (10) Business Days after Sanofi’s receipt of such request or Rib-X may make such disclosure in strict accordance with this Section 8.2; and in a case
under clause (iv), if Rib-X wishes to make use of Confidential Information that could materially adversely affect Patent Rights governed by Sanofi under 7.2.3(a), or if Sanofi wishes to make use of Confidential Information that could materially
adversely affect Patent Rights governed by Rib-X under 7.2.3(b), Rib-X or Sanofi shall notify and coordinate with the other Party the extent of disclosure through the JSC. 
 8.3 Exceptions. Notwithstanding the foregoing, the Receiving Party’s obligations under Section 8.1 will not apply to any Confidential Information of the Disclosing Party that, as shown by
competent evidence: 
 (i) is known to the Receiving Party prior to disclosure by the Disclosing Party or being
generated under this Agreement, as the case may be; or 
 (ii) either before or after the date of the disclosure
to the Receiving Party, is lawfully disclosed to the Receiving Party by a Third Party, other than on behalf of the Disclosing Party, without any violation of any obligation to the Disclosing Party; or 

(iii) either before or after the date of the disclosure to the Receiving Party or being generated by the Receiving Party,
as the case may be, becomes published or generally known to the public through no fault or omission on the part of the Receiving Party or its Representatives; or 

(iv) is independently developed by or on behalf of the Receiving Party outside of the activities contemplated by this
Agreement without reference to or reliance upon the Disclosing Party’s Confidential Information, as demonstrated by contemporaneous written records of the Receiving Party; or 

(v) is required to be disclosed by the Receiving Party to comply with Applicable Laws or legal process, including the
rules or regulations of the U.S. Securities and Exchange Commission, or similar agency in any country other than the United States, or of any stock exchange, including Nasdaq, or to defend or prosecute litigation, provided, that the Receiving Party
promptly provides prior written notice, to the extent practicable, of such disclosure to the other Party and uses reasonable efforts to avoid or minimize the degree of such disclosure. 

8.4 Additional Limits on Disclosure by Rib-X. Notwithstanding anything in this Agreement to the contrary, Rib-X agrees that,
except as specifically contemplated by the Research Plan, or, in the case of a US Profit Share Product, the Development Plan or the Commercialization Plan, or as otherwise directed by the JSC, neither Rib-X nor any of its Affiliates, will disclose
Confidential Information of Rib-X that is solely and specifically related to a Licensed Product except to the same extent as Rib-X is allowed to disclose Sanofi Confidential Information under Sections 8.1, 8.2 or 8.3. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 40 

 8.5 Publication Rights. During the Term of this Agreement, the following restrictions
will apply with respect to publications and presentations relating to Licensed Products: 
 8.5.1 Publication.

 (a) Rib-X will have the sole right, but not the obligation, to publish the results of the Research Program
after the end of the Research Term, provided that, in no event will Rib-X publish any Confidential Information of either Party related to any Licensed Product without the prior written approval of Sanofi. 

(b) Notwithstanding anything in this Agreement to the contrary, subject to paragraph (c) and Section 8.7, Sanofi
will have the sole right to publish and to make presentations or public disclosure related to Sanofi’s development and commercialization of Licensed Products in the Field conducted by or on behalf of Sanofi without the prior written consent of
Rib-X. 
 (c) The JSC will determine the publication strategy for any publications or presentation of data or
information generated arising from the development or commercialization of the US Profit Share Product. 
 8.5.2 Confidential
Information in Patents. Nothing in this Agreement will prevent either Party from filing or prosecuting a patent application or maintaining or enforcing its resulting patents related to a Licensed Product; provided, that such Party is in
compliance with Article VII. 
 8.6 Return of Confidential Information. Upon the expiration or termination of this
Agreement, the Receiving Party will return to the Disclosing Party or, at the Disclosing Party’s request, destroy all Confidential Information of the Disclosing Party in the Receiving Party’s possession and all copies and reproductions
thereof. Notwithstanding the foregoing, (i) the Receiving Party may retain one copy of the Disclosing Party’s Confidential Information for archival purposes; (ii) the Receiving Party may retain and use the Disclosing Party’s
Confidential Information solely to the extent necessary to exercise the rights and licenses of the Receiving Party expressly surviving expiration or termination of this Agreement; (iii) the Receiving Party will not be required to return or
destroy the Disclosing Party’s Confidential Information stored on automatically created system-back-up tapes; and (iv) the Receiving Party will not be required to return or destroy the Disclosing Party’s Confidential Information that
the Receiving Party is required by law to maintain. Notwithstanding the return or destruction of the Disclosing Party’s Confidential Information, the Receiving Party will continue to be bound by its obligations of confidentiality and other
obligations under this Article VIII. 
 8.7 Press Releases and Other Disclosures. The terms of this Agreement will not be
disclosed except as set forth in this Section 8.7. Rib-X and Sanofi may each issue a press release, in a form attached to this Agreement as Exhibit H-1 or Exhibit H-2, respectively, and on a date to be mutually agreed upon by the
Parties, such agreement not to be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing provisions of Section 8.5 or this Section 8.7, (i) a Party may make any disclosure or public announcement if the contents
of 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 41 

 
such disclosure or public announcement have previously been made public other than through a breach of this Agreement by such Party; (ii) if a Party reasonably determines that a public
disclosure will be required by law, including in a public filing with the U.S. Securities and Exchange Commission, such Party may disclose the existence and terms of this Agreement and any material developments that occur under this Agreement,
including in the Development or Commercialization of Licensed Products, where so required, provided, that such Party will, to the extent practicable and permitted by Applicable Law, notify the other Party and provide a copy of such proposed
disclosure or filing to such other Party at least three (3) days prior to the planned disclosure or filing and allow such other Party to comment on the proposed disclosure, which comments will be considered by the disclosing Party in good
faith; (iii) a Party may disclose the existence and terms of this Agreement, under obligations of confidentiality no less stringent than the terms set forth in this Article VIII, to bona fide potential acquirers, investors, lenders, investment
bankers or other potential financial partners in connection with such Party’s proposed financing or business combination activities and consultants and advisors advising such Party in connection with such activities; (iv) a Party may
disclose the existence and terms of this Agreement to licensors of such Party’s intellectual property licensed to the other Party hereunder, to the extent required pursuant to the relevant license agreement; (v) a Party may disclose the
existence and terms of this Agreement, under obligations of confidentiality no less stringent than the terms set forth in this Article VIII, to bona fide potential or actual licensees of such Party’s intellectual property licensed to the other
Party hereunder; and (vi) a Party may disclose the terms and existence of this Agreement, under obligations of confidentiality no less stringent than the terms set forth in this Article VIII, to bona fide potential or actual sublicensees, as
reasonably necessary in connection with an existing or potential sublicense under the licenses granted in this Agreement which sublicense is granted in accordance with this Agreement. Except as otherwise expressly provided in this Article VIII,
Sanofi will not have the right to issue press releases and make public announcements related to any Target Compound or the results of the Research Program. 
 ARTICLE IX - REPRESENTATIONS, WARRANTIES AND COVENANTS 
 9.1 Mutual
Representations. Each Party hereby represents and warrants to the other Party as of the Effective Date as follows: 
 9.1.1
It is duly organized and validly existing under the laws of its jurisdiction of incorporation and has the corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder. 

9.1.2 The execution, delivery and performance of this Agreement by such Party has been duly and validly authorized and approved by proper
corporate action on the part of such Party. It has taken all other action required by Applicable Law, its certificate of incorporation or by-laws or any agreement to which it is a party or by which it or its assets are bound, to authorize such
execution, delivery and performance. Assuming due authorization, execution and delivery on the part of the other Party, this Agreement constitutes a legal, valid and binding obligation of such Party. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 42 

 9.1.3 The execution and delivery of this Agreement, and the performance as contemplated
hereunder, by such Party will not violate any Applicable Law. 
 9.1.4 Neither the execution and delivery of this Agreement nor
the performance hereof by such Party requires such Party to obtain any permit, authorization or consent from any governmental authority (except for any Regulatory Approvals, pricing or reimbursement approvals, manufacturing-related approvals or
similar approvals necessary for development, manufacture or commercialization of Licensed Products), or from any other Third Party, and such execution, delivery and performance by such Party, including the granting of the licenses granted under this
Agreement, will not result in the breach of or give rise to any conflict, termination of, rescission, renegotiation or acceleration under or trigger any other rights under any agreement or contract to which such Party may be a party existing as of
the Effective Date. 
 9.2 Rib-X’s Representations and Warranties. Rib-X hereby represents and warrants to Sanofi as
of the Effective Date as follows: 
 9.2.1 Rib-X has the right to grant to Sanofi the rights and licenses described in this
Agreement. 
 9.2.2 Exhibit I is a complete and correct list of all Rib-X Patent Rights in the Territory Controlled by
Rib-X as of the Effective Date. 
 9.2.3 To Rib-X’s Knowledge, no Third Party is infringing any of the Rib-X Patent Rights
identified on Exhibit I. 
 9.2.4 Rib-X has not received any written notice of (i) any claim that any patent or
trade secret right owned or controlled by a Third Party would be infringed or misappropriated by the conduct of the Research Program or the manufacture, use, sale, offer for sale or importation of Rib-X Existing Compounds in the Field in the
Territory, or (ii) any threatened claims or litigation seeking to invalidate or otherwise challenge the Rib-X Patent Rights or Rib-X’s rights therein. 
 9.2.5 To Rib-X’s Knowledge, there exists no patent owned or controlled by a Third Party that would be infringed by the conduct of the Research Program or the manufacture, use, sale, offer for sale or
importation of Rib-X Existing Compounds in the Field in the Territory, provided that Sanofi understands that Rib-X has not conducted a freedom to operate search with respect to Rib-X Existing Compounds. 

9.2.6 Rib-X’s rights to Rib-X Licensed Technology are, to Rib-X’s Knowledge as of the Effective Date, held free and clear of
any liens, security interests and similar encumbrances. 
 9.2.7 None of the Rib-X Patent Rights owned by Rib-X is the subject
of any pending re-examination, opposition, interference or litigation proceedings. 
 9.2.8 Exhibit J sets forth a true
and complete list of all agreements, pursuant to which a Third Party has licensed to Rib-X any Rib-X Licensed Technology existing on the 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 43 

 
Effective Date. With respect to any such agreement pursuant to which any such Rib-X Licensed Technology is exclusively licensed to Rib-X, (i) Rib-X is not in breach under any of such
agreements, nor, to the Knowledge of Rib-X, is any other party thereto, (ii) Rib-X has not received any notice of breach under any of such agreements, (iii) Rib-X has previously provided Sanofi with access to true and complete copies of
each of such agreements; (iv) such agreements are in full force and effect; and (v) Rib-X will maintain such Agreements in full force and effect during the Term, will perform all of its obligations thereunder and will not amend any such
agreement in a manner that would adversely affect the rights and obligations of Sanofi under this Agreement. Rib-X will notify Sanofi promptly upon receiving any notice of a breach from a party thereunder. 

9.2.9 There have been no inventorship or ownership challenges with respect to any of the Rib-X Licensed Technology. 

For purposes of this Section, “Knowledge” of Rib-X shall mean the actual knowledge of, after reasonable and due inquiry
on such matter by, the members of senior management of Rib-X including, without limitation the Chief Executive Officer; Chief Financial Officer; Senior Vice President-Development; Vice President-Business Development; Vice President-Discovery; and
Vice President-Authorized House Counsel for Intellectual Property. 
 9.3 Sanofi’s Representations. Sanofi hereby
represents and warrants to Rib-X as of the Effective Date as follows: 
 9.3.1 Sanofi has the right to grant to Rib-X the rights
and licenses described in this Agreement. 
 9.4 Covenants of the Parties. Each of the Parties covenants and agrees as
follows: 
 9.4.1 Subject to Section 13.8(b), during the term of this Agreement, such Party will not, without the other
Party’s consent, grant or assign to a Third Party any rights, under the Rib-X Licensed Technology (if Rib-X is the representing Party), the Sanofi Licensed Technology (if Sanofi is the representing Party) that conflict with the rights granted
to the other Party hereunder or that would cause Control of such intellectual property to be relinquished or diminished. 

9.4.2 Each of Sanofi and Rib-X will require that all of its employees, consultants, service providers and those of its Affiliates
involved in the conduct of the Research Program, or in the development, manufacture or commercialization of Licensed Products, have entered into written confidentiality and invention assignment agreements that are consistent with the terms of this
Agreement and pursuant to which they assign any rights they may have in any inventions made during such work to Sanofi or Rib-X, respectively. 
 9.4.3 Each Party and its Affiliates will conduct, and will use Commercially Reasonable Efforts to cause its employees, Sublicensees, contractors, and consultants to conduct, all of their activities
contemplated under this Agreement in accordance with all Applicable Law. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 44 

 9.4.4 Neither Party nor any of its Affiliates has been debarred or is subject to debarment
and neither Party nor any of its Affiliates will use in any capacity, in the conduct of the Research Program or connection with the development, manufacture or commercialization of any Licensed Product, any person or entity who has been debarred
pursuant to Section 306 of the United States Federal Food, Drug, and Cosmetic Act, or who is the subject of a conviction described in such section. Each Party agrees to inform the other Party in writing immediately upon becoming aware that any
person or entity who is performing services hereunder is debarred or is the subject of a conviction described in Section 306, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of such
Party’s knowledge, is threatened, relating to the debarment or conviction of such Party or any person or entity used in any capacity by such Party or any of its Affiliates in connection with the conduct of the Research Program or in the
development, manufacture or commercialization of any Licensed Product. 
 9.5 No Warranty. EXCEPT AS OTHERWISE EXPRESSLY
SET FORTH IN THIS AGREEMENT, NEITHER PARTY HERETO MAKES ANY REPRESENTATION AND NEITHER PARTY EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT (INCLUDING ANY
LICENSED COMPOUND OR LICENSED PRODUCT), INCLUDING ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE. EACH PARTY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE RESEARCH PROGRAM WILL RESULT IN ANY CANDIDATE
COMPOUNDS OR LICENSED COMPOUNDS, OR THAT DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF LICENSED PRODUCT PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL OR THAT, IF COMMERCIALIZED, ANY PARTICULAR SALES LEVEL WILL BE ACHIEVED. 

ARTICLE X - INDEMNIFICATION 
 10.1 Indemnification by Sanofi. Sanofi will indemnify, hold harmless and defend Rib-X, its Affiliates and their respective directors, officers, employees, consultants and agents (collectively, the
“Rib-X Indemnitees”) from and against any and all expenses, cost of defense (including reasonable attorneys’ fees, witness fees and expert fees), damages, judgments, fines and amounts paid in settlement, to the extent arising
from any Third Party claim or from any claim of Yale or Howard Hughes Medical Institute for indemnification under Sections 14.1 and 14.2 of the Yale Agreement, resulting from (i) the conduct of Research activities by or on behalf of Sanofi
or any of its Affiliates; (ii) the development, manufacture, commercialization, use or importation of Licensed Products by or on behalf of Sanofi or any of its Affiliates or Sublicensees or any of their customers (including product liability
claims); (iii) the breach or failure of any of Sanofi’s representations, warranties or covenants hereunder or Sanofi’s breach of this Agreement; (iv) the negligence or willful misconduct of any Sanofi Indemnitee, as defined in
Section 10.2; or (v) any infringement of any Patent Rights of a Third Party or misappropriation of any Third Party Know-how in connection with the development, manufacture, commercialization, use or import of any Licensed Products by or on
behalf of Sanofi or any of its Affiliates or Sublicensees or any of their customers, except, in each case, to 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 45 

 
the extent attributable to the negligence or intentional misconduct of any Rib-X Indemnitee or any breach or failure of any Rib-X representations, warranties or covenants under this Agreement or
breach by Rib-X of any term of this Agreement. Notwithstanding anything in this Agreement to the contrary, in the event Rib-X exercises its US Profit Share Option, any amounts incurred by Sanofi in connection with any indemnified claim under
Section 10.1 directly and exclusively related to the development, manufacture or commercialization of the US Profit Share Product in the U.S. will be included as Third Party and Other Permitted Sales and Marketing Expenses, except to the extent
attributable to the negligence or intentional misconduct of Sanofi or any Sanofi Indemnitee, breach or failure of any of Sanofi’s representations, warranties or covenants under this Agreement or Sanofi’s breach of this Agreement.

 10.2 Indemnification by Rib-X. Rib-X will indemnify, hold harmless and defend Sanofi, its Affiliates and their
respective directors, officers, employees, consultants and agents (collectively, the “Sanofi Indemnitees”) from and against any and all expenses, cost of defense (including reasonable attorneys’ fees, witness fees and expert
fees), damages, judgments, fines and amounts paid in settlement, to the extent arising from any Third Party claim resulting from (i) the conduct of Research activities by and on behalf of Rib-X or any of its Affiliates; (ii) the research,
development, manufacture, commercialization, use or importation of any US Profit Share Products, or any products incorporating Returned Compounds by or on behalf of Rib-X or any of its Affiliates or Sublicensees or any of their customers (including
product liability claims); (iii) the breach or failure of any of Rib-X’s representations, warranties or covenants under this Agreement or Rib-X’s breach of this Agreement; (iv) the negligence or willful misconduct of any Rib-X
Indemnitee; or (v) any infringement of any Patent Rights of a Third Party or misappropriation of any Third Party Know-how in connection with the development, manufacture, commercialization, use or importation of any products incorporating
Returned Compounds by or on behalf of Rib-X or any of its Affiliates or any of their customers, except, in each case, to the extent attributable to the negligence or intentional misconduct of any Sanofi Indemnitee or any breach or failure of any
Sanofi representations, warranties or covenants under this Agreement or breach by Sanofi of any term of this Agreement. Notwithstanding anything in this Agreement to the contrary, in the event Rib-X exercises its US Profit Share Option, any amounts
incurred by Rib-X in connection with any indemnified claim under Section 10.2, to the extent related to the development, manufacture or commercialization of such US Profit Share Product in the U.S., will be included as Third Party and Other
Permitted Sales and Marketing Expenses, except to the extent attributable to the negligence or intentional misconduct of Rib-X or any Rib-X Indemnitee, breach or failure of any of Rib-X’s representations, warranties or covenants hereunder or
Rib-X’s breach of this Agreement. 
 10.3 Procedure. In the event of a claim by a Third Party against any person
entitled to indemnification under this Agreement (in such capacity, the “Indemnified Party”), the Indemnified Party must: 
 10.3.1 promptly notify the other Party (the “Indemnifying Party”) of such claim; 
 10.3.2 permit the Indemnifying Party, at the Indemnifying Party’s cost, to handle and control the claim, but the Indemnified Party will have the right to participate in the defense of the claim at
its own expense; and 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 46 

 10.3.3 give the Indemnifying Party, at the Indemnifying Party’s cost and request, all
reasonable assistance in the Indemnifying Party’s handling of the claim. 
 The Indemnifying Party may settle such claim
only with the consent of the Indemnified Party, which will not be unreasonably withheld, conditioned or delayed; provided, that the Indemnified Party will have no obligation to consent to any settlement of any such claim which imposes on the
Indemnified Party any liability or obligation which cannot be assumed and performed in full by the Indemnifying Party. The Indemnifying Party will not have any indemnity obligation with respect to any claim settled by an Indemnified Party or by any
Indemnitee without the Indemnifying Party’s prior written consent, such consent not to be unreasonably withheld, conditioned or delayed. 
 10.4 Insurance. Each Party will maintain appropriate product liability insurance with respect to its activities hereunder in such amount as such Party customarily maintains with respect to its
other products for similar patient populations and commercial markets. Each Party will maintain such insurance for so long as it continues to conduct such activities hereunder, and for so long as such Party customarily maintains insurance with
respect to sales of its other products for similar patient populations and commercial markets. 
 10.5 No Consequential
Damages. IN NO EVENT SHALL EITHER RIB-X OR SANOFI BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, EXEMPLARY, MULTIPLE OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY.
NOTHING IN THIS SECTION 10.5 IS INTENDED TO LIMIT OR RESTRICT (A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER THIS ARTICLE X, OR (B) REMEDIES AVAILABLE TO EITHER PARTY WITH RESPECT TO A BREACH OF ARTICLE VIII.

 ARTICLE XI - TERM AND TERMINATION 
 11.1 Term. This Agreement becomes effective as of the Effective Date and will continue until the earlier of (i) the end of the Research Term if Sanofi has not exercised at least one
Development and Commercialization Option as of such date; (ii) the termination of this Agreement in accordance with Section 11.2 or (iii) the expiration of the last-to-expire of all payment obligations hereunder with respect to all
Licensed Products following the cessation of all research, development, manufacturing and commercialization of Licensed Products in the Field by or on behalf of Sanofi and its Affiliates and Sublicensees (other than the Licensed Products for which
the royalty obligations hereunder have been fully paid) (the “Term”). Upon expiration of the Term (but not termination of the Agreement) the license granted to Sanofi under Section 4.2.1 will convert to perpetual, exclusive
fully-paid up, non-royalty-bearing licenses. 
 11.2 Termination. 

11.2.1 Termination For Convenience. At any time, Sanofi will have the right to terminate this Agreement, in its entirety, or on a
Licensed Compound-by-Licensed Compound 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 47 

 
basis, or on a country-by-country basis, or any combination thereof, for any or no reason upon ninety (90) days’ prior written notice to Rib-X. Notwithstanding anything to the contrary,
if Sanofi exercises its right to terminate this Agreement on a country-by-country basis prior to the end of the Royalty Term in such country of a given Licensed Product, and if Sanofi continues to sell such Licensed Product in such country, then the
Net Sales of such Licensed Product in such country shall (i) continue to be subject to the payment obligations of Article VI until such time as the Royalty Term would have expired had there not been such a country-by-country termination and
(ii) continue to be included in Net Sales for purposes of Section 6.5 and for purposes of determining the royalty rates under Section 6.7.1, provided that the foregoing provisions of this sentence will not be deemed to limit the
effect of termination of this Agreement as to a specific country under Section 11.2.3 or 11.3 with respect to such Licensed Compound in such country. 
 11.2.2 Termination For Material Breach. If either Party (the “Non-Breaching Party”) believes that the other Party (the “Breaching Party”) is in material breach of
this Agreement (including any material breach of a representation or warranty made in this Agreement), then the Non-Breaching Party may deliver written notice of such breach to the Breaching Party. If the Breaching Party fails to cure such breach
within the sixty (60) day period after the Breaching Party’s receipt of such notice, the Non-Breaching Party may terminate this Agreement in its entirety upon further written notice to the Breaching Party. Without limiting Rib-X’s
rights under this Section 11.2.2, Rib-X may terminate the license granted under Section 4.2.1 of this Agreement as to a specific Licensed Compound in the event of a material breach by Sanofi of its obligation under Section 4.5 as to
such Licensed Compound, effective upon sixty (60) days’ prior written notice if Sanofi fails to cure such breach within the sixty (60) day period after Sanofi’s receipt of such notice. 

11.2.3 Termination as to Licensed Compound. Upon termination by Sanofi or Rib-X of the license granted under Section 4.2.1 of
this Agreement as to a specific Licensed Compound, including termination as to a specific country but only as to such country: (i) such compound will no longer be a Licensed Compound and instead will be a Returned Compound and will be included
in the assignment and rights granted to Rib-X under Section 4.2.3; and (ii) the provision of Section 11.3.1, including clause (iii) of Section 11.3.1, will apply but only with respect to such Returned Compound and products
being Developed prior to the date of termination incorporating such Returned Compound. 
 11.2.4 Termination for
Bankruptcy. To the extent permitted under Applicable Law, either Party may terminate this Agreement effective immediately with written notice: 
 (a) if the other Party shall have (i) voluntarily commenced any proceeding or filed any petition seeking relief under the bankruptcy, insolvency or other similar laws of any jurisdiction,
(ii) applied for, or consented to, the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for it or for all or substantially all of its property, (iii) filed an answer admitting the
material allegations of a petition filed against or in respect of it in any such proceeding, (iv) made a general assignment for the benefit of creditors of all or substantially all of its assets, (v) admitted in writing its inability to
pay all or substantially all of its debts as they become due, or (vi) taken corporate action for the purpose of effecting any of the foregoing; or 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 48 

 (b) if an involuntary proceeding shall have been commenced, or any
involuntary petition shall have been filed, in a court of competent jurisdiction seeking: (i) relief in respect of the other Party, or of its property, under the bankruptcy, insolvency or similar laws of any jurisdiction, (ii) the
appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for such other Party or for all or substantially all of its property, or (iii) the winding-up or liquidation of such other Party; and,
in each case, such proceeding or petition shall have continued undismissed for sixty (60) days, or an order or decree approving or ordering any of the foregoing shall have continued unstayed, unappealed and in effect for thirty (30) days.

 11.2.5 Termination for Patent Challenge. If either Party or any of its Affiliates or Sublicensees challenges (the
“Challenging Party”) in administrative or judicial proceedings the validity or enforceability of a claim included in any patent to which such Challenging Party is granted a license to under this Agreement, then the non-Challenging Party
will have the right to terminate this Agreement in its entirety or such license upon thirty (30) days’ written notice to the Challenging Party; provided, however, that if (a) such patent challenge is terminated during such thirty (30) day
period or (b) if such challenge was initiated by a Sublicensee of Challenging Party and the Challenging Party terminated the corresponding sublicense, then the non-Challenging Party will not have the right to so terminate this Agreement or such
license. 
 11.2.6 Sanofi Termination of Certain Rights in Addition to Terminating. In the event that Rib-X defaults with
respect to any of its material obligations under this Agreement and does not cure such default within sixty (60) days after the receipt of a written notice from Sanofi specifying the nature of, and requiring the remedy of, such default (or, if
such default cannot be cured within such sixty (60) day period, if Rib-X does not commence and diligently continue actions to cure same during such sixty (60) day period), then Sanofi may, in addition to exercising its terminations rights
provided in Section 11.2.2, terminate Article V in whole or in part, but only if Rib-X did not previously exercise its US Profit Share Option. 
 11.3 Effects of Termination. 
 11.3.1 Effect of Termination of
Agreement. Effective upon any termination of this Agreement as to a specific Licensed Compound or upon termination of this Agreement in its entirety, the following provisions shall apply (as to the terminated Licensed Compound or Licensed
Product in the terminated countries, if this Agreement remains in effect, or as to all Licensed Compounds and Licensed Products if this Agreement is being terminated in its entirety); provided that 11.3.1(v) and 11.3.1(vii) shall not apply if Sanofi
exercises termination rights under 11.2.2, 11.2.4 or 11.2.5: 
 (i) all licenses granted by Rib-X to Sanofi
hereunder will terminate; 
 (ii) Sanofi will provide to Rib-X a fair and accurate description of the status and
results of the development and commercialization of the Licensed Products through the effective date of termination and through the Follow-on Period; 
 (iii) Sanofi will be deemed to have automatically granted to Rib-X an exclusive (even as to Sanofi), worldwide, fully paid-up, royalty-free except for the royalties set forth in Section 6.9 and
Section 11.3.2, right and license, with the right to grant sublicenses, under the Sanofi Licensed Technology, excluding any trademarks, to research, develop, manufacture and commercialize any product that was a Licensed Product as of the date
of termination in the Field in the Territory, provided that the foregoing will not be deemed a limitation of Rib-X’s rights under Section 4.2.3; 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 49 

 (iv) To the extent not previously transferred under Section 4.2.3,
then, effective upon such termination, Sanofi (i) assigns to Rib-X all right, title and interest of Sanofi and its Affiliates in all Sanofi Compound Specific Patent Rights Covering the Licensed Compounds, and Sanofi agrees to take, and to cause
its employees, Affiliates or Sublicensees, to take, all such reasonable actions and execute all such documents, as Rib-X may from time to time reasonably request to effect such assignment. 

(v) Sanofi will have an ongoing obligation to notify Rib-X in writing upon the identification of each Follow-on Compound
identified by or on behalf of Sanofi, its Affiliates or Sublicensees during the Follow-on Period. 
 (vi) Sanofi
will promptly transfer and assign to Rib-X all preclinical and clinical data (including pharmacology and biology data), regulatory documentation (including INDs, NDAs and other Regulatory Approvals and regulatory filings, and safety information),
marketing and sales information, including customer lists and other requested information or materials related to Licensed Products, including any other documented Sanofi Know-how related to such Licensed Product, in each case in the possession or
control of Sanofi or any of its Affiliates or Sublicensees and necessary or useful for the research, development, manufacture or commercialization of the Licensed Products in the Field in the Territory, including reports, records, structures and
other materials relating to process conditions, in-process controls, analytical methodology and formulation for the manufacture of Licensed Products; provided, that Sanofi may retain copies of such items for its records; further provided, that any
such transfers or assignments shall be at Rib-X’s expense. In the event of a termination as to a country, but not a termination of this Agreement in its entirety, the Parties will promptly execute an agreement for the sharing of adverse event
information with respect to Licensed Products in a form mutually agreeable to both Parties, such agreement not to be unreasonably withheld. 
 (vii) Sanofi will grant Rib-X an exclusive, worldwide, fully-paid-up, non-royalty-bearing (other than the royalty, if any, otherwise payable under Section 6.9) license to all trademarks representing
the names of the Licensed Products in the countries for which the licenses are being terminated pursuant to Section 11.2. 
 (viii) Sanofi will promptly transfer to Rib-X responsibility for prosecution and maintenance of Rib-X Patent Rights and of any Sanofi Compound Specific Patent Rights related to Returned Compounds to the
extent not previously assigned to Rib-X under Section 4.2.3 in such a manner as to ensure that there is no loss or rights, provided, that any such transfers or assignments shall be at Rib-X’s expense. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 50 

 (ix) to the extent Sanofi or its Affiliate is engaged in the manufacture of
a Licensed Product as of the effective date of termination or is having Licensed Product made, Sanofi or such Affiliate will, as requested by Rib-X, manufacture (or have manufactured) and supply Rib-X’s requirements for such Licensed Product in
the Field from the date of such termination until, with respect to each such Licensed Product, the earliest to occur of (a) such time as Rib-X secures an alternative manufacturing source committed to manufacture such Licensed Product and
process validation has been completed by such alternative source; (b) eighteen (18) months after the effective date of termination (with respect to any Licensed Product existing on the effective date of termination); or (c) such time
as Rib-X provides written notice to Sanofi that Rib-X is no longer in need of such manufacturing and supply support with respect to such Licensed Product; provided, that, with respect to each Licensed Product, Rib-X will use Commercially Reasonable
Efforts to secure a satisfactory alternative manufacturing source and to have such alternative source complete process validation as promptly as reasonably practicable following the effective date of termination and will provide written notice to
Sanofi as soon as such alternative source is secure and process validation has been completed that Rib-X is no longer in need of such manufacturing and supply support with respect to such Licensed Product. Sanofi will, at Rib-X’s request,
cooperate with Rib-X, and use reasonable efforts to try to convince any Third Party manufacturer of the relevant Licensed Product, including by using reasonable efforts to incorporate relevant provisions in the applicable agreement with such Third
Party that such Third Party manufacturer cooperate with Rib-X, in the transfer, scale-up and validation of the manufacturing process for such Licensed Product to Rib-X or Rib-X’s designee, including transfer of the master batch records and
analytical methods and other relevant records related to production, testing and release of Licensed Product, and shall make its personnel reasonably available to Rib-X to answer questions in connection with the foregoing. In addition, at
Rib-X’s option, (1) Rib-X may purchase all or any part of Sanofi’s worldwide unsold inventory of raw materials for Licensed Products, work-in-progress Licensed Products and finished goods inventory of Licensed Products and
(2) Sanofi will, and will ensure that its Affiliates, use Commercially Reasonable Efforts to assign to Rib-X any Third Party manufacturing contract relating to such Licensed Products to which Sanofi or any of its Affiliates is a party (or the
applicable provisions thereof, as the case may be). All Licensed Products supplied to Rib-X by Sanofi pursuant to this Section 11.3.1(ix) will be manufactured in compliance with then current Good Manufacturing Practices, and will be sold by
Sanofi, and purchased by Rib-X, at [***]% of COGS; and 
 (x) Sanofi and its Affiliates will make reasonable
efforts to allow Rib-X to negotiate agreements with such service providers to research, develop, manufacture or commercialize Licensed Products, including by providing any waivers of any obligations of confidentiality, non-competition and
exclusivity imposed on its Third Party service providers (including manufacturers) that are necessary to negotiate such agreements. All licenses and 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 51 

 
sublicenses granted by Sanofi pursuant to Article 4.3 which are specific to Licensed Products and assignable will be promptly assigned to Rib-X, at Rib-X’s request provided to Sanofi in
writing within ninety (90) days after the date of termination of this Agreement and will otherwise terminate; or (ii) which are not specific to Licensed Products, will, at Rib-X’s request provided to Sanofi in writing within ninety
(90) days after the date of termination of this Agreement and at Rib-X’s cost, be held for the benefit of Rib-X and Sanofi and its Affiliates will take such actions as Rib-X may reasonably request so as to provide Rib-X with the benefits
thereunder with respect to the Licensed Products. 
 11.3.2 Royalty to Sanofi under Certain Termination Scenarios. If
Sanofi exercises its termination rights under Sections 11.2.2 or 11.2.4, then Rib-X will pay a royalty to Sanofi on Net Sales of any product incorporating a compound that was at any point in time a Licensed Compound, [***]. 

11.3.3 Control. During the Term, Sanofi will not enter into any agreement or take any action that would prevent Rib-X from
receiving a license to Sanofi Know-how incorporated into any Licensed Product or other Returned Compound, or any Sanofi Patent Rights Covering Licensed Product or other Returned Compounds, as contemplated by this Agreement; provided, however, that
the foregoing shall not apply to any Know-How or Patent Rights which were developed by a Third Party and in-licensed by Sanofi after the Effective Date not specifically for Licensed Products. Notwithstanding the limitations on Sanofi’s
obligations under the preceding sentence, in the event Sanofi does not obtain the right to sublicense to Rib-X and its Affiliates and sublicensees any Know-how or Patent Rights licensed by Sanofi from a Third Party and incorporated into any Licensed
Product to the extent such Know-how or Patent Rights would be included in Sanofi Know-how or Sanofi Patent Rights if Controlled by Sanofi, then Sanofi will, at the request of Rib-X upon triggering of the licenses granted by Sanofi to Rib-X under
Section 4.2.3 or Section 11.3.1(iii), use Commercially Reasonable Efforts to assist Rib-X in obtaining a license from such Third Party to such Know-how or Patent Rights. 

11.3.4 Effect of Termination of License as to Specific Licensed Compound. In the event of termination by Rib-X under
Section 11.2.3 of the license granted to Sanofi under Section 4.2.1 with respect to a specific Licensed Compound, the provisions of Section 11.3.1 will apply but only with respect to any Licensed Products that incorporate the Licensed
Compound as to which the license under Section 4.2.1 was terminated. 
 11.3.5 Survival. 

(a) The following provisions will survive the expiration or termination of this Agreement: Sections 4.2.3, 6.9, 6.10 and
6.12 and Articles VIII, X, XI, XII and XIII. 
 (b) Each Party’s right to receive any payments accrued under
this Agreement as of the expiration or termination of this Agreement will survive the expiration or termination of this Agreement. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 52 

 11.3.6 Non-exclusive Remedy. Termination of this Agreement will be in addition to,
and will not prejudice, the Parties’ remedies at law or in equity, including the Parties’ ability to receive legal damages and/or equitable relief with respect to any breach of this Agreement, regardless of whether or not such breach was
the reason for the termination. 
 ARTICLE XII - DISPUTE RESOLUTION 

12.1 Referral of Unresolved Matters to Executives. If, the JSC does not resolve any dispute within fourteen (14) days after
the matter is first considered by it, the matter may be referred by either Party to their respective Executives (or his or her designee who must be a member of the applicable Party’s senior management team with appropriate decision-making
authority, but who is not a member of the JSC) who will meet at least once in person or by video conference to discuss the matter and use their good faith efforts to resolve the matter as soon as practicable but in no event later than fourteen
(14) days after referral. 
 12.2 Final Decision-Making. 

12.2.1 Decision-Making. If a dispute referred to the Executives has not been resolved in accordance with Section 12.1, then
the following provisions apply, in each case subject to Section 12.2.2: 
 (a) In the event the dispute
relates to an amendment to the Research Plan notwithstanding Sanofi’s other rights under this Section, the then current Research Plan will remain in effect unless the Parties mutually agree on an updated Research Plan. 

(b) In the event the dispute relates to a Development Plan or Commercialization Plan for the US Profit Share Product,
then, notwithstanding Sanofi’s other rights under this Section, unless the Parties mutually agree on an updated plan, Sanofi will have the final decision-making authority. 

(c) Each Party will have final decision-making authority with respect to day-to-day operational decisions in connection
with its activities under the Research Plan. 
 (d) Each Party will have final decision-making authority with
respect to day-to-day operational decisions in connection with its activities related to Development of the US Profit Share Product, subject to the then applicable Development Plan and the terms of this Agreement. 

(e) Each Party will retain final decision-making authority with respect to day-to-day operational decisions in connection
with the Commercialization activities related to a US Profit Share Product allocated to it under the Commercialization Plan, subject in each case to the Commercialization Plan and the terms of this Agreement and of any Co-promotion Agreement entered
into by the Parties. 
 12.2.2 Decision-Making Rules. Notwithstanding anything to the contrary set forth in
Section 12.2.1: 
 (i) in no event may the deciding Party require the other Party to perform activities
which such other Party has not agreed to perform as set forth in this Agreement or as otherwise agreed by such other Party; 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 53 

 (ii) in no event may the deciding Party unilaterally amend the terms of
this Agreement or override the non-deciding Party’s rights in this Agreement; 
 (iii) in no event may the
deciding Party unilaterally determine that it has fulfilled any obligations hereunder or that the non-deciding Party has breached any obligations hereunder; 
 (iv) in no event may the deciding Party unilaterally determine that the events required for the payment of milestone payments have or have not occurred; 

(v) in no event may the deciding Party unilaterally make a decision that is expressly stated to require the mutual
agreement of the Parties; 
 (vi) the deciding Party will not exercise its final decision-making authority in a
manner that would require the other Party to perform any act that it reasonably believes to be inconsistent with law; and 
 (vii) the decision-making Party will make its decisions in good faith, subject to the terms and conditions of this Agreement. 
 12.2.3 No Limitation. Notwithstanding the foregoing, (i) nothing in this Article XII will be construed as limiting in any way the right of a Party to seek injunctive or other equitable relief
from a court of competent jurisdiction with respect to any actual or threatened breach of this Agreement, (ii) subject to Section 12.2.2, nothing in this Article XII will override the provisions of Section 3.5 and 5.3, and
(iii) each Party will have the right to institute judicial proceedings against the other Party (or anyone acting by or through such other Party) in any court of competent jurisdiction, in order to enforce such Party’s rights under this
Agreement, through reformation of contract, specific performance, injunction or similar equitable relief. 
 12.3
Arbitration. Unless the Parties mutually agree otherwise, any dispute arising out of or related to this Agreement or its breach, termination or validity which is not resolved in accordance with Sections 12.1 or 12.2 will be finally resolved
by binding arbitration administered by the International Chamber of Commerce (“ICC”) pursuant to its Dispute Resolution Rules in effect at the time such dispute arises, and judgment on the arbitration award may be entered in any court
having jurisdiction thereof. To the extent such rules are inconsistent with this provision, this provision will control. The following rules will apply to any such arbitration: 

(a) Any demand for arbitration must be made in writing to the other Party. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 54 

 (b) There will be three arbitrators, one of whom shall be appointed by each
party and a third of whom shall be the chairman of the panel and be appointed by mutual agreement of the two arbitrators appointed by the Parties. If the two arbitrators cannot agree on the appointment of the third arbitrator within thirty
(30) days, then the ICC shall select the arbitrator. Any arbitration involving patent rights, other intellectual property rights or intellectual property will be heard by arbitrators who are expert in such areas. 

(c) The arbitration will be held in the State of New York, or such other place as the Parties agree. The arbitrators will
apply the substantive law of the State of New York in accordance with Section 13.2, without regard to conflicts of laws and except that the interpretation and enforcement of this arbitration provision will be governed by the Federal Arbitration
Act, 9 U.S.C. Section 1 et. seq. 
 (d) Neither Party will have the right independently to seek recourse
from a court of law or other authorities in lieu of arbitration, but each Party has the right before or during the arbitration to seek and obtain from the appropriate court provisional remedies to avoid irreparable harm, maintain the status quo or
preserve the subject matter of the arbitration. There shall be a stenographic record of the proceedings. The decision of the arbitrators will be final and binding upon both Parties. The arbitrators will render a written opinion setting forth
findings of fact and conclusions of law. 
 (e) The expenses of the arbitration will be borne by the Parties in
proportion as to which each Party is defeated in arbitration. Each Party will bear the expenses of its counsel and other experts. 
 (f) The arbitration will be conducted in English. 
 12.4 Equitable Relief.
Notwithstanding anything to the contrary, each of the Parties hereby acknowledges that a breach of their respective obligations under this Agreement may cause irreparable harm and that the remedy or remedies at law for any such breach may be
inadequate. Each of the Parties hereby agrees that, in the event of any such breach, in addition to all other available remedies hereunder, the non-breaching Party shall have the right, through the arbitration process described in Section 12.3
or as set forth in Section 12.2.3, to seek equitable relief to enforce the provisions of this Agreement. 
 12.5 No
Arbitration of Patent Matters. Unless otherwise agreed by the Parties, a dispute between the Parties relating to the validity, infringement or enforceability of patents will not be subject to arbitration and will be submitted to a court of
competent jurisdiction in the country in which such Patent was granted. The Parties submit to the jurisdiction of such court and irrevocably waive any assertion that the case should be heard in a different venue or forum. 

ARTICLE XIII - MISCELLANEOUS 
 13.1 No Use of Name. Except as expressly permitted under this Agreement or in the Commercialization of a US Profit Share Product, neither Party will use the name of the other Party or any of its
Affiliates in any promotional context. In addition, Sanofi agrees to comply with Article 12 of the Yale Agreement with respect to the use of names connected with Yale or the Howard Hughes Medical Institute. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 55 

 13.2 Governing Law. This Agreement and any dispute arising from the performance or
breach of this Agreement will be governed by, construed and enforced in accordance with the laws of the State of New York, other than any principle of conflict or choice of laws that would cause the application of the laws of any other jurisdiction;
provided, that with respect to matters involving enforcement of intellectual property rights, the laws of the applicable country will apply. 
 13.3 Waiver. Waiver by a Party of a breach hereunder by the other Party will not be construed as a waiver of any succeeding breach of the same or any other provision. No delay or omission by a
Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder will operate as a waiver of any right, power or privilege by such Party. No waiver will be effective unless made in writing with specific reference
to the relevant provisions of this Agreement and signed by a duly authorized representative of the Party granting the waiver. 

13.4 Notices. All notices, instructions and other communications hereunder or in connection herewith will be in writing, will be
sent to the address specified in this Section 13.4 and will be: (i) delivered personally; or (ii) sent via a reputable one or two-day, international courier service. 
 Notices to Rib-X will be addressed to: 
 Rib-X Pharmaceuticals 

300 George Street, Suite 301 
 New Haven, CT 06511-6663 
 Attention: President and Chief Executive Officer

 Notices to Sanofi will be addressed to: 
 Sanofi 
 174, avenue de France 

75013, Paris France 
 Attention: General Counsel 
 With copies to: 

Sanofi 
 174,
avenue de France 
 75013, Paris France 
 Attention: Vice President, Corporate Licenses 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 56 

 13.5 Entire Agreement; Amendment. This Agreement (including all attachments hereto)
contains the complete understanding of the Parties with respect to the subject matter hereof and supersedes all prior understandings and writings relating to such subject matter, including (i) any and all term sheets relating to the
transactions contemplated by this Agreement and exchanged between the Parties prior to the Effective Date and (ii) the Confidentiality Agreement between the Parties dated as of [***]. No amendment, change or addition to this Agreement will be
effective or binding on either Party unless reduced to writing and duly executed on behalf of both Parties. 
 13.6
Headings. Headings in this Agreement are for convenience of reference only and will not be considered in construing this Agreement. 
 13.7 Severability. If any provision of this Agreement is held unenforceable by a court or tribunal of competent jurisdiction because it is invalid or conflicts with any law of any relevant
jurisdiction, the validity of the remaining provisions will not be affected. In such event, the Parties will negotiate a substitute provision that, to the extent possible, accomplishes the original business purpose. 

13.8 Assignment. 
 (a) Assignment Provisions. This Agreement may not be assigned or otherwise transferred by either Party, without the written consent of the other Party such consent not to be unreasonably withheld,
conditioned or delayed; provided, however, that either Party may, without such consent, assign this Agreement, in whole or in part, (i) to any of its Affiliates, and (ii) to a Third Party successor or purchaser of all or substantially all
of its business or assets to which this Agreement relates, whether by a merger, sale of stock, sale of assets or other similar transaction, provided that the Third Party successor or purchaser provides written notice to the other Party that such
Third Party agrees to be bound by the terms of this Agreement. Any purported assignment in violation of this Section 13.8 will be void. Any permitted assignee will assume all obligations of its assignor under this Agreement. 

(b) Effect of Change of Control. Notwithstanding anything in this Agreement to the contrary in the event of a
Change of Control, as defined in paragraph (d), of Rib-X, any licenses granted by Rib-X to Sanofi under this Agreement will [***]. 
 (c) Effect of Change of Control on Exclusivity. Notwithstanding anything in this Agreement to the contrary, in the event of a Change of Control of a Party, [***]. 

(d) Definition of Change of Control. For purposes of this Section, “Change of Control” means, with
respect a Party any of the following: (a) the sale or disposition of all or substantially all of the assets of such Party or its direct or indirect parent to a Third Party; or (b) (i) the acquisition by a Third Party which constitutes one
person, as such term is used in Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), together with any of such person’s “affiliates”

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 57 

 
or “associates”, as such terms are defined in the Exchange Act, other than an employee benefit plan (or related trust) sponsored or maintained by such Party or any of its Affiliates, of
more than fifty percent (50%) of the outstanding shares of voting capital stock of such Party or its direct or indirect parent corporation, or (ii) the acquisition, merger or consolidation of such Party or its direct or indirect parent
with or into another entity, other than, in the case of this clause (b), an acquisition or a merger or consolidation of such Party or its direct or indirect parent in which the holders of shares of voting capital stock of such Party or its direct or
indirect parent, as the case may be, immediately prior to such acquisition, merger or consolidation will beneficially own, directly or indirectly, at least fifty percent (50%) of the shares of voting capital stock of the acquiring third party
or the surviving corporation in such acquisition, merger or consolidation, as the case may be, immediately after such acquisition, merger or consolidation. 
 13.9 Counterparts. This Agreement may be executed in any number of counterparts (including .pdf or fax), each of which will be deemed an original but all of which together will constitute one and
the same instrument. 
 13.10 Force Majeure. No Party will be liable for failure of or delay in performing obligations
set forth in this Agreement, and no Party will be deemed in breach of its obligations as a result of such failure or delay, if such failure or delay is due to any cause reasonably beyond the control of such Party, which may include natural disaster,
explosion, fire, flood, tornadoes, thunderstorms, peril of the sea, earthquake, war, terrorism, riots, embargo, losses or shortages of power, labor stoppage, substance or material shortages, damage to or loss of product in transit, events caused by
reason of laws of any Regulatory Authority or events caused by acts or omissions of a Third Party. The Party affected by such force majeure will provide the other Party with full particulars thereof as soon as it becomes aware of the same (including
its good faith estimate of the likely extent and duration of the interference with its activities), and will use Commercially Reasonable Efforts to overcome the difficulties created thereby and to resume performance of its obligations as soon as
practicable. Nothing in this Section will be deemed a limitation of a Party’s right to terminate this Agreement under Section 11.2. 
 13.11 Non-solicitation. During the Research Term and [***], Sanofi will not, and will ensure that its Affiliates do not, without Rib-X’s prior written consent, directly or indirectly recruit,
solicit, induce to hire for employment or as an independent contractor, any employee of Rib-X or its Affiliates, or any individual who is an independent contractor to Rib-X or its Affiliates and who spends at least half of his/her typical
contracting week providing services to such Rib-X or its Affiliates, or induce or attempt to induce any such employee to terminate his or her employment with Rib-X or its Affiliates or otherwise cease his or her relationship with Rib-X or its
Affiliates. The foregoing restriction will not prohibit the placement of advertising of general circulation that may be received or viewed by the employees or such independent contractors of Rib-X or its Affiliates or the interviewing of any
employee or such independent contractor of such other Party who responds to such advertising. 
 13.12 Third Party
Beneficiaries. None of the provisions of this Agreement will be for the benefit of or enforceable by any Third Party other than the Indemnitees. No other Third 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 58 

 
Party will obtain any right under any provision of this Agreement or will by reason of any such provision have the right under this Agreement to make any claim in respect of any debt, liability
or obligation (or otherwise) against either Party. 
 13.13 Relationship of the Parties. Each Party will bear its own
costs incurred in the performance of its obligations hereunder without charge or expense to the other, except as expressly provided in this Agreement. Neither Party will have any responsibility for the hiring, termination or compensation of the
other Party’s employees or for any employee compensation or benefits of the other Party’s employees. No employee or representative of a Party will have any authority to bind or obligate the other Party for any sum or in any manner
whatsoever, or to create or impose any contractual or other liability on the other Party without such other Party’s approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, the legal relationship
under this Agreement of each Party to the other Party will be that of independent contractor. Nothing in this Agreement will be construed to establish a relationship of partners or joint venturers between the Parties. 

13.14 Performance by Affiliates. Either Party may use one or more of its Affiliates (and, in the case of Sanofi, its Sublicensees)
to perform its obligations and duties hereunder, and, Affiliates of a Party are expressly granted certain rights herein; provided, that each such Affiliate or Sublicensee will be bound by the corresponding obligations of such Party and the relevant
Party will remain liable hereunder for the prompt payment and performance of all their respective obligations hereunder. 

13.15 Construction. Each Party acknowledges that it has been advised by counsel during the course of negotiation of this
Agreement, and, therefore, that this Agreement will be interpreted without regard to any presumption or rule requiring construction against the Party causing this Agreement to be drafted. In construing this Agreement, (i) use of the singular
includes the plural and vice versa; (ii) “including” means “including without limitation”, and (iii) except where the context otherwise requires, the word “or” is used in the inclusive sense. 

[Remainder of page intentionally left blank.] 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 59 

 IN WITNESS WHEREOF, the Parties have entered into this Collaboration and License Agreement
as of the Effective Date. 
  

			
	RIB-X PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Mark Leuchtenberger

		 	Mark Leuchtenberger
		 	President and Chief Executive Officer
	
	SANOFI
		
	By:	 	 /s/ Philippe Goupit

		 	Name: Philippe Goupit
		 	Title: Vice President, Corporate Licenses

 [Execution Page] 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Exhibit A 

Research Plan 

Exhibit A1. Organisation 
 The two
Alliance managers will initially be [***] (Rib-X) and [***] (Sanofi). The Rib-X members of the joint steering will initially comprise [***] and [***], and the Sanofi members will be [***],[***] and [***] ([***] as non-voting member). 

In addition to the JSC outlined in Article 3, other joint teams will be formed as follows: 

 

	•	 	 A joint project team whose function will be to oversee the day to day running of the drug discovery component of the collaboration (from initial
synthesis through to identification of a development candidate) across initially [***]. The members of the joint project team and their oversight responsibilities will be: 

[***] 
 Proposed
Meeting frequency to be defined by the JSC. 
  

	•	 	 “[***] teams” ensuring coordination of the day to day medicinal chemistry on each [***]: meeting frequency to be defined by the JSC.

  

	•	 	 A joint assay team responsible for assay harmonisation and validation. Meeting frequency to be defined by the JSC. 

 

	•	 	 A joint development team to oversee and coordinate pre-clinical and clinical development of drug candidates, the members of which will be [***] and
[***] from Rib-X, along with a project director ([***] (Sanofi), a CMC expert or a clinician from Sanofi (to be determined by [***] when a compound enters pre-clinical development). Meeting frequency to be defined by the JSC.

  

	•	 	 A joint commercial team comprising [***] members from each company. 

 It is to be noted that the development and commercial teams are to be formed as and when necessary and membership can vary as a function of development status of the compound. The decision on when to form
the team and its composition is made by the JSC. Also the composition of the teams above may also be subject to modification as the collaboration progresses. 
 Exhibit A2. Work sharing and Resources 
 The assignment of responsibilities for the major
activities will be as follows 
  

	•	 	 Chemistry 

  

	 	•	 	 [***] to perform X-ray Crystallography 

  

	 	•	 	 [***] to share computational chemistry, medicinal chemistry, laboratory scale–up and early process work to shadow medicinal chemistry ([***]). It
should be noted that [***] will provide sufficient access for [***] computational chemists to the software and tools necessary to enable de novo drug design. 

 

	 	•	 	 [***] to perform library synthesis as relevant. 

  

	•	 	 Biochemistry & Microbiology 

  

	 	•	 	 [***] to perform ribosomal MOA studies, preliminary MIC90s, and resistance studies. 

 

	 	•	 	 [***] to do cell free translation assays, time kill, MBC and primary MIC panel. The strains for primary panel and for primary efficacy studies will be
from the [***] strain collection. [***] will transfer the cell-translation assay to [***]). 

  

	 	•	 	 The expanded microbiology panels are to be [***] and or performed by [***], and will need to cover both European and [***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

	•	 	 Pharmacology 

  

	 	•	 	 [***] to perform the [***] assay. 

  

	 	•	 	 [***] to perform some thigh infection PK/PD studies (different strains/species to those used by [***]). 

 

	 	•	 	 [***] to perform some thigh infection PK/PD work (different strains/species to those used by [***]). 

 

	 	•	 	 [***] and/or [***] to set up and use other in-vivo models for compound evaluation if deemed appropriate by the Joint Project Team.

  

	•	 	 ADMET and Physical Chemistry 

  

	 	•	 	 [***] to measure protein binding. 

  

	 	•	 	 [***] to measure thermodynamic aqueous solubilities at pH [***] and [***], microsomal lability, cytotoxicity in HepG2 and CHO cells.

  

	 	•	 	 [***] to perform logD @ pH [***], pKa, hepatocyte clearance, CYP profiling (3A4 contribution, inhibition, MBI and induction; 2D6 inhibition),
Caco-2-cell permeability, Ames, MNT and hERG and other safety pharmacology studies such as receptor and enzyme profiling for secondary effects. It should be noted that [***] is committed to provide timely access of the collaboration to its ADMET
platforms. 

  

	•	 	 Animal Pharmacokinetics (PK - according to intended route(s) of administration) 

 

	 	•	 	 [***] to perform mouse and rat PK, although it is understood that [***] will be responsible for at least [***] the studies.

  

	 	•	 	 [***] to perform [***], which may be outsourced. 

 [***] will be responsible continuing drug discovery in [***], and the other [***] will be exploited by [***]; for example Rib-X may work on [***] and Sanofi may work on [***] or vice versa (to be
determined at the kick off meeting). The resources allocated to each [***] are summarized in the following table. 
  

					
	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]

  

	*	Chemistry coordinator preferably resident for some period of time at [***] **[***] process chemist to be involved in all [***] 

The resources allocated by Rib-X to the joint assay team will be [***] people working on ribosome biochemistry, [***] on microbiology, [***] on
pharmacology, [***] on bioanalyticals; and [***] on formulation. In total Rib-X will contribute [***] FTEs to the discovery stage of the collaboration. Those allocated by Sanofi will comprise [***] biologists (including microbiology and
pharmacology), [***] FTEs for Disposition/Safety and [***] FTEs for other Project support (analyticals, formulation, library production and Process bench chemists) giving a total of [***] FTEs: this number will change significantly (increase) when a
candidate for regulatory development studies has been identified. 
 Other resource allocations may include the following considerations:

  

	•	 	 Synthesis of major intermediates may be outsourced to a company chosen by the JSC. 

 

	•	 	 As candidates for regulatory pre-clinical drug safety studies are identified, [***] will be responsible for allocating resources for scale up and
process chemistry. 

  

	•	 	 If compounds active by the oral route are desired in near-term, [***] may reinforce [***]’s efforts in designing prodrugs.

  

	•	 	 [***] will be approached for the large scale preparation of DNA, RNA, ribosomes, etc., for assays and crystallography design efforts.

  

	•	 	 [***] may explore other potential sources of beam lines. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Exhibit A3 Initial Work plan and collaboration flow chart. 

The Alliance managers of both companies will organize a kick-off meeting to take place within a month of signature of the Collaboration and License
Agreement. The object of this meeting will be to provide a formal presentation of partner companies, people and Project, to organize the project team and to plan the technology transfer necessary for each party to perform its agreed tasks.

 As part of the opening phase of the collaboration the Discovery Project Team will 

 

	•	 	 Coordinate the establishment of a shared data-room (e.g. a secure e-room), which will contain a shared database enabling registration of new compounds,
biological data input and SAR query as well as a virtual meeting room. 

  

	•	 	 Be responsible for the validation of key assays. Assay selection and validation will be performed by taking [***] Exemplar Compounds from each [***]
testing them in a battery of tests including the full [***] profiling platform; in parallel, they will be assessed in a panel of tests within [***] (Physical chemistry, ADME/T and cytotoxicity). In addition to the [***] Exemplar compounds, small
sets of compounds (N~10) will be selected to test activity ranges in key assays (e.g., cell-free translation). The results will then be assessed by the JSC, and Collaborative Lead Optimization will commence and the selection of [***] for the
“Joint Team” will be finalised. 

  

	•	 	 Be responsible for the harmonization of bacterial strain collections for in vitro and in-vivo tests and the calibration of assays used by
[***]. 

  

	•	 	 Finalize [***] teams and priorities. 

  

	•	 	 Train Sanofi synthetic teams in key approaches and ensure ample supply of major intermediates for optimization. 

 

	•	 	 Share the [***] approach with [***] project team and design tools/models with [***] computational chemist. 

 

	•	 	 Finalize the flow chart, definitions and compound progression criteria, to be approved by the JSC. 

Lead optimization Lead optimization will be then performed according to the Project flow chart (Figure 1). Those items in the flow chart that are shaded
are required for a compound to progress. It should be noted that additional tests may be included subject to JSC approval as the collaboration evolves. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Figure 1 Proposed Discovery Flow Chart 
 [***] 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Exhibit B 

Rib-X Internal Compound Modeling Criteria and List of Rib-X Existing Compounds 

Modeling criteria, including a description of the computational tools used for prospective design as well as a listing of specific data models that exist
and will be shared with Sanofi during the collaboration, are described in Exhibit E2, “Rib-X Know-How”. 
 As of July 16, 2011,
there exist [***] RX-04 compounds that have been prepared, registered and entered into the RX-04 screening workflow. [***]. In the project database, the latter are represented collectively as “[***]” compounds. Compound characterization,
including NMR and LC-MS traces, are stored for each molecule. Compounds exist both in liquid and dry stock. 
  

	
	 Table 1. [***] Compounds, July 16, 2011 (RX-00XXXX)

	[***]
	

  

	
	 Table 2. [***] Compounds, July 16, 2011 (RX-00XXXX)

	[***]
	

  

	
	 Table 3. [***] Compounds, July 16, 2011 (RX-00XXXX)

	[***]
	

  

	
	 Table 4. Other RX-04 [***] Molecules, July 16, 2011
(RX-00XXXX)

	[***]
	

 In addition to these, there exist [***] sets (N = [***] in each set) of targeted compounds that address hypotheses
currently under investigation by the team. 2D chemical structures for the targeted compounds as well as computational data that support them are available in the dataroom and will be shared with Sanofi. Thematically, they cover the following areas:

  

					
	 [***]
	 	 Description
	 	 N

		 	[***]	 	

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Exhibit C 

Description of [***] 
 General description 
 [***] 
 Each [***] contains an array of atoms that forms at least [***] hydrogen bonds with the [***] of the 50S ribosomal subunit. This array usually comprises [***], and a [***], as drawn below. These interact
with a ribosomal RNA base, [***] numbering, that resides in the [***] of the large ribosomal subunit (50S). 
 Each [***] (schematically
abbreviated as a boxed “P” in the graphic below) can be elaborated with optional [***] (for example, A and/or Y and/or Z). These optional [***] may be added to the [***] to increase binding affinity for the 50S [***] and to tune molecular
properties. Improving molecular properties is critical for improved antibacterial spectrum, greater antibacterial potency, and better safety and efficacy. 
 [***] 
 While the [***] itself contributes a great deal to the overall binding affinity to the
[***] 
 Additional [***] ([***]) can optionally be added to other portions of the [***] to improve further the ribosomal affinity and
properties. For example, some of these [***]. Notably, the different architectures of the various [***] allow these [***]. 
 Specific
examples of [***] 
 Of the various [***] synthesized, [***] have been most thoroughly explored: the [***] and [***]. Of these [***], most of
the recent effort has been concentrated on the [***] to drive to the first clinical candidate. The [***] have in turn been much more thoroughly investigated than the [***]. 
 A [***], the [***], has also been explored to a limited extent, and this [***] did show promise. A fair amount of early work was done on a [***], which also was active. An active [***] was also explored
to a limited extent. A few compounds with a [***] were synthesized, but these showed very poor activity in MICs as well as in cell-free translation assays. These compounds apparently prefer a [***] form that does not match the [***] consensus
defined above. 
  

					
	 [***]
	  	 [***] Number
	  	 [***]

		  	[***]	  	

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Exhibit D 

Target Profiles 

[***] 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Exhibit E 

Rib-X Know-how to be provided to 
 Sanofi for Conduct of the Research Program 
 Exhibit E1. X-ray Crystal Structure
Coordinates 
 As part of the technology transfer that will occur upon commencement of the research collaboration, Rib-X Pharmaceuticals will
provide all atomic coordinates for the structures of RX-04 compounds in complex with the [***] 50S ribosomal subunit that have been determined to date. These structures were solved using X-ray crystallographic methods, and the coordinates have been
refined against corresponding X-ray diffraction data. The listed files have been superimposed upon a reference set of [***] 50S coordinates. Also included in the transfer is the structure of one compound bound to the [***] 70S ribosome ([***]). The
files are stored in Protein Data Bank format (*pdb). The coordinate files which will be included in the initial transfer are listed, below. 

[***] 
 Exhibit E2. Computational Design and
Available Models 
 Computational design tools used at Rib-X fall under the collective umbrella known as “Analog”. The individual
programs, developed by Professor William L. Jorgensen of Yale University, are given, below: 
  

			
	 Program name
	  	 Description

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

 [***], the workhorse of the computational design efforts, produces atomic coordinates, in *pdb format, for every
hypothetical ribosome-ligand complex. Additionally, it produces a flat file, in *csv format, of the intermolecular, and intramolecular parameters describing the ribosome-ligand interaction as well as [***] properties for the ligand. In addition to
the parameters given in [***], we compute a measure of ligand efficiency (total intermolecular interaction energy divided by number of atoms in ligand) a as well as a good/bad ratio of interactions. These have been helpful in prioritizing among
molecules to prepare, when the focus is on improving affinity for the ribosome. These, and parameters from a refined structure from [***], are imported into [***], a statistical program, for analysis. Linear regression models describing affinity as
well as TPP2 activity will be shared in the collaboration as well as *pdb files for hypothetical molecules. These derive initially from a cluster analysis (Ward’s hierarchical, using molecular features with pairwise correlations £ 80%), have been subjected to screening design and are refined using successive linear regression studies. [***]. It should be noted that targeted compound lists, such as those given in the table, above, are
supported by other cluster members that may be additionally prepared if the properties in a particular cluster point to interesting activity or molecular properties. 
 Exhibit E3. Assay Protocols, Bacterial Strain Collections and Compound Sets for Assay Harmonization and Validation 
 Rib-X Pharmaceuticals will provide assay protocols for all in vitro and in vivo assays, including murine models of infection, used to evaluate RX-04 compounds. Additionally, protocols for
bioanalysis will be shared. Directories housing these protocols have been constructed in the Rib-X dataroom; the folder names are given, below. 
  

			
	Bioanalytical Methods	 	Mechanism of action
	Crystallization	 	Microbiological activity
	CYPs	 	Microsomal lability
	Cytotoxicity	 	Protein Binding
	In vitro translation	 	Solubility
	In vivo methods	 	

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Bacterial strains used in the RX-04 primary microbiological activity screen panel are found in under
“primary_panel_bacterial_strains.doc”. A set of [***] ([***]) compounds – [***] control compounds and [***] contemporary RX-04 compounds, chosen to harmonize and validate biochemical assays (translation, CYPs and
cytotoxicity) across sites – may be found in the file “Validation_Set.xls”. 
 Exhibit E4. Synthetic Protocol for
Preparation of Compounds on the Existing RX-04 [***] 
 Complete protocols for the synthesis of analogs on the [***] major [***] ([***] as
[***] as [***] and [***] as [***]) plus one relatively unexplored [***] ([***]) will be transferred to Sanofi. These have been included in the dataroom under “Synthetic Protocols”. Specific final targets, shown as exemplars, are described;
the associated RX-numbers are noted in the table, below. 
 [***] 
 Exhibit E5. Preparative Scale Syntheses on the Lead [***] ([***]) 
 The following
preparative scale syntheses are provided in the dataroom under “Synthetic Protocols”: 
  

	 	•	 	 Synthesis of [***] on a 10-15g scale 

  

	 	•	 	 Synthesis of [***] on a 10-15g scale 

  

	 	•	 	 Synthesis of [***] on a 10-15g scale 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Exhibit F 

Example of Calculation of Net Profit/Loss 
 [FOR ILLUSTRATIVE PURPOSES ONLY] 
 Quarterly True-Up 

At the end of each Calendar Quarter, the Parties will calculate the net payment one Party shall make to the other Party (the “Quarterly
True-Up”) equal to (a) the US Profit Split minus (b) the Development Payments for such Quarter. 
 US Profit Split 

The US Profit Split shall mean [***] per cent ([***] %) of the US profits in a Quarter. US Profits shall mean aggregate Net Sales of US Profit Share
Products in the US in the Quarter less the sum of (a) [***], (b) [***], and (c) [***] in the Quarter. 
 An example of a
calculation of the US Profit Split in a Quarter would be: 
  
  

					
	Aggregate	  	Sanofi	  	Rib-X

 [***] 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Exhibit G 

Key Countries for Patent Filings 
  

			
	PCT Application	  	EPC Countries Including All extension states:
		
	Regional EP Application	  	 [***]

		
	[***]	  	

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Exhibit H-1 

Form of Rib-X Press Release 
 Rib-X Pharmaceuticals and Sanofi Sign a Research Collaboration Agreement on Novel Classes of Antibiotics 
 — Novel technology targets bacterial ribosomes creating an entirely new class of antibiotic therapeutics —  
 NEW HAVEN, Conn. - July 6, 2011 - Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license with Sanofi (EURONEXT: SAN and
NYSE: SNY) for novel classes of antibiotics resulting from Rib-X’s RX-04 program for the treatment of resistant Gram-positive and resistant Gram-negative pathogens. 
 Rib-X’s RX-04 program employs a proprietary approach for rational drug design resulting in entirely new families of compounds that have demonstrated efficacy at low, single doses in murine infection
models. The RX-04 development program has shown antibacterial activity against a number of the most difficult to treat, clinically important, multi-drug resistant Gram-negative and Gram-positive pathogens. The Rib-X RX-04 program targets bacterial
ribosomes, an internal cell component, where proteins are synthesized from amino acids and RNA. Recently presented data confirms the novel classes directly impact ribosome function and exert their anti-bacterial activity by interfering with protein
synthesis. 
 Under the terms of the agreement, Rib-X will receive $10 million in an upfront payment. Rib-X is also eligible to receive up to an
additional $9 million in near-term research-based milestones and will be eligible to receive further payments for the achievement of research, preclinical, regulatory and commercial milestones. Sanofi has the right to develop multiple products under
this agreement. Except for those assets licensed to Sanofi through the agreement, Rib-X retains its rights to the discovery platform and its future programs. The agreement could result in up to $86 million in development and regulatory milestones on
a per product basis. Commercial milestones could exceed $100 million on a per product basis. Rib-X retains a co-promotion option in the United States on one of the molecules coming from the collaboration. Royalty rates on net sales could reach low
double digit figures. 
 “We could not be more excited about partnering with a preeminent global pharmaceutical company such as Sanofi.
This partnership reflects our shared commitment to staying ahead of the growing problem of antibiotic resistance by delivering new standards of care for patients in need,” said Mark Leuchtenberger, President and Chief Executive Officer at Rib-X
Pharmaceuticals. “The RX-04 program’s completely novel classes of antibiotics should lead to true breakthrough therapies and we look forward to working in partnership with Sanofi to advance these treatments into the clinic and eventually
bring them to the global market. Importantly, this agreement will enable Rib-X to aggressively advance our clinical stage candidates, delafloxacin and radezolid, towards pivotal trials and support additional discovery-stage programs like RX-05 and
RX-06.” 
 “We are very enthusiastic about entering into this collaboration with Rib-X,” said Elias Zerhouni, M.D., President,
Global Research & Development, Sanofi. “The clinical need for new antibiotics is reaching crisis level, yet the antibiotic pipeline is running dry and fewer and fewer companies are working to develop drugs in this space. This
partnership exemplifies Sanofi’s commitment to translate novel approaches for treatment into patient solutions addressing the global critical need to combat the rising threat of antibiotic drug resistance.” 

About Multi-drug Resistant Bacteria 

Multi-drug resistant bacteria are an increasing public health crisis. Infections caused by such bacteria result in longer hospital stays and may lead to
death. According to the WHO, every year at least 25,000 patients in the European Union alone die from an infection caused by multi-drug resistant bacteria and estimated additional health-care costs and productivity losses are at least 1.5 billion
Euros. Bacteria come in two major classes, defined by their appearance when stained to make them visible under a microscope: Gram-positive, which appear as violet blue typically lack the outer membrane found in Gram-negative bacteria, which appear
pink after staining. 
 About Sanofi 
 Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with
seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
http://www.sanofi.com. 
 About Rib-X Pharmaceuticals, Inc. 
 Rib-X Pharmaceuticals is developing broad spectrum antibiotics with superior coverage, safety and convenience to deliver new standards of care for patients with serious infections. The Company’s
Nobel Prize winning platform enables a unique understanding of how antibiotics combat infection and has generated an industry leading pipeline spanning all phases of research and clinical development. http://www.rib-x.com. 

 For Rib-X 
 Jarrod Longcor 
 Senior Director, Business Development 

Rib-X Pharmaceuticals 
 203-624-5627 

jlongcor@rib-x.com 
 Public and
Investor Relations 
 Sarah Cavanaugh/Kari Watson 
 MacDougall BioMedical Communications 
 781-235-3060 

scavanaugh@macbio.com 

kwatson@macbiocom.com 
  

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Exhibit H-2 

Form of Sanofi Press Release 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Exhibit I 

Rib-X Research Patent Rights 
  

	1.	[***] – WO2011047319: Antimicrobial Compounds and Methods of Making and Using the Same 

 

	2.	[***] – WO2011047323: Antimicrobial Compounds and Methods of Making and Using the Same 

 

	3.	[***] – WO2011047320: Antimicrobial Compounds and Methods of Making and Using the Same 

 

	4.	[***], US 6,638,908 Crystals of the Large Ribosomal Subunit 

  

	5.	[***], US 6,939,828 Crystals of the Large Ribosomal Subunit 

  

	6.	[***], US 6,947,844 Modulators of Ribosomal Function and Modulators Thereof 

 

	7.	[***], US 7,504,486 The Determination and Uses of Atomic Structures of Ribosomes and Ribosomal Subunits and their Ligand Complexes 

 

	8.	[***], US 6,952,650 Modulators of Ribosomal Function and Modulators Thereof 

 

	9.	[***], US 6,947,845 Method of Identifying Molecules that Bind to the Large Ribosomal Subunit 

 

	10.	[***] Protein Synthesis Modulators 

  

	11.	[***] Protein Synthesis Modulators 

  

	12.	[***] Protein Synthesis Modulators 

  

	13.	[***] Protein Synthesis Modulators 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Exhibit J 

Third Party Agreements 
  

	1.	[***] Master Services Agreement 

  

	2.	[***] Work Order 8 and Amendments 

  

	3.	[***] Master Services Agreement 

  

	4.	[***] Master Services Agreement 

  

	5.	[***] Master Services Agreement 

  

	6.	Yale License Agreement 

  

	7.	Cemcomco License Agreement 

  

	8.	[***] License Agreement – Pseudomonas PA0750 

  

	9.	[***] License Agreement – Pseudomonas Strains with various pump knockouts 

 

	10.	[***] License Agreement 

  

	11.	[***] License Agreement 

  

	12.	[***] Master Services Agreement 

  

	13.	[***] Master Services Agreement 

  

	14.	[***] Master Services Agreement 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended.License and supply agreement between the Registrant and CyDex Pharmaceuticals

 Exhibit 10.29 
 LICENSE AND SUPPLY AGREEMENT 
 THIS
LICENSE AND SUPPLY AGREEMENT (this “Agreement”) is made this 30th day of November, 2010 (the “Effective Date”) between: 

CYDEX PHARMACEUTICALS, INC., a Delaware corporation with offices at 10513 W. 84th
Terrace, Lenexa, Kansas 66214 (“CyDex”); and 
 RIB-X PHARMACEUTICALS,
INC., a Delaware corporation with offices at 300 George Street, Suite 301, New Haven, CT 06511 (“Company”). 
 RECITALS 
 WHEREAS, CyDex is engaged in the business
of developing and commercializing novel drug delivery technologies designed to enhance the solubility and effectiveness of existing and development-stage drugs; 

WHEREAS, CyDex is the exclusive worldwide licensee of Captisol®, a patented drug formulation system designed to enhance the solubility and stability of drugs; 

WHEREAS, Company desires to obtain a license to use such patented drug formulation system in
connection with its development and commercialization of the Compound (defined below) and CyDex is willing to grant such license to Company under the terms and conditions set forth herein; and 

WHEREAS, CyDex desires to sell Captisol® to Company, and Company desires to purchase Captisol® from CyDex, in accordance with the terms and conditions contained herein; 
 NOW, THEREFORE, in consideration of the following mutual promises and other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the
parties, intending to be legally bound, agree as follows: 
  

	1.	DEFINITIONS. 

 For the purposes of this Agreement, the following terms shall have the meanings as defined below: 
 1.1 “Affiliate” means, with respect to any party, any entity controlling, controlled by, or under common control with such party, during and for such time as such control exists. For
these purposes, “control” shall refer to the ownership, directly or indirectly, of at least fifty percent (50%) of the voting securities or other ownership interest of the relevant entity. 

1.2 “Captisol” means Captisol®, also known scientifically as sulfobutylether ß(beta) cyclodextrm, sodium salt. 
 1.3 “Captisol Data Package” means (a) all toxicology/safety and other relevant scientific safety data owned, licensed or developed by CyDex and its Affiliates; and (b) all
toxicology/safety and other relevant scientific safety data owned, licensed or developed by the 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 1

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
licensees or sublicensees of CyDex or its Affiliates or other third parties (to the extent permitted in the applicable license or other agreements between CyDex and/or its Affiliates and such
licensees, sublicensees or other third parties), in each case on Captisol alone (and not in conjunction with a product formulation). 
 1.4 “Captisol Improvement” means any technology or improvement related to Captisol alone, whether or not patentable, that is developed by Company or its Affiliates or Sublicensees, solely
or jointly with a third party. 
 1.5 “Claim” has the meaning specified in Section 10.1.

 1.6 “Clinical Grade Captisol” means Captisol which (a) has been manufactured under GMP conditions,
(b) is intended for use in humans, and (c) is intended for clinical trials for the Licensed Product. 
 1.7
“Commercial Grade Captisol” means Captisol which (a) has been manufactured under GMP conditions, (b) is intended for use in humans, and (c) is intended for commercial sale of the Licensed Product. 

1.8 “Commercial Launch Date” means, in any particular country, the first sale by Company, its Affiliates or Sublicensees
of the Licensed Product. 
 1.9 “Compound” means that certain pharmaceutical compound known as RX-3341 with the
United States Adopted Name delafloxacin meglumine, a quinolone antibiotic, and any other pharmaceutically acceptable salt version of the foregoing compound. 
 1.10 “Confidential Information” has the meaning specified in Section 8.1. 
 1.11 “Detailed Forecast” has the meaning specified in Section 3.2(b). 
 1.12 “Disclosing Party” has the meaning specified in Section 8.1 hereof. 
 1.13 “DMF” means a Drug Master File for Captisol, as on file as of the Effective Date, and as hereafter updated from time to time during the Term, by CyDex with the FDA or an equivalent
filing made outside the United States. 
 1.14 “FDA” means the United States Food and Drug Administration, or
any successor thereto. 
 1.15 “Field” means the treatment of bacterial infections and all other therapeutic,
prophylactic and palliative uses other than anti-fungal and ophthalmic uses. 
 1.16 “GMP” means the current
good manufacturing practices for bulk excipients as set forth in: 
 (i) 21 C.F.R. parts 210 and 211 of the U.S. Code of Federal
Regulations; 
 (ii) the International Conference on Harmonization (ICH) Guide Q7; and 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 2

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 (iii) U.S. Pharmacopoeia <1078>; 

as of the Effective Date or as may be amended or re-enacted from time to time and as interpreted in accordance with then-current industry standards and
FDA policies. 
 1.17 “IND” means an Investigational New Drug application, as defined in the United States
Federal Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or similar application filed with an equivalent regulatory body in another country. 
 1.18 “Indemnitee” has the meaning specified in Section 10.4. 
 1.19 “Indemnitor” has the meaning specified in Section 10.4. 
 1.20 “Licensed Patents” means all patents and patent applications in the Territory which cover Captisol, or its composition, manufacture, import, sale or use, or the composition,
manufacture, import, sale or use of Licensed Product, and which now or at any time during the Term are owned by CyDex or any Affiliate of CyDex or licensed to CyDex or any CyDex Affiliate with the right to sublicense, including any and all
extensions, renewals, continuations, substitutions, continuations-in-part, divisions, patents-of-addition, reissues, reexaminations and/or supplementary protection certificates to any such patent applications and patents. Set forth in Exhibit
A attached hereto is a list of the Licensed Patents as of the Effective Date. Such Exhibit A may be updated or corrected by CyDex from time to time during the Term as necessary to make the list complete, provided a failure to
so update or correct the list shall not have any effect on the scope of the definition. 
 1.21 “Licensed
Product” means the Compound combined with or formulated using Captisol in an intravenous dosage form/formulation, or a form/formulation intended to be reconstituted for intravenous administration, for ultimate use in humans. For clarity,
the Licensed Product shall not include any product which is a combination product incorporating the Compound with any other active pharmaceutical ingredient. 
 1.22 “Losses” has the meaning set forth in Section 10.1. 
 1.23 “Manufacturing Standards” means Captisol delivered by CyDex under this Agreement: 
 (i) meets Specifications; 
 (ii) has been manufactured in accordance with the
processes set forth in the DMF; 
 (iii) has been manufactured in accordance with GMP and all other applicable laws and
regulations; and 
 (iv) is not adulterated within the meaning of the United States Food, Drug and Cosmetic Act, as amended (the
“Act”), and shall not be an article which may not, under the provisions of the Act, be introduced into interstate commerce. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 3

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 1.24 “Marketing Approval” means final approval of an NDA by the FDA, or
final approval of a comparable document filed with an equivalent health regulatory authority in any other country or in the European Union (using the centralized process or mutual recognition), including all required marketing, pricing or
reimbursement approvals. 
 1.25 “NDA” means a New Drug Application, as defined in the United States Federal
Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or similar application filed with an equivalent regulatory body in another country. 
 1.26 “Net Sales” means gross amounts invoiced by Company, its Affiliates and Sublicensees for sales of the Licensed Product, less the following: (a) normal and customary trade,
quantity and/or cash discounts, allowances and rebates actually allowed or given; (b) returns, refunds and credits actually allowed for rejections, defects or recalls of Licensed Product, outdated or returned Licensed Product;
(c) government mandated rebates and other compulsory payments, credits, adjustments and rebates actually paid or deducted; (d) other price adjustments, allowances, credits, chargeback payments, discounts, and rebates, which are reasonable
and consistent with industry practices; (e) normal and customary wholesaler’s discounts; (f) distributor commissions and fees paid to third party wholesalers for distribution of Licensed Product which are reasonable and consistent
with industry practice, not to exceed [***] percent ([***]%); (g) amounts previously included in Net Sales of Licensed Product that are written-off by Company or any of its Affiliates or Sublicensees, as the case may be, as uncollectible, in
accordance with commercially reasonable practices; (h) freight, postage, shipping insurance and other transportation expenses (if separately identified on the invoice); and (i) sales, value-added, excise or use taxes, tariffs, duties and
customs fees and other taxes imposed with respect to specific sales. In addition, in the event industry practices change such that an item substantially similar in character or substance to any of the foregoing but not specifically included in
clauses (a) through (i) becomes a customary deduction in the calculation of “Net Sales”, CyDex shall not unreasonably withhold its agreement to amend the foregoing definition to include such item as a deduction for purposes of
calculating “Net Sales”. In the case of a sale of Licensed Product between or among Company and/or its Affiliates and Sublicensees for resale, Net Sales shall be calculated as above only on the gross amount invoiced on the first arm’s
length sale. 
 1.27 “Notice of Default” has the meaning specified in Section 13.2. 

1.28 “Notice of Termination” has the meaning specified in Section 13.2. 

1.29 “[***]” has the meaning specified in Section 8.5. 

1.30 “Purchase Volume Limitations” has the meaning specified in Section 3.2(c). 

1.31 “Receiving Party” has the meaning specified in Section 8.1. 

1.32 “Ql”, “Q2, “Q3”, and “Q4” have the meanings specified in
Section 3.2(b). 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 4

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 1.33 “Research Grade Captisol” means Captisol which has not been
manufactured under GMP conditions and is not suitable for use in humans, but which meets CyDex’s specifications for Research Grade Captisol. 
 1.34 “SEC” has the meaning specified in Section 8.3. 

1.35 “Specifications” means the specifications for Captisol set forth in Exhibit B hereto, as such may be
amended from time to time pursuant to Section 3.4. 
 1.36 “Study” has the meaning specified in
Section 6.3. 
 1.37 “Sublicensees” has the meaning specified in Section 2.3, but shall
not include wholesalers and other third party distributors who solely purchase Licensed Product in final finished form from Company or any of its Affiliates or Sublicensees for re-sale in such form or for re-sale after completion of final packaging
and labeling. 
 1.38 “Term” has the meaning specified in Section 13.1. 

1.39 “Testing Methods” has the meaning specified in Section 3.5(a). 

1.40 “Third-Party Manufacturer” has the meaning specified in Section 3.6. 

1.41 “Territory” means the entire world. 
 1.42 “Valid Claim” means a claim in any unexpired, issued patent which has not been irrevocably abandoned or held to be invalid or unenforceable by a non-appealed or unappealable decision
of a court or other authority of competent jurisdiction, and which is not admitted to be invalid through disclaimer or dedication to the public. 
 1.43 “Volume Threshold” has the meaning specified in Section 3.1. 
  

	2.	GRANT OF RIGHTS. 

 2.1 License Grants from CyDex to Company. 
 (a) Licensed
Patents. Subject to the terms and conditions of this Agreement, including but not limited to payment of the amounts set forth in Section 4.1 below, CyDex hereby grants to Company an exclusive, nontransferable (except with respect to
the assignment provision in Section 14.15 and the sublicensing provisions of Sections 2.3 and 2.4) license during the Term under the Licensed Patents, solely to research, develop, make, have made, use, market, distribute,
sell, have sold, export, offer for sale and import the Licensed Product in the Territory in the Field. Notwithstanding the foregoing, to the extent that any Licensed Patents are licensed to CyDex or its Affiliates by a third party on a non-exclusive
basis, the license granted to Company in the foregoing sentence shall be exclusive as to CyDex and non-exclusive as to any third party. Company shall not, and shall not have the right under the foregoing license to, make, use, sell, offer for sale,
or import the Licensed Product for any other purposes. Company may not sublicense the Licensed Patents, except as expressly set forth in Sections 2.3 and 2.4 below. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 5

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 (b) Captisol Data Package. Subject to the terms and conditions of
this Agreement, including but not limited to payment of the amounts set forth in Section 4.1 below, CyDex hereby grants to Company a non-exclusive, nontransferable (except with respect to the assignment provision in
Section 14.15 and sublicensing provisions of Sections 2.3 and 2.4) license during the Term under the rights of CyDex and any of its Affiliates in and to the Captisol Data Package, solely to research, develop, make, have
made, use, market, distribute, sell, have sold, export, offer for sale and import the Licensed Product in the Territory in the Field. Company may not sublicense its rights to the Captisol Data Package, except as expressly set forth in Sections
2.3 and 2.4 below. 
 (c) Scope of Licenses. Without limiting the generality of the foregoing,
CyDex grants no rights to Company to manufacture, import, sell or offer for sale bulk Captisol, except as set forth in Section 3.7(d). Licensee acknowledges that not all rights of CyDex related to Captisol are included within the rights
licensed under this Section 2.1, given that CyDex shall supply Company’s requirements of Captisol for the Licensed Product, subject to Section 3.7(d). Company shall not attempt to reverse engineer, deconstruct or in any
way determine the structure or composition of Captisol. CyDex shall not be liable to Company for violation of Company’s exclusive rights hereunder by parties which are not Affiliates of CyDex, provided that if a third party is infringing any
Licensed Patents in a manner that is in violation of Company’s exclusive rights, and CyDex is not taking steps to stop such infringement either directly against the infringer or against the infringer’s source of the infringing product,
then the royalty payable by CyDex will be reduced by [***] percent ([***]%) during any period in which such infringement continues. Company acknowledges and agrees that (i) CyDex shall not be required to obtain or maintain patent rights in the
Territory for the Licensed Patents, (ii) except as provided in this Agreement with respect to the Licensed Product, CyDex shall not be restricted in making sales of Captisol or licensing rights to other parties, and (iii) CyDex does not
warrant or indemnify Licensee or its Affiliates and Sublicensees against the Licensed Product infringing third party rights. 

2.2 Grant of License from Company to CyDex. Company hereby grants to CyDex a nonexclusive, transferable, perpetual, worldwide and
royalty-free license, with the right to grant sublicenses (through multiple tiers of sublicensees), under Company’s and its Affiliates’ and Sublicensees’ rights in and to Captisol Improvements to develop, make, have made, use, market,
distribute, import, export, sell and offer for sale Captisol or any Captisol Improvement (other than for use with Compound) and products formulated with Captisol or any Captisol Improvement (other than the Licensed Product in the Field). If, during
the Term, any of (a) Company, (b) Affiliates to whom Company has provided rights under the licenses granted to Company by CyDex pursuant to Section 2.1, or (c) Sublicensees pursuant to the practice of their respective
sublicenses from Company under Section 2.3, file any patent application claiming Captisol anywhere in the world, CyDex shall be deemed automatically to have a nonexclusive, transferable, perpetual, worldwide and royalty-free license,
with the right to grant sublicenses (through multiple tiers of sublicensees), under the claims relating specifically to Captisol to make, have made, use, market, distribute, import, sell, and offer for sale Captisol (other than for

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 6

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
use with Compound) and all products formulated with Captisol (other than the Licensed Product in the Field). Company shall provide prompt notice to CyDex of any Captisol Improvement, and shall
notify and consult with CyDex at least thirty (30) days prior to the filing of any patent application claiming Captisol or any Captisol Improvement. 
 2.3 Sublicensing. Company shall have the right to grant sublicenses to its Affiliates and licensees of the Licensed Product (collectively “Sublicensees”) under the licenses granted
to Company pursuant to Section 2.1; provided that Company warrants that each such Sublicensee shall first be advised of the restrictions set forth in this Agreement with respect to the transfer of the rights sublicensed to such
Sublicensee and such Sublicensee shall enter into an agreement (in substantially the form of Exhibit E hereto or such other form as CyDex shall approve, such approval to not be unreasonably withheld, conditioned or delayed) with
Company pursuant to which such Sublicensee shall acknowledge and agree to observe and be bound by the applicable restrictions set forth in this Agreement. Other than as specifically provided in and this Section 2.3 and
Section 2.4, Company shall not have the right to grant sublicenses to any third party under the licenses granted pursuant to Section 2.1. 
 2.4 Contracting. Company may manufacture the Licensed Product (but, except as set forth in Section 3.7(d), not the bulk Captisol) or contract the manufacture of the Licensed Product
(but, except as set forth in Section 3.7(d), not the manufacture of bulk Captisol) with reputable FDA-inspected third party manufacturers upon notification to CyDex in writing of Company’s intent to do so (such notice to include the
identity and location of the proposed third party manufacturers). To the extent necessary to engage a third party manufacturer for the Licensed Product, Company shall be permitted under this Agreement to grant any such third party manufacturer a
sublicense under the licenses granted to Company pursuant to Section 2.1 solely for such purposes; provided that Company warrants and shall procure, as a condition precedent thereto, that (a) any such third party manufacturer
shall first be advised of the restrictions set forth in this Agreement with respect to the transfer of the rights licensed to Company and its Sublicensees hereunder and (b) any such third party manufacturer shall enter into an agreement (in
substantially the form of Exhibit E hereto) with Company pursuant to which such third party manufacturer shall acknowledge and agree to observe and be bound by the applicable restrictions set forth in this Agreement. 

 

	3.	MANUFACTURE AND SUPPLY OF CAPTISOL. 

3.1 Purchase of Captisol. Company agrees that, subject to Section 3.7, Company and its Affiliates and Sublicensees
shall purchase Captisol for use in the formulation of Licensed Product exclusively from CyDex and that, except as set forth in Section 3.7(d), this Agreement does not grant Company, its Affiliates or Sublicensees the right to manufacture
(or have manufactured on their behalf) Captisol without CyDex’s prior written consent. CyDex agrees that CyDex shall produce (or have produced for it) and sell to Company one hundred percent (100%) of Company’s and its
Affiliates’ and Sublicensees’ requirements for Captisol for use in the formulation of Licensed Product, during the Term and subject to the provisions of this Agreement and provided that, and notwithstanding anything to
the contrary in this Agreement, in no event shall CyDex be obligated to supply to Company or its Affiliates or Sublicensees more than an aggregate quantity of [***] ([***]) kilograms of Captisol per year (the “Volume

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 7

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
Threshold”). Purchases of Captisol may include Research Grade Captisol, Clinical Grade Captisol and/or Commercial Grade Captisol. Company may place orders for Captisol on behalf of its
Affiliates and Sublicensees; provided, however that: (a) Company shall instruct CyDex as to the location for the shipment thereof; (b) Company shall guarantee payment to CyDex of all amounts payable with respect thereto; and
(c) if Company requests that CyDex deliver such orders to Company for re-delivery thereof by Company to its Affiliates or Sublicensees, Company shall comply with all applicable laws, rules and regulations applicable to the transportation of
Captisol from Company to its Affiliates and Sublicensees. 
 3.2 Supply Terms. 

(a) Long-term Forecast. No later than [***] ([***]) months prior to the anticipated Commercial Launch Date by
Company or its Affiliates or Sublicensees of a Licensed Product in any particular country, Company shall provide CyDex with a forecast setting forth Company’s nonbinding estimate of the required quantities of Commercial Grade Captisol for each
of the following [***] ([***]) years. Such long-term nonbinding forecast shall thereafter be updated by Company at least once every [***] ([***]) months. 
 (b) Binding Detailed Forecast. At least [***] ([***]) [***] prior to the first order of Commercial Grade Captisol, Company shall deliver to CyDex a detailed rolling forecast setting forth
Company’s requirements and anticipated delivery schedules for Commercial Grade Captisol for each calendar quarter during the succeeding twelve (12) month period (the “Detailed Forecast”). For purposes of this Agreement, a
calendar quarter means the consecutive three (3) month period ending March 31, June 30, September 30, and December 31, respectively. The parties acknowledge and agree that the first calendar quarter covered in the
Detailed Forecast may be for a period less than the full three (3) month period but that each subsequent calendar quarter shall be for a full three (3) month period. The Detailed Forecast shall thereafter be updated by Company quarterly on
a rolling basis, no later than the [***] of each calendar quarter, so that each calendar quarter CyDex shall have been provided with a rolling Detailed Forecast for each calendar quarter during the twelve (12) month period commencing on the
first day of the next calendar quarter following the date on which such Detailed Forecast is submitted. The Detailed Forecast shall be [***] Company, subject to the permissible variances set forth in Section 3.2(c) below, with respect to
the first, second, and third calendar quarters covered by such updated Detailed Forecast (“Ql”, “Q2”, “Q3”, respectively, and where the fourth calendar quarter shall be “Q4”). If
Company fails to provide any updated Detailed Forecast in accordance with this Section 3.2(b), [***]. 
 (c) Detailed Forecast Variances. Each updated Detailed Forecast may modify the amount of Commercial Grade Captisol estimated in the previous Detailed Forecast in accordance with the following
limitations (the “Purchase Volume Limitations”): 
 (i) for the Q1 covered by such
updated Detailed Forecast, no change may be made to the forecast provided for the Q2 in the immediately preceding Detailed Forecast without the prior express written consent of CyDex; 

(ii) for the Q2 covered by such updated Detailed Forecast, no change in excess of a [***] percent ([***]%) volume
increase or decrease may be made to the forecast provided for the Q3 in the immediately preceding Detailed Forecast without the prior express written consent of CyDex; and 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 8

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 (iii) for the Q3 covered by such updated Detailed Forecast, no change
in excess of a [***] percent ([***]%) volume increase or decrease may be made to the forecast provided for the Q4 in the immediately preceding Detailed Forecast without the prior express written consent of CyDex. 

In each case CyDex’s consent may be conditioned on such payment or other terms as CyDex may require. 

(d) Purchase Orders. Together with each Detailed Forecast provided under Section 3.2(b), Company shall
place a firm purchase order with CyDex in a form mutually agreed upon by the parties, for Company’s order of Commercial Grade Captisol for Q1 delivery consistent with the Detailed Forecast. Each purchase order, for all grades of Captisol, shall
specify: (i) the grade of Captisol ordered (i.e., Commercial Grade Captisol, Clinical Grade Captisol or Research Grade Captisol); (ii) quantities; (iii) delivery dates; and (iv) reasonable shipping instructions. CyDex
shall deliver orders of Captisol to Company on or within five (5) business days of Company’s requested delivery dates; provided, however, that the purchase order is received by CyDex at least ninety (90) days prior to the
stipulated delivery date. No purchase order shall be binding upon CyDex until accepted by CyDex in writing; provided that CyDex (x) shall accept in writing within ten (10) days after CyDex’s receipt of each purchase order for Clinical
Grade Captisol or Research Grade Captisol, (y) shall accept in writing within ten (10) days after CyDex’s receipt of each purchase order for Commercial Grade Captisol from Company with respect to the quantities of Captisol ordered
that do not exceed the Purchase Volume Limitations, and (z) shall notify Company of CyDex’s ability to fill any quantities of such purchase order for Commercial Grade Captisol that are in excess of the Purchase Volume Limitations (but
under the Volume Threshold) within thirty (30) days after CyDex’s receipt of such purchase order. CyDex shall not be obligated to accept such orders to the extent that the quantities of Commercial Grade Captisol ordered exceed the Purchase
Volume Limitations, but CyDex shall use good faith efforts to fill such orders for such excess quantities (provided that such quantities are less than the Volume Threshold) from available supplies. If CyDex, despite the use of good faith efforts, is
unable to supply such quantities that exceed the Purchase Volume Limitations to Company, such inability to supply shall not be deemed to be a breach of this Agreement by CyDex or a failure by CyDex to supply for any purpose. If any purchase order or
other document submitted by Company hereunder or any invoice or other document passing between the parties contains terms or conditions in addition to or inconsistent with the terms of this Agreement, the terms of this Agreement shall control and
prevail and such additional or inconsistent terms are hereby expressly rejected. 
 3.3 Delivery. CyDex shall deliver to
Company or Company’s designee each order of Captisol, packed for shipment in accordance with CyDex’s customary practices and the Specifications, EXW (Incoterms 2000) CyDex’s production point or storage facilities. Title and risk of
loss and/or damage to Captisol shall pass to Company upon delivery of Captisol to Company or Company’s designee at CyDex’s production point or storage facilities. Company agrees, after Commercial Launch Date, to maintain an inventory of
Captisol sufficient to supply 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 9

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
at least [***] ([***]) days’ worth of Company’s requirements. Quantities actually delivered to Company or Company’s designee pursuant to an accepted purchase order may vary from
the quantities reflected in such purchase order by up to [***] percent ([***]%) and still be deemed to be in compliance with such purchase order; provided, however, that Company shall only be invoiced and required to pay for the quantities of
Captisol that CyDex actually delivers to Company or Company’s designee. CyDex will use commercially reasonable efforts to include, in the next shipment of Captisol to Company, any quantities ordered pursuant to an accepted purchase order but
not delivered. 
 3.4 Modified Specifications. CyDex may change the Specifications during the Term with written
notification to Company. In such event, CyDex shall give Company at least [***] ([***]) days to respond to such notice of change. Company and CyDex shall cooperate regarding initiating any changes to the Specifications and to have such change
approved by all regulatory agencies having jurisdiction. In addition, if any regulatory agency having jurisdiction requires CyDex to implement any changes to the Specifications, CyDex shall use all reasonable efforts to make such changes. If a
regulatory agency requires a change to the Specifications where such change is specific to Captisol as implemented in the Licensed Product, then [***] shall be responsible for the costs incurred to generate such unique, modified Specifications,
provided that the parties will mutually agree on such costs prior to CyDex’s commencement of implementation of such change. In the event of a change initiated by CyDex, if requested by Company, CyDex shall provide to Company the right to
purchase an amount of Captisol not greater than a [***] ([***]) [***] supply prior to such change in Specifications in order to allow the Company to maintain supply of Licensed Product until the new Specifications are validated with Licensed
Product. 
 3.5 Quality Control; Acceptance and Rejection. 

(a) Quality Control. CyDex shall conduct or have conducted quality control testing of Captisol prior to shipment in
accordance with the Specifications and other CyDex-approved quality control testing procedures (the “Testing Methods”). CyDex shall retain or have retained accurate and complete records pertaining to such testing. Each shipment of
Captisol hereunder shall be accompanied by a certificate of analysis for each lot of Captisol therein. 
 (b)
Acceptance Testing. Company shall have a period of [***] ([***]) days from the date of receipt to test or cause to be tested Captisol supplied under this Agreement. Company or its designee shall have the right to reject any shipment of Captisol
that does not conform with the Specifications at the time of delivery pursuant to Section 3.3 hereof when tested in accordance with the Testing Methods or that otherwise does not meet the Manufacturing Standards. All shipments of
Captisol shall be deemed accepted by Company unless CyDex receives written notice of rejection from Company within such [***] ([***]) day period describing the reasons for the rejection in reasonable detail. Once a delivery of Captisol is accepted
or deemed accepted hereunder, Company shall have no recourse against CyDex in the event Captisol is subsequently deemed unsuitable for use for any reason, except as provided in Section 10 below. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 10

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 (c) Confirmation. After its receipt of a notice of rejection from
Company pursuant to Section 3.5(b) above, CyDex shall notify Company as soon as reasonably practical but no later than [***] ([***]) days whether it accepts Company’s basis for rejection and Company shall cooperate with CyDex in
determining whether such rejection was necessary or justified. If the parties are unable to agree as to whether a shipment of Captisol supplied by CyDex or its Third-Party Manufacturer hereunder meets the Specifications, such question shall be
submitted to an independent quality control laboratory mutually agreed upon by the parties. The findings of such independent laboratory shall be binding upon the parties. The cost of the independent quality control laboratory shall be borne by the
party whose results are shown by such laboratory to have been incorrect. 
 (d) Return or Destruction of
Rejected Shipments. Company may not return or destroy any batch of Captisol until it receives written notification from CyDex that CyDex does not dispute that the batch fails to meet the Specifications. CyDex will indicate in its notice either
that Company is authorized to destroy the rejected batch of Captisol or that CyDex requires return of the rejected Captisol. Upon written authorization from CyDex to do so, Company shall promptly destroy the rejected batch of Captisol and provide
CyDex with written certification of such destruction. Upon receipt of CyDex’s request for return, Company shall promptly return the rejected batch of Captisol to CyDex. In each case, CyDex will reimburse Company for the documented, reasonable
costs associated with the destruction or return of the rejected Captisol within thirty (30) days. 
 (e)
Refund or Replacement. Company shall not be required to pay any invoice with respect to any shipment of Captisol properly rejected pursuant to this Section 3.5. Notwithstanding the foregoing, Company shall be obligated to pay in full
for any rejected shipment of Captisol that is subsequently determined to meet the Specifications in all material respects, irrespective of whether Company has already paid CyDex for a replacement shipment. If Company pays in full for a shipment of
Captisol and subsequently properly rejects such shipment in accordance with this Section 3.5, Company shall be entitled, upon confirmation that such shipment failed to meet the Specifications in all material respects, either: (i) to
a refund or credit equal to the purchase price paid with respect to such rejected shipment; or (ii) to require CyDex to replace such rejected shipment at no additional cost to Company. Company acknowledges and agrees that, except for the
indemnification obligations set forth in Section 10 below, Company’s rights to a refund or credit for or to receive replacement of properly rejected shipments of Captisol hereunder shall be Company’s sole and exclusive remedy,
and CyDex’s sole obligation, with respect to non-conforming Captisol delivered hereunder. 
 (f)
Exceptions. Company’s rights of rejection, return, refund and replacement set forth in this Section 3.5 shall not apply to any Captisol that is non-conforming due to damage (i) caused by Company, its Affiliates or
Sublicensees or their respective employees or agents, including but not limited to, misuse, neglect, improper storage, transportation or use beyond any dating provided or (ii) that occurs subsequent to delivery of such Captisol to the carrier
at the point of origin, including but not limited to any damage caused thereafter by accident, fire or other hazard and CyDex shall have no liability or responsibility to Company with respect thereto. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 11

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 3.6 Facilities and Inspections. Without limiting CyDex’s responsibility under
this Agreement, CyDex shall have the right at any time to satisfy its supply obligations to Company hereunder either in whole or in part through arrangements with third parties engaged to perform services or supply facilities or goods in connection
with the manufacture or testing of Captisol (each, a “Third-Party Manufacturer”). CyDex shall give Company at least sixty (60) days prior written notice of any such arrangement. The parties hereby agree that [***] is a
Third-Party Manufacturer as of the Effective Date of this Agreement. CyDex shall permit no more than two (2) of Company’s authorized representatives, during normal working hours and upon reasonable prior notice to CyDex but in no event
less than sixty (60) days’ prior notice, to inspect that portion of all CyDex facilities utilized for the manufacture, preparation, processing, storage or quality control of Captisol or such facilities of any Third-Party Manufacturer, once
per calendar year per facility for existing facilities (unless the inspection reveals material deficiencies or concerns which require additional follow-up inspections, including without limitation, noncompliance with GMP, Specifications or any
applicable law). In addition, CyDex shall permit any such inspection of a new facility (one time per new facility) upon not less than sixty (60) days’ prior notice and such initial inspection shall not count as a yearly inspection under
the preceding sentence. If any such inspection is of a facility of a Third Party Manufacturer, Company shall pay, on a pass through basis, the amount charged to CyDex by its Third Party Manufacturer specifically by reason of Company’s
participation in such inspection. Company’s authorized representatives shall be accompanied by CyDex personnel at all times, shall be qualified to conduct such manufacturing audits, shall comply with all applicable rules and regulations
relating to facility security, health and safety, and shall execute a written confidentiality agreement with terms at least as restrictive as those set forth in Section 8 hereof. In no event shall any such manufacturing audit exceed two
(2) days in duration. Company shall ensure that its authorized representatives conduct each manufacturing audit in such a manner as to not interfere with the normal and ordinary operations of CyDex or its Third-Party Manufacturer. CyDex shall
inform Company of any regulatory inspection that may impact Captisol or the Licensed Product and shall provide Company with a summary of the outcome of such inspection and a copy of any Form 483 or other letter of deficiency received from a
regulatory agency inspection, subject to confidentiality obligations of CyDex to Third Parties related to matters other than Captisol alone. Except as expressly set forth in this Section 3.6, neither Company nor its Affiliates, Sublicensees or
their respective employees or representatives shall have access to CyDex’s facilities or the facilities of any Third-Party Manufacturer. 
 3.7 Inability to Supply. 
 (a) Notice. CyDex shall
notify Company if CyDex is unable to supply the quantity of (i) Commercial Grade Captisol ordered by Company in accordance with the Purchase Volume Limitations set forth in Section 3.2(c) or (ii) Research Grade Captisol or
Clinical Grade Captisol ordered by Company as set forth in Section 3.2(d) above: (1) within twenty (20) days after CyDex’s receipt of a purchase order from Company as provided in Section 3.2(d); or
(2) immediately upon becoming aware of an event of force majeure or any other event that would render CyDex unable to supply to Company the quantity of Captisol that CyDex is required to supply hereunder. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 12

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 (b) Allocation. If CyDex is unable to supply to Company the quantity
of Captisol that CyDex is required to supply hereunder, CyDex (i) shall allocate its available Captisol among Company and any other purchasers of Captisol with which CyDex then has an on-going contractual relationship, in proportion to the
quantity of Captisol for which each of them has orders pending at such time and (ii) shall take all reasonable steps necessary to minimize supply delays. The supply allocation provided in this Section 3.7(b) shall be CyDex’s
sole obligation and Company’s sole and exclusive remedy for any supply shortage. 
 (c) Shortage of
Supply and Back-Up Manufacturing Rights. If (1) CyDex fails to timely supply to Company at least [***] percent ([***]%) of the quantities of Captisol properly forecasted and ordered by Company (and provided such order was within the
Purchase Volume Limitations) that conform to the Specifications for [***] ([***]) [***] or (2) CyDex is unable to supply or to timely supply to Company the quantity of Captisol that CyDex is required to deliver to Company pursuant to accepted
purchase orders due to an event of Force Majeure that actually lasts, or is expected to last, for more than [***] ([***]) days (each, a “Failure to Supply”), then the following provisions shall be applicable: 

(i) Alternate Facility. First, at Company’s written request, CyDex shall use commercially reasonable efforts
to procure that its Third Party Manufacturer validate and qualify a backup manufacturing facility for the manufacture of Captisol. 
 (ii) Alternate Supplier. Second, at Company’s written request, if the Third Party Manufacturer is unable to validate and qualify an alternate facility pursuant to clause (i) above, CyDex
shall use commercially reasonable efforts to qualify one or more alternate suppliers for the manufacture of Captisol, including without limitation, obtaining Third-Party Manufacturer’s reasonable cooperation with CyDex to qualify such alternate
supplier. 
 (iii) Transfer of Manufacturing Technology. Third, if CyDex is unable to procure an alternate
facility pursuant to clause (i) above or alternate supplier pursuant to clause (ii) above within [***] ([***]) days of the first occurrence of the Failure to Supply event, Company may, by providing written notice of the occurrence of such
Failure to Supply, elect to assume manufacturing of Captisol under its Manufacturing License (as defined in paragraph (d)). In the event Company elects to use another supplier to manufacture and supply Captisol pursuant to this
Section 3.7(c), CyDex, within sixty (60) days of receipt of Company’s written notice, shall provide Company with the documentation, know-how and technical information that is necessary to make and have made Captisol, and shall
fully cooperate with Company in the implementation of the manufacturing process. Company shall pay for (i) CyDex’s reasonable actual out of pocket costs related to such activities, and (ii) the reasonable costs of the time of
CyDex’s employees and contractors incurred for such transfer of the manufacturing process at the rate of $[***] per person per hour. To the extent practicable, CyDex shall continue to supply Company with its needs of Captisol under the terms of
this Agreement until Company is capable of doing so. 
 (d) Manufacturing License. CyDex hereby grants to
Company a non exclusive, non-transferable license (without the right to sublicense other than to its contract manufacturers designated under Section 3.7(c)(iii) under all intellectual property rights owned or

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 13

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
licensed by CyDex and its Affiliates solely to make, or to have made, Captisol for the purpose of meeting Company’s requirements of Captisol for use in the manufacture of the Licensed
Product in the Territory (“Manufacturing License”) for the remainder of the Term; provided that such Manufacturing License shall not be exercised until the occurrence of a Failure to Supply. For clarity, the Manufacturing License
shall not include the right to make Captisol for any other product or for any third party other than Company’s Affiliates and Sublicensees, and Company’s exercise of the Manufacturing License and back-up manufacturing right pursuant to
Section 3.7(c) hereof shall not be deemed a violation of this Agreement. Notwithstanding anything in this Agreement to the contrary, upon exercise of its Manufacturing License, Company shall thereafter no longer be required to purchase
any of its requirements of Captisol from CyDex under this Agreement to the extent Company has become obligated to purchase its requirements for Captisol from the back-up manufacturer under this Section. 

 

	4.	COMPENSATION. 

 4.1 Payments and Royalties for Licenses. 
 (a) One-Time
Fee. Company shall pay to CyDex a non-refundable, one-time fee of three hundred thousand dollars ($300,000) in partial consideration of the rights granted Company under this License and Supply Agreement, which amount shall be due and payable in
full upon the Effective Date. 
 (b) Milestone Payments. Within ten (10) days following the first
occurrence of each of the milestone events listed below with respect to Licensed Product, Company shall provide written notice to CyDex of the achievement of such milestone event, and within thirty (30) days of the occurrence of each of the
milestone events, pay to CyDex the applicable non-refundable milestone fee listed next to each such event in further consideration of the rights granted Company hereunder. The milestone payments are as follows: 

 

					
	 MILESTONE
	  	MILESTONE
PAYMENT
	 
	 Upon the commencement of [***]
	  	 	US$[***]	  
	 Upon the commencement of [***]
	  	 	US$[***]	  
	 Upon filing of [***]
	  	 	US$[***]	  
	 Upon receipt of the [***]
	  	 	US$[***]	  
	 Upon receipt of the [***]
	  	 	US$[***]	  
	 Upon the [***]
	  	 	US$[***]	  

 (c) Royalties. 

(i) In addition to amounts payable pursuant to Sections 4.1(a) and 4.1(b) above, Company shall,
subject to the adjustments set forth in this Section, make royalty payments to CyDex during the Term on a calendar quarterly basis, in an amount equal to [***] ([***]%) of the applicable Net Sales during such quarter arising from the
sale of the Licensed Product in the Territory, commencing on the first Commercial Launch Date of the Licensed Product in the Territory. All royalties payable to CyDex pursuant to this Section 4.1(c)(i) shall be due and payable within
thirty (30) days after the conclusion of each calendar quarter. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 14

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 (ii) Following the expiration of the last Valid Claim of the Licensed
Patent to expire in the country of sale, on a country-by-country basis, Company shall have the right to reduce by [***] percent ([***]%) the royalty payments owed pursuant to Section 4.1(c)(i) with respect to Net Sales arising from the
sale of Licensed Product in such country. All royalties payable to CyDex pursuant to this Section 4.1(c) shall be due and payable within thirty (30) days after the conclusion of each calendar quarter. Company’s obligation to
pay royalties pursuant to this Section 4.1(c) shall continue, on a country-by-country basis, in the country of sale until the tenth (10th) anniversary of the expiration date of the last Valid Claim of a Licensed Patent to expire in such
country, provided that, if there has never been a Valid Claim of a Licensed Product in the country of sale, then the royalty obligation will terminate on the tenth anniversary of first Commercial Launch Date in such country. 

(iii) CyDex will be responsible for all amounts due to third parties on the manufacturing, use or sale of bulk
Captisol under agreements to which CyDex is a party. In the event Company requires a license to any third party intellectual property covering the manufacture or composition of bulk Captisol (but not the use of bulk Captisol within the Licensed
Product): 
  

	 	(A)	CyDex shall have the [***] to seek to acquire, using commercially reasonable efforts, such license at [***]. If CyDex is successful, such rights shall be included
within the license granted to Company pursuant to Section 2.1 (a) or (b) above [***] hereunder. 

  

	 	(B)	If after [***] ([***]) days CyDex has not acquired such license, then Company may seek to acquire, using commercially reasonable efforts, such license at [***],
provided that Company may offset [***] ([***]%) of any upfront payments, milestones, royalties and other amounts paid to such third party under such license against amounts due to CyDex under this Agreement. Amounts available for offset under
this Section and not used as a credit against payments due to CyDex in the period incurred may be carried over to future periods until fully utilized. 

(iv) In establishing the royalty structure hereunder, the parties recognize, and Company acknowledges, the
substantial value of the various obligations being undertaken by CyDex under this Agreement, in addition to the grant of the licenses under the Licensed Patents and Captisol Data Package, to enable the rapid and effective market introduction of the
Licensed Product in the Territory. The parties have agreed to the payment structure set forth herein as a convenient and fair mechanism to compensate CyDex for these obligations. 

4.2 Pricing for Captisol. 
 (a) Pricing. The purchase prices for Captisol are as specified in Exhibit C attached hereto. CyDex reserves the right to increase the purchase prices set forth on Exhibit
C on [***] during the Term, by written notice to Company, by a percentage equal to the aggregate percentage increase, if any, in the Producer Price Index, Pharmaceutical Preparation Mfg
-

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 15

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
pcu325412325412 PCU as reported by the Bureau of Labor Statistics, U.S. Department of Labor, for the 12-month period ending October 31 of the prior year. The minimum order for Commercial
Grade Captisol shall be in [***] ([***]) [***] increments. Notwithstanding the foregoing, if Company fails to order for any Q1 a quantity of Commercial Grade Captisol to be delivered during such Q1 that is equal to or greater than the quantity of
Commercial Grade Captisol Company is obligated to purchase pursuant to the applicable Detailed Forecast (the difference between the quantity of Commercial Grade Captisol Company is obligated to purchase in Q1 pursuant to the applicable Detailed
Forecast and the amount of Commercial Grade Captisol that Company actually orders in Q1, the “Shortfall”), then provided that (i) CyDex has used commercially reasonable efforts to mitigate and (ii) CyDex is not in breach
of its supply obligation under this Agreement, Company agrees to reimburse CyDex for the cost of any raw materials and supplies acquired or used in anticipation of supplying Company with such Shortfall to the extent that such raw materials and
supplies cannot be redeployed to other projects and any resulting Commercial Grade Captisol cannot be resold to other customers or utilized by Company in the next [***] ([***]) day period. 

(b) Invoicing; Payment. CyDex shall invoice Company upon shipment of each order of Captisol. All invoices shall be
sent to the address specified in the applicable purchase order, and each invoice shall state the purchase price for Captisol in such shipment, plus any insurance, taxes, shipping costs or other costs incidental to such purchase or shipment initially
paid by CyDex but to be borne by Company hereunder; provided, however, that if such insurance, taxes, shipping costs or other costs incidental to such purchase or shipment initially paid by CyDex but to be borne by Company are not known at
the time CyDex invoices Company for the purchase price for the Captisol ordered by Company, CyDex may invoice such costs at a later date. Payment of such invoices shall be made within thirty (30) days after the date thereof. 

4.3 Currency. All amounts due hereunder are stated in, and shall be paid in, U.S. dollars. Net Sales based on foreign revenue will
be converted to U.S. dollars at the average rate of exchange over the thirty (30) days preceding the date payment is due based on the exchange rates published in The Wall Street Journal, Eastern U.S. Edition. Company shall provide CyDex,
together with each royalty payment owed pursuant to Section 4.1(c) above, a schedule detailing the calculation of Net Sales resulting from the conversion of foreign revenue to U.S. dollars as set forth herein. 

4.4 Taxes. All amounts due hereunder exclude all applicable sales, use, and other taxes, and Company will be responsible for
payment of all such taxes (other than taxes based on CyDex’s income), fees, duties, and charges, and any related penalties and interest, arising from the payment of amounts due hereunder or the sublicense or license, as the case may be, under
the Licensed Patents and Captisol Data Package hereunder. Company shall make all payments to CyDex hereunder free and clear of, and without reduction for, any withholding taxes; any such taxes imposed on payments of amounts to CyDex hereunder will
be Company’s sole responsibility, and Company will provide CyDex with official receipts issued by the appropriate taxing authority, or such other evidence as the CyDex may reasonably request, to establish that such taxes have been paid. Company
shall indemnify and hold CyDex harmless from any and all such taxes and any actions brought against CyDex by any taxing authority with respect to such taxes. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 16

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 4.5 Late Payments. Unpaid balances shall accrue interest, from due date until paid,
at a rate equal to the lesser of (i) the prime rate, as reported in The Wall Street Journal, Eastern U.S. Edition, on the date such payment is due, plus an additional two percent (2%) or (ii) the maximum rate permitted under
applicable law. If any amount due hereunder and not subject to a reasonable, good-faith dispute by Company remains outstanding for more than forty-five (45) days after its due date, CyDex may, in addition to any other rights or remedies it may
have, refuse to ship Captisol hereunder except upon payment by Company in advance. 
  

	5.	RECORDS; REPORTS; AUDIT. 

 5.1 Records. During the Term and for a period of three (3) years thereafter, Company shall, and shall require its Affiliates and Sublicensees to, maintain complete and accurate records
relating to Net Sales of Licensed Product, provided that records for any given calendar year shall not be required to be retained for more than three (3) years after the end of such calendar year. 

5.2 Reports. 
 (a) Quarterly Reports. Within thirty (30) calendar days following the conclusion of each calendar quarter during the Term after the date of first commercial sale of Licensed Product, Company
shall provide CyDex with written reports with respect to such calendar quarter that set forth in reasonable detail complete and accurate records of Company’s, its Affiliates’ and Sublicensees’ Net Sales of the Licensed Product on a
country-by-country basis in the Territory during such period and showing the currency calculation for such period as specified in Section 4.3. 

(b) Annual Reports. Annually, by December 31st of each calendar year during the Term, Company shall provide CyDex
with written reports that: (i) describe in reasonable detail Company’s progress made toward achievement of the milestones specified in Section 4.1(b) above during such calendar year; (ii) summarize in reasonable detail
Company’s communications and meetings involving the FDA related to Captisol during such calendar year; (iii) detail a nonbinding estimate Company’s anticipated preclinical and clinical use of Captisol for the next calendar year;
(iv) provide CyDex with Company’s non-binding, reasonable, estimated rolling projection for sales of the Licensed Product in the Territory, in terms of volume quantities and Net Sales values for the next [***] ([***]) [***]; and
(v) set forth such other information regarding Captisol as mutually agreed upon by the parties. 
 5.3 Audit. During
the Term and for a period of [***] ([***]) years thereafter, CyDex shall have the right, no more frequently than once per year and only during normal business hours and upon reasonable notice, to inspect and audit Company’s and its
Affiliates’ and Sublicensees’ records required to be maintained under Section 5.1 relevant to Net Sales. No calendar year may be audited more than once or more than three years after the end of such year. The costs of such
audits shall be borne solely by CyDex; provided, however, that in the event such an audit reveals either a failure by Company to pay any applicable milestone payment due or an underpayment by Company of royalties owed hereunder, Company shall
immediately (i) pay CyDex all amounts by which Company has underpaid CyDex as revealed by the audit, plus interest accrued thereon (from the applicable original due date) at the 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 17

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
rate set forth in Section 4.5 above and (ii) reimburse CyDex for the costs of such audit if such underpayment is more than [***] percent ([***]%) of the total due for the
relevant period. In the event the audit report shows an overpayment by Company, CyDex shall refund the amount of the overpayment to Company within thirty (30) days of receipt of the audit report. All information concerning royalty payments and
reports, and any information learned in the course of any audit or inspection under this Section 5.3, shall be deemed to be Confidential Information of Company, subject to the terms and provisions of Section 8 below, except
to the extent necessary for CyDex to enforce its rights under this Agreement. 
  

	6.	DEVELOPMENT AND COMMERCIALIZATION BY COMPANY. 

6.1 Diligence. Company agrees that, during the Term, it will (i) use, and shall require its Affiliates and Sublicensees to
use, commercially reasonable efforts to obtain Marketing Approval in at least one of the US, EU and Japan (the “Major Markets”) and to market, promote, and sell Licensed Product thereafter in each country in which Marketing Approval is
obtained, in an effort to maximize Net Sales and royalties payable under this Agreement, and (ii) comply with the requirements set forth in Exhibit D hereto. For clarity, in the event that Company fails to use commercially
reasonable efforts to meet the requirements of the foregoing sentence, CyDex shall, as its sole remedy, have the right to terminate this Agreement pursuant to Section 13.2 hereof. 

6.2 Costs and Expenses. Company shall be solely responsible for all costs and expenses related to its development and
commercialization of the Licensed Product, including without limitation costs and expenses associated with all preclinical activities and clinical trials, and all regulatory filings and proceedings relating to the Licensed Product. 

6.3 In Vivo Studies. If Company wishes to conduct any in vivo study (preclinical or clinical, in animals or in humans, each a
“Study”) of the Licensed Product utilizing Captisol, then Company shall notify CyDex of any such Study and the name of the protocol therefor in writing at least fourteen (14) days prior to commencing such Study for pre-clinical
studies, and at least thirty (30) days prior to commencing such Study for clinical studies, and the following provisions shall apply: 
 (a) Dosing. Company shall not exceed the maximum allowable dosing levels of Captisol specified in Exhibit E hereto without the written consent of CyDex. 

(b) Review of Protocol. Company shall provide information regarding each protocol for each Study and agrees to
allow CyDex to review and comment upon the aspects of such protocol which pertain solely to the use and administration of Captisol. Company shall give due consideration and reasonably incorporate any input that CyDex provides regarding such protocol
to the extent it pertains solely to the use and administration of Captisol. 
 (c) Evaluation. If CyDex
reasonably determines that such study would generate data related to Captisol alone that would materially adversely affect use of Captisol, CyDex shall notify Company within the above-specified review periods, and the parties shall discuss and
attempt to resolve the matter in good faith. If the parties cannot resolve such matter within fifteen (15) days after CyDex notifies Company of such determination, then the dispute 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 18

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
shall be presented to the Chief Executive Officer of each party, or his or her respective designee, for resolution. If the parties’ Chief Executive Officers, or their respective designees,
cannot resolve the dispute within thirty (30) days of being requested by a party to resolve such dispute, either party may initiate a short-form arbitration proceeding pursuant to Section 14.4(b) below. 

(d) Compliance with Laws. Company represents and warrants that each Study will be performed in accordance with all
applicable laws, regulations and requirements. Company will provide or cause to be provided all appropriate warnings to participants enrolled in each Study and obtain or cause to be obtained appropriate documentation of informed consent from all
participants in each such Study. 
 (e) Adverse Events. Company agrees to immediately inform CyDex if any
adverse effects are observed and ascribed to Captisol in any Study in accordance with Section 7.3 hereof. To accurately track adverse events and preserve the validity of each Study involving Captisol, Company shall only use Captisol
supplied by CyDex for each such Study, and shall not use and any other cyclodextrin product supplied by a third party in the same Study unless a Failure to Supply event has occurred. 

(f) Reporting and Study Data. Within three (3) months after the completion of the Final Study Report for the
relevant Study, Company shall provide to CyDex a summary of the data and results of each Study that pertain solely to Captisol, and Company hereby grants to CyDex a non-exclusive, royalty-free license (with the right to sublicense) to use and
disclose such data, including without limitation to update the DMF for Captisol. 
 (g) Review of Regulatory
Filings and Publications. At least fourteen (14) days prior to a submission of any proposed written publication material or regulatory submission (which shall be subject to the restrictions of Section 8 hereof) reporting the
results of a Study, Company shall provide to CyDex for CyDex’s review and comment a copy of the portion of such proposed written publication, material or regulatory submission reporting results of a Study that refers to Captisol alone. Company
shall give due consideration to and reasonably incorporate any input that CyDex provides regarding the portion of any publication that refers to Captisol alone. 
 6.4 Right of Reference. Company shall have the right to reference the DMF solely in connection Company’s regulatory filings submitted in connection with INDs or equivalent filings or obtaining
Marketing Approval for the Licensed Product. 
 6.5 Access to Company’s Data. CyDex shall have the right to
reference and utilize all toxicology/safety and other relevant scientific data developed on Captisol alone (and not in conjunction with a product formulation) by Company, its Sublicensees or Affiliates in connection with CyDex’s development and
commercialization of Captisol or compounds, at no cost to CyDex. Upon request by CyDex, Company shall either provide CyDex with a copy of all such data or shall make such data accessible to CyDex at such times and locations mutually agreed upon by
the parties. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 19

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	7.	REGULATORY MATTERS. 

 7.1 Captisol Information Submitted for Regulatory Review. Except as otherwise set forth herein, Company shall be solely responsible for all communications with regulatory agencies in connection
with the Licensed Product. Notwithstanding the foregoing, Company shall provide CyDex with copies of the portions of all regulatory submissions related to Captisol data alone (and not in conjunction with any product formulation) thirty
(30) days prior to submission and shall allow CyDex to review and comment upon said submissions. If CyDex reasonably determines that any data on Captisol alone included in such submission would materially adversely affect another product
utilizing Captisol, CyDex shall notify Company within thirty (30) days of receipt of such submission, and the parties shall discuss and attempt to resolve the matter in good faith. If the parties cannot resolve such matter within thirty
(30) days after CyDex notifies Company of such a determination, then the dispute shall be presented to the Chief Executive Officer of each party, or his or her respective designee, for resolution. If the parties’ Chief Executive Officers,
or their respective designees, cannot resolve the dispute within thirty (30) days of being requested by a party to resolve such dispute, either party may initiate a short-form arbitration proceeding pursuant to Section 14.4(b)
below. Company shall inform CyDex of meetings with the FDA (or other regulatory agencies in the Territory) regarding the Licensed Product, a reasonable period of time prior to such event (with reasonableness determined by how much notice Company
has of such meeting) and shall allow CyDex to participate in any FDA (or other regulatory agency) review that might reasonably include inquiries regarding Captisol. If Company submits written responses to the FDA that include data on Captisol alone,
CyDex shall be permitted to review such written materials prior to submission. If CyDex reasonably objects to the contents of such written responses relating to Captisol alone, the parties agree to cooperate in working toward a reasonable and
mutually agreeable response. 
 7.2 Material Safety. CyDex shall promptly provide Company, in writing, from time to time,
with (a) relevant information currently known to it regarding handling precautions, toxicity and hazards with respect to Captisol, and (b) the then-current material safety data sheet for Captisol. Notwithstanding the foregoing or anything
in this Agreement to the contrary, Company is solely responsible for (i) use of all documentation provided by CyDex, including without limitation, use in any regulatory submission to the FDA or any other regulatory agency in the Territory,
(ii) document control and retention, and (iii) determining the suitability of any documentation provided by CyDex hereunder for use in any regulatory submission. 
 7.3 Adverse Event Reporting. 
 (a) By Company.
Company shall adhere, and shall require that its Affiliates, Sublicensees, co-marketers and distributors adhere, to all requirements of applicable law and regulations that relate to the reporting and investigation of any adverse event, including
without limitation an unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease, whether or not considered Captisol or Licensed Product-related, which occurs or worsens following
administration of Captisol or Licensed Product. Company shall provide CyDex with copies of all reports of any such adverse event which is serious (any such adverse event involving Captisol or the Licensed Product that results

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 20

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
in death, is life-threatening, requires or prolongs inpatient hospitalization, results in disability, congenital anomaly or is medically important (i.e., may require other medical or surgical
intervention to prevent other serious criteria from occurring)) which Company has reason to believe is associated with Captisol within ten (10) business days following (i) Company’s submission of any such report to any regulatory
agency, or (ii) receipt from Company’s Sublicensee, co-marketer or distributor of any such report submitted to any regulatory agency. Company shall also advise CyDex regarding any proposed labeling or registration dossier changes affecting
Captisol. Reports from Company shall be delivered to the attention of Vice President, Chief Scientific Officer, CyDex, with a copy to Chief Executive Officer, CyDex, at the address set forth in Section 14.7. The parties shall mutually cooperate
with regard to investigation of any such serious adverse event, whether experienced by Company, CyDex or any Affiliate, Sublicensee, co-marketer or distributor of Company. 

(b) By CyDex. For products being developed by CyDex of its Affiliate (for which CyDex or its Affiliate holds the
relevant IND) CyDex shall adhere, and shall require that its Affiliates adhere, to all requirements of applicable law and regulations that relate to the reporting and investigation of any adverse event, including without limitation an unfavorable
and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease attributed to Captisol. CyDex shall provide Company with copies of all reports of any such adverse event which is serious (any such adverse event
attributed to Captisol that results in death, is life-threatening, requires or prolongs inpatient hospitalization, results in disability, congenital anomaly or is medically important (i.e., may require other medical or surgical intervention to
prevent other serious criteria from occurring)) which CyDex has reason to believe are associated with Captisol within two (2) business days following (i) CyDex’s submission of any such report to any regulatory agency, or
(ii) receipt from CyDex of any such report. CyDex shall also advise Company regarding any proposed labeling or registration dossier changes affecting Captisol. Reports from CyDex shall be delivered to the attention of Vice President, Chief
Scientific Officer, Company, with a copy to Chief Executive Officer, Company, at the address set forth in Section 14.7. 

7.4 Product Recalls. If any Captisol should be alleged or proven not to meet the Specifications, Company shall notify CyDex
immediately, and both parties shall cooperate fully regarding the investigation and disposition of any such matter. If (i) Company and CyDex agree in writing that it is appropriate to recall any Licensed Product, or (ii) the FDA requires
the recall of any Licensed Product, and in either case such recall is due to the failure of Captisol to conform to the relevant Specifications or to otherwise meet the Manufacturing Standards at the time of delivery by CyDex, then CyDex agrees, upon
substantiation thereof, to refund the purchase price for such Captisol and to pay the out-of-pocket costs of Company and its Affiliates and Sublicensees related to such recall, provided that such obligations shall be (i) the sole remedy
of Company regarding such recall, and (ii) subject to Section 11 (Limitation of Liability) below, provided that the foregoing limitations will not apply to CyDex’s indemnification obligation with respect to third party personal
injury or death products liability claims under Section 10.1. Company shall maintain records of all sales of Licensed Product and customers sufficient to adequately administer any such recall, for a period of [***] ([***]) years after
expiration or termination of this Agreement. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 21

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	8.	CONFIDENTIALITY. 

 8.1 Definition. Company and CyDex each recognizes that during the Term, it may be necessary for a party (the “Disclosing Party”) to provide Confidential Information (as defined
herein) to the other party (the “Receiving Party”) that is highly valuable, the disclosure of which would be highly prejudicial to such party. The disclosure and use of Confidential Information will be governed by the provisions of
this Section 8. Neither Company nor CyDex shall use the other’s Confidential Information except as expressly permitted in this Agreement. For purposes of this Agreement, “Confidential Information” means all
information disclosed by the Disclosing Party to the Receiving Party and designated in writing by the Disclosing Party as “Confidential” (or equivalent), and all material disclosed orally which is declared to be confidential by the
Disclosing Party and confirmed in writing delivered to the Receiving Party within thirty (30) days of such disclosure, including but not limited to product specifications, data, know-how, formulations, product concepts, sample materials,
business and technical information, financial data, batch records, trade secrets, processes, techniques, algorithms, programs, designs, drawings, and any other information related to a party’s present or future products, sales, suppliers,
customers, employees, investors or business. Without limiting the generality of the foregoing, CyDex’s Confidential Information includes all materials provided as part of the Captisol Data Package. Notwithstanding anything in this Agreement to
the contrary other than Section 8.3 (Exceptions), Company’s Confidential Information includes all information and materials provided to CyDex under this Agreement related to Licensed Product; Net Sales; the status of development
activities; Studies; and regulatory filings, in each case whether or not marked or identified as confidential. 
 8.2
Obligation. CyDex and Company agree that they will disclose the other’s Confidential Information to its own officers, employees, consultants and agents only if and to the extent necessary to carry out their respective responsibilities under
this Agreement or in accordance with the exercise of their rights under this Agreement, and such disclosure shall be limited to the maximum extent possible consistent with such responsibilities and rights. Neither party shall disclose Confidential
Information of the other to any third party without the other’s prior written consent, and any such disclosure to a third party shall be pursuant to the terms of a non-disclosure agreement no less restrictive than this Section 8 provided
Company shall not require such consent for disclosure of Confidential Information of CyDex to Company’s Affiliates and Sublicensees. Each party shall take such action to preserve the confidentiality of each other’s Confidential Information
as it would customarily take to preserve the confidentiality of its own Confidential Information (but in no event less than a reasonable standard of care). Each party will return all the Confidential Information disclosed to the other party pursuant
to this Agreement, including all copies and extracts of documents, within sixty (60) days of the request, promptly following the expiration or termination of this Agreement, except as required by law to be retained and provided that neither
party shall be required to return or destroy Confidential Information included in regulatory filings or submissions or maintained on automatically created system back-up media. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 22

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 8.3 Exceptions. The use and non-disclosure obligations set forth in this
Section 8 shall not apply to any Confidential Information, or portion thereof, that the Receiving Party can demonstrate: 
 (i) at the time of disclosure is in the public domain; 

(ii) after disclosure, becomes part of the public domain, by publication or otherwise, through no fault of the
Receiving Party; 
 (iii) at the time of disclosure is already in the Receiving Party’s possession,
and such prior possession can be properly demonstrated by the Receiving Party, with the exception of Confidential Information exchanged between parties prior to the execution of this Agreement; or 

(iv) is made available to the Receiving Party by an independent third party, provided, however, that to the
Receiving Party’s knowledge, such information was not obtained by said third party, directly or indirectly, from the Disclosing Party hereunder. 
 In addition, the Receiving Party may disclose information that is required to be disclosed by law, by a valid order of a court or by order or regulation of a governmental agency including but not limited
to, regulations of the United States Securities and Exchange Commission (the “SEC”), or in the course of litigation, provided that in all cases the Receiving Party shall give the other party prompt notice of the pending
disclosure and makes a reasonable effort to obtain, or to assist the Disclosing Party in obtaining, a protective order preventing or limiting the disclosure and/or requiring that the Confidential Information so disclosed be used only for the
purposes for which the law or regulation required, or for which the order was issued. 
 8.4 Injunction. Each party
agrees that should it breach or threaten to breach any provisions of this Section 8, the Disclosing Party will suffer irreparable damages and its remedy at law will be inadequate. Upon any breach or threatened breach by the Receiving
Party of this Section 8, the Disclosing Party shall be entitled to seek injunctive relief in addition to any other remedy which it may have, without need to post any bond or security. 

8.5 Third Party Information. Company acknowledges that CyDex’s Confidential Information includes information developed by
[***] (“[***]”) that is confidential to both CyDex and [***]. In so far as Confidential Information of [***] is disclosed, [***] is a third-party beneficiary of this Section 8 of this Agreement and may enforce it or seek
remedies pursuant to it in accordance with its terms. 
  

	9.	REPRESENTATIONS AND WARRANTIES. 

9.1 Mutual Representations and Warranties. Each party represents and warrants to the other as follows: 

(i) it is a corporation duly organized and validly existing under the laws of the state or country of its
incorporation; 
 (ii) it has the complete and unrestricted power and right to enter into this Agreement
and to perform its obligations hereunder; 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 23

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 (iii) this Agreement has been duly authorized, executed and delivered
by such party and constitutes a legal, valid and binding obligation of such party enforceable against such party in accordance with its terms except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, receivership,
moratorium, fraudulent transfer, or other similar laws affecting the rights and remedies of creditors generally and by general principles of equity; 
 (iv) the execution, delivery and performance of this Agreement by such party do not conflict with any agreement, instrument or understanding, oral or written, to which such party is a party or by
which such party may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having authority over such party; 

(v) all consents, approvals and authorizations from all governmental authorities or other third parties required to
be obtained by such party in connection with the execution and delivery of this Agreement have been obtained; 

(vi) no person or entity has or will have, as a result of the transactions contemplated by this Agreement, any
right, interest or valid claim against or upon such party for any commission, fee or other compensation as a finder or broker because of any act by such party or its agents, or, with respect to Company, because of any act by its Affiliates or
Sublicensees; 
 (vii) it has not entered into any agreement with any third party that is in conflict with
the rights granted to the other party pursuant to this Agreement; and 
 (viii) neither it nor its
Affiliates has been debarred or is subject to debarment, and such party will not use in any capacity in connection with this Agreement any person or entity who has been debarred pursuant to Section 306 of the United States Federal Food, Drug
and Cosmetic Act. 
 9.2 Additional CyDex representations, Warranties, and Covenants. CyDex represents, warrants, and
covenants to Company as of the Effective Date that: 
 (i) CyDex has the full right, power, and authority
to grant, and is not prohibited by the terms of any agreement to which it is a party from granting, the licenses granted to Company under this Agreement. 
 (ii) CyDex has not granted and will not grant to any third party any rights inconsistent with the rights and licenses granted herein. 

(iii) CyDex holds good title to and is the legal and beneficial owner of, or otherwise has the right to license to
Company, the Licensed Patents. 
 (iv) There are no pending claims, judgments, or settlements against or
owed by CyDex or pending with respect to the Licensed Patents, and CyDex has not received written notice of any threatened claims or litigation seeking to invalidate or render unenforceable any of the Licensed Patents. During the term of this
Agreement, CyDex shall promptly notify Company in writing upon learning of any such actual or threatened claim, judgment, or settlement. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 24

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 (v) CyDex has not received any notice of termination or breach under
any of the existing agreements pursuant to which CyDex has rights or licenses to Licensed Patents, and is not aware of any circumstances that could, with the passage of time, result in any claim of breach. CyDex covenants that it will take any and
all action required to maintain such agreements in effect, and will notify Company in writing within one week of receipt of any notice of termination or breach. 
 (vi) To CyDex’s knowledge, the manufacture and delivery of bulk Captisol, and its composition of matter, does not infringe or misappropriate the intellectual property rights of any third
party, and CyDex has not received any notice alleging that the manufacture, delivery or composition of bulk Captisol infringes any intellectual property rights of a third party. 

9.3 Limited Warranty. CyDex warrants solely to Company that all Captisol sold to Company shall (i) conform to the respective
Specifications (as applicable for Research Grade Captisol, Clinical Grade Captisol or Commercial Grade Captisol) in all material respects at the time of delivery; (ii) shall have been manufactured in accordance with the process described in the
DMF; and (iii) shall meet the other Manufacturing Standards. CyDex’s sole obligation, and Company’s sole and exclusive remedy, for any breach of such warranty shall be as set forth in Sections 3.5(e) (Refund or Replacement) and
10.1 (Indemnification by CyDex) hereof. 
 9.4 Disclaimer. THE WARRANTIES SET FORTH IN THIS SECTION 9 ABOVE
ARE PROVIDED IN LIEU OF, AND EACH PARTY HEREBY DISCLAIMS, ALL OTHER WARRANTIES, EXPRESS AND IMPLIED, RELATING TO THE SUBJECT MATTER OF THIS AGREEMENT, CAPTISOL, THE LICENSED PATENTS OR THE CAPTISOL DATA PACKAGE, INCLUDING BUT NOT LIMITED TO THE
IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT OF THIRD PARTY RIGHTS. CYDEX’S WARRANTIES UNDER THIS AGREEMENT ARE SOLELY FOR THE BENEFIT OF COMPANY AND MAY BE ASSERTED ONLY BY COMPANY AND
ANY ASSIGNEE OF COMPANY’S RIGHTS UNDER THIS AGREEMENT PURSUANT TO SECTION 14.15 BELOW AND NOT BY ANY AFFILIATE, SUBLICENSEE OR ANY CUSTOMER OF COMPANY, ITS AFFILIATES OR SUBLICENSEES. COMPANY, ITS AFFILIATES AND SUBLICENSEES SHALL BE
SOLELY RESPONSIBLE FOR ALL REPRESENTATIONS AND WARRANTIES THAT COMPANY, ITS AFFILIATES OR SUBLICENSEES MAKE TO ANY CUSTOMER OF COMPANY, ITS AFFILIATES OR SUBLICENSEES. 
  

	10.	INDEMNIFICATION. 

 10.1 By CyDex. CyDex shall defend, indemnify and hold Company and its Affiliates and Sublicensees, and each of their respective directors, officers and employees, harmless from and against any and
all damages, liabilities, costs and expenses (including the reasonable costs and expenses of attorneys and other professionals) (collectively “Losses”) incurred by Company 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 25

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
in connection with any claim, demand, action or other proceeding (each, a “Claim”) by a third party, to the extent such Losses arise out of (a) failure of Captisol delivered
under this Agreement to conform to the Manufacturing Standards; (b) CyDex’s breach of this Agreement, including without limitation any failure of its representations and warranties set forth in Section 9.1 or 9.2 to have
been accurate when made or any breach of the covenants set forth in this Agreement; or (c) the negligence or intentional misconduct of CyDex or any of its Affiliates, or any of their respective directors, officers, employees or Third Party
Manufacturers, provided CyDex will not have an indemnification obligation with respect to any Claim to the extent that Company has an indemnification obligation under Section 10.2. 

10.2 By Company. Company shall defend, indemnify and hold CyDex and its Affiliates, and each of their respective directors,
officers and employees, harmless from and against any and all Losses incurred by CyDex in connection with of any Claim by a third party, to the extent such Losses arise out of: (a) the use or sale of the Licensed Product by Company, its
Affiliates, Sublicensees, distributors, agents or other parties; (b) the manufacture, use, handling, promotion, marketing, distribution, importation, sale or offering for sale of Licensed Products; (c) interactions and communications with
governmental authorities, physicians or other third parties; or (d) Company’s breach of this Agreement, including without limitation any of its representations and warranties set forth in Section 9.1, provided Company will not
have an indemnification obligation with respect to any Claim to the extent that CyDex has an indemnification obligation under Section 10.1. 
 10.3 Expenses. As the parties intend complete indemnification, all costs and expenses of enforcing any provision of this Section 10 shall also be reimbursed by the Indemnitor.

 10.4 Procedure. The party intending to claim indemnification under this Section 10 (an
“Indemnitee”) shall promptly notify the other party (the “Indemnitor”) of any Claim in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall assume the defense thereof
whether or not such Claim is rightfully brought; provided, however, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitee, unless Indemnitor does not assume the defense, in
which case the reasonable fees and expenses of counsel retained by the Indemnitee shall be paid by the Indemnitor. The Indemnitee, and its employees and agents, shall cooperate fully with the Indemnitor and its legal representatives in the
investigations of any Claim. The Indemnitor shall not be liable for the indemnification of any Claim settled or compromised by the Indemnitee without the written consent of the Indemnitor. 

 

	11.	LIMITATION OF LIABILITY. 

 EXCEPT FOR DAMAGES FOR WHICH A PARTY IS RESPONSIBLE PURSUANT TO ITS INDEMNIFICATION OBLIGATIONS SET FORTH IN SECTION 10 ABOVE, EACH PARTY SPECIFICALLY DISCLAIMS ALL LIABILITY FOR AND SHALL IN NO
EVENT BE LIABLE FOR ANY INCIDENTAL, SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES, EXPENSES, LOST PROFITS, LOST SAVINGS, INTERRUPTIONS OF BUSINESS OR OTHER DAMAGES OF ANY KIND OR CHARACTER WHATSOEVER ARISING OUT OF OR RELATED TO THIS AGREEMENT

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 26

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
OR RESULTING FROM THE MANUFACTURE, HANDLING MARKETING, SALE, DISTRIBUTION OR USE OF LICENSED PRODUCT OR USE OF THE LICENSED PATENTS AND CAPTISOL DATA PACKAGE, REGARDLESS OF THE FORM OF ACTION,
WHETHER IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY WAS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. COMPANY SHALL HAVE NO REMEDY, AND CYDEX SHALL HAVE NO LIABILITY, OTHER THAN AS EXPRESSLY SET FORTH IN THIS AGREEMENT. EXCEPT
WITH RESPECT TO THE INDEMNIFICATION SPECIFICALLY PROVIDED IN SECTION 10 ABOVE, IN NO EVENT SHALL CYDEX’S TOTAL AGGREGATE LIABILITY FOR ALL CLAIMS ARISING OUT OF OR RELATED TO THIS AGREEMENT EXCEED THE GREATER OF (1) THE TOTAL AMOUNT
OF THE UPFRONT PAYMENTS AND MILESTONES PAID TO CYDEX BY COMPANY AS OF SUCH DATE, OR (2) THE TOTAL AMOUNTS PAID BY COMPANY TO CYDEX PURSUANT TO SECTION 4 OF THIS AGREEMENT DURING THE TWENTY-FOUR (24) MONTH PERIOD IMMEDIATELY
PRECEDING THE EVENT GIVING RISE TO LIABILITY. EXCEPT FOR DAMAGES FOR WHICH A PARTY IS RESPONSIBLE PURSUANT TO ITS INDEMNIFICATION OBLIGATIONS SET FORTH IN SECTION 10 ABOVE, NO ACTION, REGARDLESS OF FORM, ARISING OUT OF OR RELATED TO THIS
AGREEMENT MAY BE BROUGHT BY EITHER PARTY MORE THAN TWO (2) YEARS AFTER SUCH PARTY HAS KNOWLEDGE OF THE OCCURRENCE THAT GAVE RISE TO THE CAUSE OF SUCH ACTION. 
  

	12.	MANAGEMENT OF LICENSED PATENTS. 

12.1 Prosecution and Maintenance. CyDex shall maintain, at its sole cost and expense and using reasonable discretion, the Licensed
Patents set forth on Exhibit A. CyDex shall have the sole right to control the prosecution and maintenance of patent applications and the selection of countries where patent applications are filed related to the Licensed
Patents. 
 12.2 Infringement by Third Parties. If Company becomes aware that a third party may be infringing a Licensed
Patent, it will promptly notify CyDex in writing, providing all information available to Company regarding the potential infringement. CyDex shall take whatever, if any, action it deems appropriate, in its sole discretion, against the alleged
infringer. If CyDex elects to take action, Company shall, at CyDex’s request and expense, cooperate and shall cause its employees to cooperate with CyDex in taking any such action, including but not limited to, cooperating with the prosecution
of any infringement suit by CyDex. Company shall not take any such action against the alleged infringer without the written consent of CyDex, provided that if CyDex fails to pursue action regarding a potential infringement under this Section in a
given country, and does not give its consent and cooperation to Company in pursuing any such action, Company’s royalty obligation with respect to sales of Licensed Product in such country shall cease as if the applicable royalty term had ended.

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 27

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

	13.	TERM AND TERMINATION. 

 13.1 Term. The term of this Agreement (the “Term”) shall commence on the Effective Date and shall continue in effect thereafter until the expiration of Company’s obligation to
pay royalties under Section 4.1(c), unless terminated earlier as set forth herein. Upon expiration of this Agreement at the end of the Term, the licenses granted to Company under Section 2.1 shall convert to fully paid-up
licenses, subject to Sections 13.2 and 13.5 hereof. 
 13.2 Termination by CyDex. If Company should violate
or fail to perform in any material respect any term or covenant of this Agreement, then CyDex may give written notice of such default (a “Notice of Default”) to Company. If Company should fail to cure such default within thirty
(30) days (or fifteen (15) days with respect to any payment obligation) of the date of such notice or prior to the natural expiration date of this Agreement, whichever is shorter in duration, CyDex shall have the right to terminate this
Agreement by a second written notice (a “Notice of Termination”) to Company. If Notice of Termination is sent to Company, this Agreement shall automatically terminate on the effective date of such notice. Notwithstanding the above,
failure to pay milestones or royalties as described in Section 4 above will result in termination of this Agreement immediately upon delivery of a Notice of Termination to Company. In addition, CyDex may terminate this Agreement
immediately upon written notice to Company in the event Company makes an assignment for the benefit of creditors or has a petition in bankruptcy filed for or against it that is not dismissed within ninety (90) days of such filing. 

13.3 Termination by Company. Company shall have the right at any time to terminate this Agreement in whole by giving CyDex at
least ninety (90) days prior written notice. 
 13.4 Effect of Termination. Following the early termination of this
Agreement, all rights granted to Company herein shall immediately terminate and each party shall, at the request of the other Party, promptly return or destroy all relevant records and materials in its possession or control containing the other
party’s Confidential Information with respect to which the former party does not retain rights hereunder; provided, however, that (i) each party may retain one archival copy of such records and materials solely to be able to monitor
its obligations that survive under this Agreement; and (ii) neither party shall be required to return or destroy any records included in regulatory filings or maintained on automatically created system back-up media. 

13.5 Survival. Notwithstanding any other provisions of this Agreement, any liability or obligation of either party to the other
for acts or omissions prior to the termination or expiration of this Agreement shall survive the termination or expiration of this Agreement. Such termination or expiration shall not relieve either party from obligations that are expressly indicated
to survive termination or expiration of this Agreement, nor shall any termination or expiration of this Agreement relieve Company of its obligation to pay CyDex (a) royalties for all Licensed Product sold by Company, its Affiliates or
Sublicensees prior to the effective date of such expiration or termination consistent with the terms of Sections 4.1, 4.3 and 4.5, or (b) sums due in respect of Captisol shipped prior to termination or expiration of this
Agreement. Notwithstanding anything in this Agreement to the contrary, Sections 2.2 (Grant of License from Company to CyDex) with respect to Captisol Improvement developed during the Term, 3.5 (Quality Control; Acceptance and
Rejection), 4.3 (Currency), 4.4 (Taxes), 4.5 (Late Payments), 5  

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 28

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 
(Records; Reports; Audits), 6.3(f) (Reporting and Study Data), 6.5 (Access to Company’s Data), 7.3 (Adverse Event Reporting), 7.4 (Product Recalls), 8
(Confidentiality), 9.3 (Disclaimer), 10 (Indemnification), 11 (Limitation of Liability), 13.4 (Effect of Termination), 13.5 (Survival), and 14 (General Provisions) shall survive termination or expiration of
this Agreement. 
  

	14.	GENERAL PROVISIONS. 

 14.1 Non-Solicitation. During the Term and for a period of [***] ([***]) [***] thereafter, neither party shall solicit, induce, encourage or attempt to induce or encourage any employee of the other
party with whom such party has had direct contact to terminate his or her employment with such other party or to breach any other obligation to such other party. This section is not meant to encompass general solicitations such as may be found in
newspaper advertisements and the like and the interviewing or hiring of any person who responds to a general solicitation. 

14.2 Relationship of Parties. Each of the parties hereto is an independent contractor and nothing in this Agreement is intended or
shall be deemed to constitute a partnership, agency, employer-employee or joint venture relationship between the parties. No party shall incur any debts or make any commitments for the other. 

14.3 Compliance with Law. Each Party agrees to comply, and to require its Affiliates and Sublicensees to comply with all
applicable international, federal, state and local laws, rules and regulations, including, but not limited to, import/export restrictions, laws, rules and regulations governing use and patent, copyright and trade secret protection, in the
performance of its activities as contemplated by this Agreement. 
 14.4 Arbitration. 

(a) Procedure. Except as otherwise expressly set forth in Section 14.4(b) below, any and all disputes
or controversies arising out of or relating to this Agreement shall be exclusively and finally resolved by binding arbitration in accordance with the commercial arbitration rules of the American Arbitration Association (“AAA”) then
in effect, in [***]. The arbitration shall be conducted by an arbitrator reasonably knowledgeable about the pharmaceutical industry and acceptable to CyDex and Company. I f CyDex and Company cannot agree on a single arbitrator within thirty
(30) days after a demand for arbitration has been made, CyDex shall appoint an arbitrator, Company shall appoint an arbitrator, the two (2) arbitrators shall appoint a third arbitrator, and the three (3) arbitrators shall hear and
decide the issue in controversy. If either party fails to appoint an arbitrator within forty five (45) days after service of the demand for arbitration, then the arbitrator will be appointed by the AAA. Except as to the selection of
arbitrators, the arbitration proceedings shall be conducted promptly and in accordance with the rules of the AAA then in effect. The expenses of any arbitration, including the reasonable attorney fees of the prevailing party, shall be borne by the
party deemed to be at fault or on a pro-rata basis should the arbitration conclude in a finding of mutual fault. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 29

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 (b) Short-Form Arbitration. Any dispute subject to short-form
arbitration as provided in this Agreement shall be exclusively and finally resolved by binding arbitration in accordance with the commercial arbitration rules of the AAA then in effect, in [***] by a single arbitrator reasonably knowledgeable about
the pharmaceutical industry and appointed in accordance with such rules. Such arbitrator shall make his or her determination on the basis of “baseball arbitration” principles. THE FORGOING
REMEDY SHALL BE EACH PARTY’S SOLE AND EXCLUSIVE REMEDY WITH
RESPECT TO ANY SUCH DISPUTE. The expenses of any arbitration, including the reasonable attorney fees of the prevailing party, shall be borne by the party deemed to be at
fault or on a pro-rata basis should the arbitration conclude in a finding of mutual fault. In each case, the parties and arbitrator shall use all diligent efforts to complete such arbitration within thirty (30) days of appointment of the
arbitrator. 
 (c) Confidentiality of Proceedings. All arbitration proceedings hereunder shall be
confidential and the arbitrator(s) shall issue appropriate protective orders to safeguard each party’s Confidential Information. Except as required by law, no party shall make (or instruct the arbitrator(s) to make) any public announcement with
respect to the proceedings or decision of the arbitrator(s) without prior written consent of the other party, except as required by law to be disclosed. 
 (d) Interim Equitable Relief. Each party shall, in addition to all other remedies accorded by law and permitted by this Agreement, be entitled to equitable relief (including but not limited to
interim injunctive relief) in any court having jurisdiction to protect its interests. Neither party shall commence any court proceeding or action against the other to resolve any dispute, except (i) to enforce an arbitral award rendered
pursuant to this Section 14.4, or (ii) for such interim injunctive relief. 
 (e) Binding
Effect. The provisions of this Section 14.4 shall survive any expiration or termination of this Agreement, and shall be severable and binding on the parties hereto, notwithstanding that any other provision of this Agreement may be
held or declared to be invalid, illegal or unenforceable. 
 14.5 Costs and Expenses. Except as otherwise expressly
provided in this Agreement, each party shall bear all costs and expenses associated with the performance of such party’s obligations under this Agreement. 
 14.6 Force Majeure. Neither party shall be liable for failure to perform, or delay in the performance of, its obligations under this Agreement (other than payment obligations) when such failure or
delay is caused by an event of force majeure. For purposes of this Agreement, an event of force majeure means any event or circumstance beyond the reasonable control of the affected party, including but not limited to, war,
insurrection, riot, fire, flood or other unusual weather condition, explosion, act of God, peril of the sea, strike, lockout or other industrial disturbance, sabotage, accident, embargo, breakage of machinery or apparatus, injunction, act of
governmental authority, compliance with governmental order on national defense requirements, or inability to obtain fuel, power, raw materials, labor or transportation facilities. If, due to any event of force majeure, either party shall be
unable to fulfill its obligations under this Agreement (other than payment obligations), the affected party shall immediately notify the other party of such inability and of the period during which such inability is expected to continue and shall
use commercially reasonable efforts to mitigate the length and effect of such force majeure event. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 30

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 14.7 Notices. Any notice, request, or communication under this Agreement shall be
effective only if it is in writing and personally delivered; sent by certified mail, postage pre-paid; facsimile with receipt confirmed and a copy sent by mail or courier; or by nationally recognized overnight courier with signature required,
addressed to the parties at the addresses stated below or such other persons and/or addresses as shall be furnished in writing by any party in accordance with this Section 14.7. Unless otherwise provided, all notices shall be sent:

 If to CyDex, to: 
 CyDex Pharmaceuticals, Inc. 
 10513 W. 84th Terrace 

Lenexa, KS 66214 
 Attention: President 
 Fax: (913) 685-8856 

If to Company, to: 
 Rib-X Pharmaceuticals, Inc. 
 300 George Street, Suite 301 

New Haven, CT 06511 
 Attention: Chief Executive Officer 
 Fax: (203) 624-5627 

If sent by facsimile transmission, the date of transmission shall be deemed to be the date on which such notice, request or communication was given and
confirmed, provided the confirmation copy is also sent by mail or courier. If sent by overnight courier, the next business day after the date of deposit with such courier shall be deemed to be the date on which such notice, request or communication
was given. If sent by certified mail, the third business day after the date of mailing shall be deemed the date on which such notice, request or communication was given. 
 14.8 Use of Name. Commencing upon receiving regulatory approval in the United States for the Licensed Product, or upon use by Company, its Affiliate or Sublicensee of the name CyDex or Captisol
pursuant to the following sentence, Company hereby grants CyDex a non-exclusive, non-transferable license during the Term to use Company’s name, logo and other trademarks solely to identify Licensed Product as a product incorporating Captisol
in marketing and other materials for customers, investors and potential customers and investors, including but not limited to use in connection with materials filed with the SEC or other regulatory agencies. CyDex hereby grants to Company and its
Affiliates and Sublicensees the right to use the name CyDex and Captisol and associated logos and trademarks in connection with any and all descriptions of Licensed Product or related to Licensed Product. Except as otherwise provided herein, neither
party shall have any right, express or implied, to use in any manner the name, logos, trademarks or other designation of the other party or any other trade name or trademark of the other party for any purpose, except as may be required by applicable
law or regulation. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 31

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 14.9 Public Announcements. Except for such disclosure as is deemed necessary, in the
reasonable judgment of a party, to comply with applicable laws or regulations, securities filings or the rules of the NYSE or NASDAQ, no announcement, news release, public statement, publication, or presentation relating to the existence of this
Agreement, or the terms hereof, will be made without the other party’s prior written approval, which approval shall not be unreasonably withheld. Notwithstanding the above, once the content and timing of a public announcement of the fact that
the parties have entered into this Agreement has been agreed to between the parties and such announcement has been made, either Party shall be free to disclose to third parties the fact that it has entered into the Agreement with the other party
(including a description of the field of use of the Licensed Product, but without disclosing the economic terms thereof), as well as any other information contained in said public announcement. In the event of a required public announcement under
the first sentence of this paragraph, the party making such announcement shall provide the other party with a copy of the proposed text prior to such announcement sufficiently in advance of the scheduled release of such announcement to afford such
other party a reasonable opportunity to review and comment upon the proposed text and the timing of such disclosure and the other party shall consider in good faith such comments. Notwithstanding anything in this Agreement to the contrary, in no
event will CyDex have a right to make any disclosure or give any presentation of the results of clinical testing of Licensed Product without Company’s prior written consent. 

14.10 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York
(without giving effect to any conflicts of law principles that require the application of the law of a different state). 

14.11 Entire Agreement; Amendment. This Agreement and all Exhibits attached hereto or thereto contain the entire agreement of the
parties relating to the subject matter hereof and supersede any and all prior agreements, written or oral, between CyDex and Company relating to the subject matter of this Agreement. This Agreement may not be amended unless agreed to in writing by
both parties. 
 14.12 Binding Effect. This Agreement shall be binding upon, and the rights and obligations hereof shall
apply to the CyDex and Company and any successor(s) and permitted assigns. The name of a party appearing herein shall be deemed to include the names of such party’s successors and permitted assigns to the extent necessary to carry out the
intent of this Agreement. 
 14.13 Waiver. The rights of either party under this Agreement may be waived from time to
time, singularly or in combination, and the waiver of one or more such rights shall not be deemed to be a waiver of any one or more of the others. No waiver of any breach of a term, provision or condition of this Agreement shall be deemed to have
been made by either party unless such waiver is addressed in writing and signed by an authorized representative of that party. The failure of either party to insist upon the strict performance of any of the terms, provisions or conditions of this
Agreement, or to waive any right contained in this Agreement, shall not be construed as a waiver or relinquishment for the future of any such term, provision, condition or option or the waiver or relinquishment of any other term, provision,
condition or option. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 32

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 14.14 Severability. If a final judicial determination is made that any provision of
this Agreement is unenforceable, this Agreement shall be rendered void only to the extent that such judicial determination finds such provisions unenforceable, and such unenforceable provisions shall be automatically reconstituted and become a part
of this Agreement, effective as of the date first written above, to the maximum extent they are lawfully enforceable. 

14.15 Assignment. Neither party may assign its rights or delegate its obligations under this Agreement, in whole or in part, by
operation of law or otherwise, to any third party without the prior written consent of the other party, which consent shall not be unreasonably withheld. Notwithstanding the foregoing, either party may assign its rights and delegate its obligations
under this Agreement to an Affiliate or to a third party successor, whether by way of merger, sale of all or substantially all of its assets, sale of stock or otherwise, without the other party’s prior written consent. As a condition to any
permitted assignment hereunder, the assignor must guarantee the performance of any assignee to the terms and obligations of this Agreement. Any assignment not in accordance with this Section 14.15 shall be void. 

14.16 Headings. The descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in
construing or interpreting any of the provisions of this Agreement. 
 14.17 Counterparts. This Agreement may be executed
in two counterparts, each of which shall constitute an original document, but both of which shall constitute one and the same instrument. 
 [Remainder of this page left blank intentionally] 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 33

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective
Date. 
  

			
	CYDEX PHARMACEUTICALS, INC.
		
	By:	 	/s/ Allen K. Roberson
	Name:	 	Allen K. Roberson
	Title:	 	CFO

  

			
	RIB-X PHARMACEUTICALS, INC.
		
	By:	 	/s/ Mark Leuchtenberger
	Name:	 	Mark Leuchtenberger
	Title:	 	CEO

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE 34

 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as
amended. 

 EXHIBIT A 
 LICENSED PATENTS 
  

									
	[***]
	 Country
	  	Filing Date	  	Serial No.	  	Patent No.	  	Expiration Date
	 United States
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 [***]
	  	[***]	  	[***]	  	[***]	  	
					
	 Australia
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 EPO
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Austria
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Belgium
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 France
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Germany
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Great Britain (UK)
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Greece
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Italy
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Luxembourg
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Netherlands
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Sweden
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Switzerland
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Korea
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Canada
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Russia
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Japan
	  	[***]	  	[***]	  	[***]	  	[***]

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE A-1

 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

									
	[***]
	 Country
	  	Filing Date	  	Serial No.	  	Patent No.	  	Expiration Date
	 United States
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 [***]
	  	[***]	  	[***]	  	[***]	  	
					
	 Australia
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 EPO
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Austria
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Belgium
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Denmark
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Djibouti
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 France
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Germany
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Great Britain (UK)
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Greece
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Ireland
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Italy
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Luxembourg
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Monaco
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Netherlands
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Portugal
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Spain
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Sweden
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Switzerland
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Korea
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Canada
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Japan
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Russia
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Georgia
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Armenia
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Kyrgyzstan
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Moldova
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Tajikistan
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Turkmenistan
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 Uzbeckistan
	  	[***]	  	[***]	  	[***]	  	[***]

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE A-2

 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

									
	[***]
	 Country
	  	Filing Date	  	Serial No.	  	Patent No.	  	Expiration Date
	 United States
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 EPO
	  		  		  		  	
					
	 Belgium
	  	[***]	  	[***]	  		  	
					
	 Denmark
	  	[***]	  	[***]	  		  	
					
	 Djibouti
	  	[***]	  	[***]	  		  	
					
	 France
	  	[***]	  	[***]	  		  	
					
	 Germany
	  	[***]	  	[***]	  		  	
					
	 Great Britain (UK)
	  	[***]	  	[***]	  		  	
					
	 Greece
	  	[***]	  	[***]	  		  	
					
	 Ireland
	  	[***]	  	[***]	  		  	
					
	 Italy
	  	[***]	  	[***]	  		  	
					
	 Luxembourg
	  	[***]	  	[***]	  		  	
					
	 Brazil
	  	[***]	  	[***]	  		  	
					
	 Canada
	  	[***]	  	[***]	  		  	
					
	 China
	  	[***]	  	[***]	  		  	
					
	 Austria
	  	[***]	  	[***]	  		  	
					
	 India
	  	[***]	  	[***]	  		  	
					
	 Israel
	  	[***]	  	[***]	  		  	
					
	 Japan
	  	[***]	  	[***]	  		  	
					
	 Korea
	  	[***]	  	[***]	  		  	
					
	 Mexico
	  	[***]	  	[***]	  		  	
					
	 Russian Federation
	  	[***]	  	[***]	  		  	

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE A-3

 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

									
	[***]
	 Country
	  	Filing Date	  	Serial No.	  	Patent No.	  	Expiration Date
	 United States
	  	[***]	  	[***]	  	[***]	  	[***]
					
	 United States CON
	  	[***]	  	application	  		  	
					
	 EPO
	  	[***]	  		  		  	
					
	 Austria
	  	[***]	  	application	  		  	
					
	 Belgium
	  	[***]	  	application	  		  	
					
	 France
	  	[***]	  	application	  		  	
					
	 Germany
	  	[***]	  	application	  		  	
					
	 Great Britain (UK)
	  	[***]	  	application	  		  	
					
	 Greece
	  	[***]	  	application	  		  	
					
	 Italy
	  	[***]	  	application	  		  	
					
	 Luxembourg
	  	[***]	  	application	  		  	
					
	 Netherlands
	  	[***]	  	application	  		  	
					
	 Sweden
	  	[***]	  	application	  		  	
					
	 Switzerland
	  	[***]	  	application	  		  	
					
	 Canada
	  	[***]	  	application	  		  	
					
	 China
	  	[***]	  	application	  		  	
					
	 Japan
	  	[***]	  	application	  		  	
					
	 Brazil
	  	[***]	  	application	  		  	
					
	 Mexico
	  	[***]	  	application	  		  	
					
	 Eurasia
	  	[***]	  	application	  		  	
					
	 Turkmenistan
	  	[***]	  	application	  		  	
					
	 Republic of Belarus
	  	[***]	  	application	  		  	
					
	 Republic of Tajikistan
	  	[***]	  	application	  		  	
					
	 Russia
	  	[***]	  	application	  		  	
					
	 Azerbaijan Republic
	  	[***]	  	application	  		  	
					
	 Republic of Kazakhstan
	  	[***]	  	application	  		  	
					
	 Kyrgyzstan
	  	[***]	  	application	  		  	
					
	 Republic of Armenia
	  	[***]	  	application	  		  	
					
	 Republic of Moldova
	  	[***]	  	application	  		  	

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE A-4

 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT B 
 SPECIFICATIONS 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE B-1

 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

											
	

	  	[***]	  	[***] [***]	  
	  	  	[***]	  	 	[***]    	  
	  	[***]	  

					
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]

					
			
		  	 [***]
	  	
			
	 [***]
	  		  	[***]
			
		  	 [***]        
	  	

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE B-2

 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT C 
 PURCHASE PRICE FOR CAPTISOL 
 CLINICAL GRADE MATERIAL

  

			
	 Individual Order Quantity
	  	Price
	 [***]
	  	$[***]/kg
		
	 [***]
	  	$[***]/kg

 COMMERCIAL PRICE FOR MATERIAL 

 

			
	 Annual Order Quantity
	  	Price
	 [***]
	  	$[***] per kg
		
	 [***]
	  	$[***]/kg
		
	 [***]
	  	$[***]/kg
		
	 [***]
	  	$[***]/kg

 *    *    *    *    *

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE C-1

 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT D 
 SPECIFIED DILIGENCE REQUIREMENTS 
 [***]. 

*    *    *    *    * 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE D-1

 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT E 
 FORM OF UNDERTAKING 
 THIS AGREEMENT (this “Agreement”) is made this
         day of             , 20     (the “Effective Date”), by and between RIB-X
PHARMACEUTICALS, INC., a Delaware corporation with offices at 300 George Street, Suite 301, New Haven, CT 06511 (“Rib-X”), and [*NAME OF COMPANY*], a
             with offices at                     
(“Company”). 
 RECITALS 

WHEREAS, Rib-X and CYDEX PHARMACEUTICALS,
INC., a Delaware corporation with offices at 10513 W. 84th Terrace, Lenexa, Kansas 66214 USA (“CyDex”) are parties to that certain License and Supply Agreement dated as of
            , 2010 (the “L&SA”) related to the license of certain rights and the supply by CyDex to Rib-X of CAPTISOL®, also known scientifically as sulfobutylether ß(beta) cyclodextrin, sodium salt, which is a patented drug
formulation system designed to enhance the solubility and stability of drugs (“CAPTISOL”); 

WHEREAS, defined terms which are used but not defined in this Agreement shall have the meanings given to them in
the L&SA; 
 WHEREAS, Rib-X and Company are parties to that certain [*Name of Agreement*] dated as of
            , 20     (the “Contract”), which requires the execution and delivery of this Agreement by Rib-X and Company [*for the
following territory:              (the “Sublicense Territory”)*]; and 
 WHEREAS, Company desires to obtain a sublicense from Rib-X, pursuant and subject to the terms and conditions of the L&SA and the Contract, [*to use CAPTISOL as follows:
‘Note: To be inserted upon execution of undertaking]. 
 NOW,
THEREFORE, in consideration of the following mutual promises and other good and valuable consideration, the receipt and sufficiency of which is acknowledged, the parties, intending to be legally bound, agree as
follows: 
 1. L&SA Undertaking. Company undertakes and agrees to observe and perform the following obligations to
the same extent as Rib-X is obligated to CyDex pursuant to the L&SA, but, in each case, solely with respect to activities of Company and its Affiliates: [Note: Agreement to include at a minimum the following provisions: Sections 2.2
(Grant of License from Company to CyDex); [if Company is purchasing CAPTISOL directly from CyDex, Section 3 (Manufacture and Supply of CAPTISOL), 4.2 (Pricing for CAPTISOL), 4.3 (Currency), 4.4 (Taxes), and 4.5 (Late Payments)], 5 (Records;
Reports; Audit)]; [if Sublicensee is assuming Rib-X’s development obligations, 6 (Development and Commercialization by Company), and 7 (Regulatory Matters)], 8 (Confidentiality), 10 (Indemnification), 11 (Limitation of Liability), 12
(Management of Licensed Patents), 13.5 (Survival), and 14 (General Provisions).] For clarity, Company acknowledges and agrees that CyDex may directly enforce, as an intended third-party beneficiary of this Agreement, such obligations under the
L&SA against Company. 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE E-1

 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 2. Contract Undertaking. Company undertakes and agrees for the benefit of CyDex to
observe and perform Company’s obligations under the Contract that relate to the L&SA. For clarity, Company acknowledges and agrees that CyDex may directly enforce, as an intended third-party beneficiary of this Agreement, such obligations
under the Contract against Company. Rib-X and Company agree that a full copy of the executed Contract shall be provided to CyDex within thirty (30) days after the Effective Date which may be redacted to delete confidential provisions not
relevant to the L&SA. 
 3. No CyDex Liability. Company acknowledges and agrees that CyDex shall have no liability to
Company under the L&SA (as Company is not a party to the L&SA) or the Contract (as CyDex is not a party to the Contract). The enforcement of any obligation of CyDex under the L&SA shall only be pursued by Rib-X pursuant to the L&SA.

 4. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New
York (without giving effect to any conflicts of law principles that require the application of the law of a different state). 

5. Counterparts. This Agreement may be executed in two counterparts, each of which shall constitute an original document, but both
of which shall constitute one and the same instrument. 
 IN WITNESS WHEREOF, the parties have executed this Agreement as
of the Effective Date. 
  

									
	RIB-X PHARMACEUTICALS, INC.	 		 	[*NAME OF COMPANY*]
					
	By:	 	 	 		 	By:	 	 
					
	Name:	 	 	 		 	Name:	 	 
					
	Title:	 	 	 		 	Title:	 	 

  
  

					
		  	LICENSE AND SUPPLY AGREEMENT	  	PAGE E-2

 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT F 

 

					
	

	  	CAPTISOL DOSING        	  	

  

																							
	
                      
        [***]

	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
												
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
												
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
												
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	  		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
												
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  		  		  		  	  	[***]	  		  		  		  		  	

 Notes: [***] 

  
  

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}]]